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ABSTRACT  
 
Introduction: Peripartum cardiomyopathy (PPCM) is defined as a disorder of unknown aetiology that 
occurs between one month antepartum and five months postpartum in women without pre-existing heart 
disease. While the incidence of PPCM has been reported between 1: 2392 and 15000 live births in the USA, 
the disease is ubiquitous on the African continent with an incidence ranging from 1: 100 to 1: 1000 
deliveries. The mortality rate ranges between 15 and 40.7%, while 23 to 54% of patients recover completely. 
Aim of this thesis was to describe the clinical profile of 100 PPCM patients, identify predictors of negative 
outcome, analyze differences in kinetics of cardiac function biomarkers, pro-inflammatory cytokines, 
markers of re-modeling and prolactin in cardiac function improvers versus non-improvers and investigate a 
possible autoimmune component in the pathogenesis of PPCM.  
 
Methods: We conducted a single centre, prospective study of 100 newly diagnosed patients meeting 
diagnostic criteria for PPCM. All patients received standard anti-failure therapy with diuretics (furosemide, 
aldactone), the β-blocker carvedilol, ACE-inhibitor perindopril and digoxin if indicated. Clinical assessment, 
2-dimensional echocardiographic studies and blood analysis were systematically performed at time of 
presentation, after six and twelve months of therapy.  
 
Findings: Fifteen patients died within the follow-up period of six months and eight were not available for 
full follow-up since they moved to remote areas. Patients who completed six months of treatment showed a 
significant reduction of heart rate, left ventricular dimensions and significant improvement in 
scintigraphically and echocardiographically derived values for left ventricular ejection fraction (p< 0.0001) 
and NYHA functional class (p< 0.001). However, normalization of LVEF (>50%) was only observed in 18 
(23%) of the patients. Baseline plasma levels of Fas/Apo-1 (OR = 3.56, CI 95% = 1.35–9.42) and NYHA FC 
(OR = 2.67, CI 95% = 1.04–6.83) were independent predictors of death.  
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The markers of cardiac function (NT-proBNP*, Fas/APO-1* and oxidized LDL*) and the pro-inflammatory 
cytokines (interleukin-1*, interleukin-6*, IFN-gamma*, TNF-alpha* and C-reactive protein) were 
significantly higher at baseline in 43 PPCM patients than in controls (*P<0.0001). While the marker of re-
modeling matrix-metallo-proteinase-2* was significantly higher, transforming-growth-factor-beta1 was 
significantly lower in PPCM patients (P=0.002). Vascular endothelial growth factor, matrix-
metalloproteinase-9 and placental growth factor did not differ between groups, while big endothelin-1* was 
significantly higher in PPCM patients.  
The pregnancy related hormone prolactin was significantly higher* in PPCM patients than in peripartum 
controls and subsequently decreased significantly (P=0.002) in cardiac function improvers, but not in non-
improvers. Analysis between cardiac function improvers and non-improvers from baseline to six months 
revealed significant differences for Δ IFN-gamma (P=0.0181).  
Investigating a possible auto-immune component in the aetiology of PPCM, we identified β1-adrenoreceptor 
antibodies in serum of PPCM patients and mapped their reactivity exclusively to epitopes on the second 
extra-cellular loop (RAESDE and DEARRCY), while those from DCMO patients bind to epitopes on the 
first (30%) and second extra-cellular loop (ARRCYND and PKCCDF). The β1-adrenoreceptor agonist-like 
antibodies identified in PPCM patients are part of the IgG2 and IgG3 subclass, while those from DCMO 
patients belong to the IgG2 subclass. Furthermore we demonstrated that β1-adrenoreceptor antibodies in 
serum of PPCM patients prevented desensitization of the receptor. The β1-adrenoreceptor antibodies in 
serum of PPCM patients were not detectable in serum of non PPCM peripartum controls and are different 
from those found in patients with DCMO, suggesting that PPCM forms a distinct disease entity. We 
demonstrated a positive correlation between the activity of the β1-adrenoreceptor antibodies and serum 
expression levels of the marker of cardiac function NT-proBNP from baseline to twelve months (rs=0.58, 2-
tailed P=0.0228), 95% CI (0.10 to 0.84).  
Investigating the cause for high prolactin expression levels in serum of PPCM patients, we identified a 
STAT3 deficit in a PPCM mouse model. Significantly increased levels of cathepsin D cause the cleavage of 
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the physiological 23-kDa form of prolactin into a 16-kDa form in PPCM patients, but not in non-PPCM 
peripartum controls. This initiated another clinical study, investigating the effect of the prolactin-inhibitor 
bromocriptine in addition to standard heart failure therapy in known PPCM patients, presenting with a 
subsequent pregnancy. Comparison of clinical and echocardiographic data of these patients to others on 
standard heart failure therapy demonstrated preservation or improvement of left ventricular dimensions and 
systolic function as well as NYHA FC.  
 
Conclusion: 
While a wide range of parameters, reflecting cardiac dysfunction and pro-inflammatory immune activation, 
were elevated in all PPCM patients at time of first presentation, indicating their involvement in the initiation 
of the disease, we found significant differences over time between cardiac function improvers and non-
improvers for ΔIFN-gamma (P=0.0181) serum levels, suggesting their role in disease progression. 
Heightened IFN-gamma expression could indicate an ongoing T-cell mediated autoimmune response and an 
insult to the cardiac muscle, resulting in fibrosis and inability to improve left ventricular systolic function.  
Prolactin represents a stimulatory link between the neuroendocrine and immune systems, promoting pro-
inflammatory immune responses. Interestingly, we found significantly higher (P<0.0001) serum prolactin 
levels in PPCM patients at time of first presentation than in peripartum controls, suggesting the hormone’s 
role during the initial acute phase of PPCM. Several authors have described the induction of IFN-gamma by 
prolactin. Disease progression and the ongoing autoimmune insult by beta1-adrenergic autoantibodies 
appear to be driven by IFN-gamma. This pro-inflammatory cytokine remained high in PPCM non-
improvers, decreased in improvers, was previously implicated in the development of autoimmune disease 
and its suppression leads to desensitization of β-adrenoreceptors. Together with the β1-adrenoreceptor 
autoantibodies that we have identified in PPCM patients and their demonstrated property to also prevent 
desensitization of β1-adrenoreceptors, patients experience an adrenergic overdrive, leading to cardiac 
myocyte insult.  
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While the pathogenesis of PPCM appears to be multifactorial, our task as scientists remains to find out, how 
the monolith was erected. Specifically, it appears promising to investigate the effects of bromocriptine in 
addition to standard heart failure therapy in a randomised, double-blinded clinical study. Although one could 
argue that prolactin regulated expression of IFN-gamma and other cytokines may explain the gender-specific 
differences in autoimmunity, it has been shown that elevated serum prolactin concentrations are associated 
with accelerated autoimmune disease in both female and male mice. Possibly, prolactin does not only play a 
role in the pathogenesis of PPCM, but also in other forms of cardiomyopathy, affecting males and females 
alike. It would be interesting to study prolactin serum expression levels in male and female patients with 
idiopathic DCMO. Clearly, further studies into the unfolding pathogenesis of PPCM are indicated. 
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PLGF   Placental growth factor 
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PPCM   peripartum cardiomyopathy 
STAT3  signal transducer and activator of transcription 3  
TGF-β  transforming growth factor β 
TNF-alpha  tumor necrosis factor alpha 
U+E   urea and electrolytes 
VEGF   vascular endothelial growth factor 
VSMC   vascular smooth muscle cells 
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1. INTRODUCTORY CHAPTERS AND LITERATURE REVIEW 
 
1.1 Definition 
Peripartum cardiomyopathy (PPCM) was first described by Virchow in 1870 and is defined as a disorder of 
unknown pathogenesis in which left ventricular dysfunction and symptoms of heart failure occur between 
the last month of pregnancy and the first five months postpartum. PPCM is an exclusion diagnosis based on 
the absence of an identifiable cause of heart failure or recognizable heart disease prior to the last month of 
pregnancy (1). It is a distinct entity of dilated cardiomyopathy (1, 2) that is incompletely characterized (3). 
In contrast, pregnancy related cardiomyopathy might present during the second or early third trimester.  
Diagnosis requires echocardiographic evidence of left ventricular systolic dysfunction (ejection fraction < 
45%, fractional shortening < 30%) (4). Heart failure occurring earlier in pregnancy might be caused by 
previously unsuspected dilated cardiomyopathy unmasked by the haemodynamic and hormonal stress of 
pregnancy and possibly forms a different entity. Women developing symptoms of cardiac failure earlier than 
the last gestational month are diagnosed as having pregnancy-associated cardiomyopathy (5). Other possible 
causes of heart failure during the peripartum period, such as infectious, toxic, or metabolic disorders and 
ischaemic or valvular heart disease need to be considered. Complications of late pregnancy, including 
toxaemia and amniotic or pulmonary embolism, which may mimic heart failure, should be ruled out before 
the diagnosis of PPCM is made (6).  
In the past, authors reporting cases of PPCM made the diagnosis solely on clinical grounds. That is, pregnant 
or postpartum patients with signs and symptoms of heart failure and with consistent radiographic features 
were given the diagnosis. With the advent of two-dimensional echocardiography techniques, it has been 
established that pregnant patients may at times have clinical features mimicking heart failure and yet have 
normal ventricular size and function. Therefore it is likely that previous studies may have erroneously 
included some patients with a diagnosis of PPCM. Common causes for such misdiagnoses include 
accelerated hypertension, diastolic ventricular dysfunction, pulmonary embolism or the high-output state of 
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pregnancy itself (6). The above emphasize the importance of correct diagnosis in efforts to answer important 
questions about incidence, prevalence, treatment, and prognosis (1).  
 
1.2 Epidemiology of PPCM 
The incidence of PPCM varies from 1:100 to 1:10000 between geographical regions (table 1.1) and tends to 
be associated with low socioeconomic standards (7). PPCM is most common in women of African descent 
(8-10). The highest incidence of pregnancy associated heart failure in the world has been reported from the 
Zaria province of Nigeria, but it is important to note that the incidence of PPCM might have been 
overestimated in some areas due to the absence of echocardiography, possibly resulting in other causes of 
systolic heart failure being diagnosed as PPCM. PPCM is a rare condition in Europe but a very frequent 
disease in Sahelian Africa (11). In Nigeria PPCM formed the most common  cause of cardiac failure among 
the females in the north, while it is rarely reported from the south (12). While the incidence in the United 
States has previously been described as 1:10000 (13), recent studies reported a higher incidence of 1:2392 to 
1:4000 live births (14, 15).   
 
Location Incidence Year Source 
Nigeria (Zaria)  1:100 1978  (16) 
Haiti 1:300 2005 (14) 
South Africa (Durban) 1:1000 1995 (17) 
South Africa (Johannesburg)  1:3000 1961  (18) 
China (Taiwan) 1:6147  1992 (19) 
USA  1:2392 to 1:10000 2002, 
2004, 
2005 
(13-15) 
Table 1.1: Incidence of PPCM in different geographical regions 
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Retrospective record review of earlier studies without echocardiography disclosed that a high percentage of 
these women had previous unreported underlying illness such as hypertension, mitral stenosis, 
thyrotoxicosis, sepsis, anaemia or pre-eclampsia that may have contributed to the onset of cardiac failure 
suggesting the incidence may be lower than indicated (6, 20, 21).  
PPCM appears to have a more malignant course in developed countries with a proportion associated with 
histological evidence of myocarditis (22). There is a need for a large scale epidemiologic studies of the 
incidence, prevalence, determinants and outcome of cardiomyopathy in Africa to form strategies for the 
optimal treatment and prevention of heart muscle disease on the continent (22).  
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1.3 Risk factors of PPCM 
Early reports suggested that PPCM was more prevalent in women above 30 years of age, but the syndrome 
has been reported in patients of a wide range of ages (18, 23, 24). Veille et al. reported PPCM to be more 
frequent in multiparous women (25). In a study from the cardiological departments of French university 
hospitals multiparity and twin pregnancies were identified as predisposing factors (26). Researchers from 
Banjul, The Gambia reported on five out of 28 patients had twin pregnancies (18%, p <  0.001) (27). Also 
Fillmore et al. reported an increased risk for patients with twin pregnancies (28).Although PPCM has been 
reported in all ethnic groups, the majority of American patients are of African descent (25). In a study from 
Sahelian Africa heat, hard physical exertion during pregnancy, hypertension, sodium diet, ablutions with hot 
water during the postpartum period, selenium deficiency and probably latent myocarditis have been named 
as risk factors (11). Poor nutrition was initially thought to be associated with the development of PPCM (24), 
but several reports have disproved this connection (29, 30).  
Case reports have associated PPCM with maternal cocaine abuse (31), enterovirus infection (32) or selenium 
deficiency (33), but these were not confirmed epidemiologically. In a more recent report Fett et al. have 
ruled out a role for selenium deficiency as a risk factor for PPCM (29). On the other hand Lampert et al. 
reported a link between long-term oral tocolytic therapy and subsequent development of PPCM (34). The 
main risk factors that have been identified so far for PPCM thus include advanced maternal age, multiparity, 
African descent, twinning, and long-term tocolysis (6). 
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1.4 Aetiology of PPCM 
There has been and continues to be considerable controversy with regards to the aetiology of human PPCM 
(8). While some studies have suggested a role for salt intolerance (35), others have shown a correlation with 
sexually transmitted diseases (36), Chlamydia pneumoniae (37), and strenuous aerobic exercise throughout 
the last trimester (38). One hypothesis that was forwarded was that PPCM was due to an interaction between 
prolactin-selenium resulting in selenium deficiency and/or autoimmunity (39) but data from the studies 
conducted by Fett et al. suggest these etiologies to be highly unlikely (29). Also in Dakar, Senegal, serum 
selenium and vitamin B1 levels were measured in PPCM patients and found to be normal (40).  
Other studies have suggested that patients might be suffering from a quiescent heart muscle disease as a 
consequence of  a previous viral myocarditis and that cardiac volume overload functioned as a trigger to 
precipitate the disease (35) 
A role for autoimmune effector mechanisms in the aetiology of PPCM has also been entertained. Thus, the 
concept that has been forwarded is that generalized immunosuppression is a hallmark of pregnancy which 
returns to normal shortly following delivery. However, in select cases the return to normal is accompanied 
by abnormal rebound resulting in autoimmunity and disease. This view was supported by a case report from 
Osaka, Japan, which showed that three PPCM patients developed positive anti-heart reactive antibodies as 
detected by an indirect immunofluorescence assay, and one had antibody to heart myosin detected by 
enzyme-linked immunosorbent assay shortly following delivery. The authors concluded  that heart failure is 
induced by postpartum autoimmune myocarditis (41).  
Autoantibodies that target 25 kDa, 33 kDa, or 37 kDa proteins expressed by normal cardiac tissues have 
been identified in PPCM patients from Haiti (42). A case report described high titers of antiactin antibodies 
9 months after the delivery supporting the theory that the peripartum cardiomyopathy is of autoimmune 
aetiology (43), however, a study from Niamey, Niger demonstrated the absence of a humoral autoimmunity 
process in PPCM (44). 
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Sanderson et al. suggest that the primary event in PPCM reported from the Zaria province in Nigeria is fluid 
retention which leads to a form of high output cardiac failure. The postpartum practices in this area (taking 
high sodium diets and lying on heated beds) almost certainly cause the fluid to accumulate initially, but the 
heart may be unable to meet the demands either because of pre-existing heart muscle disease or, more likely, 
because of a rise of the peripheral resistance due to the volume expansion, overburdens such dilated hearts 
and leads to myocardial damage (45). There are few reports on familial occurrence of PPCM (46). A study 
from Niamey, Niger, reported an association of enterovirus infection with PPCM (32). PPCM shows a high 
incidence of myocarditis (47) and was identified in 29% of patients with PPCM (48). Bultmann et al. 
detected viral genomes in endomyocardial biopsy specimen in eight of 26 PPCM patients (30,7%) but also in 
10 of 33 control subjects (30,3%) (49). The detected viruses (PVB 19, HHV 6, EBV, HCMV) have been 
related to inflammatory cardiomyopathy but also have a high prevalence in healthy populations (50, 51). The 
role of endomyocardial biopsy remains controversial and is likely to be clinically useful only if performed 
early in the course of the disease (52). Estrogen (53, 54), progesterone (55) and prolactin (56) have been 
shown to have profound effects on the cardiovascular system, but no distinct hormonal disorder has been 
identified in PPCM.  
In summary, the literature is wealthy with studies attempting to propose aetiologies for PPCM. However, to 
date no study has clearly identified a distinct cause of this disease (6).   
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1.5 Pathophysiology of heart failure and PPCM 
1.5.1 A general pathophysiological approach towards heart failure 
The cardiomyopathies are a group of diseases that affect the heart muscle itself and are not the result of 
hypertension or congenital or acquired valvular, coronary, or pericardial abnormalities. When the 
cardiomyopathies are classified on an aetiological basis, two fundamental forms are recognized: A primary 
type, consisting of heart muscle disease of unknown cause and a secondary type, consisting of myocardial 
disease of known cause or associated with a disease involving other organ systems. In many cases, like 
PPCM however, it is not possible to arrive at a specific aetiologic diagnosis, and thus it is helpful to classify 
the cardiomyopathies into one of three types (dilated, restrictive, hypertrophic) on the basis of differences in 
their pathophysiology and clinical presentation as detailed below: 
• Dilated: Left and/or right ventricular enlargement, impaired systolic function, congestive heart 
failure, arrhythmias and emboli.  
• Restrictive: Endomyocardial scarring or myocardial infiltration resulting in restriction to left and/or 
right ventricular filling.  
• Hypertrophic: Disproportionate left ventricular hypertrophy, typically involving septum more than 
free wall, with or without an intraventricular systolic pressure gradient; usually of a non-dilated left 
ventricular cavity (9).  
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Figure 1.1: Classification of cardiomyopathies (57) 
 
In Western populations about one in three cases of congestive heart failure (CHF) is due to dilated 
cardiomyopathy, with the remainder the consequence of coronary artery disease. Left and/or right ventricular 
systolic pump function is impaired, leading to progressive cardiac enlargement and hypertrophy, a process 
called remodeling. Symptoms of CHF typically appear only after remodeling has been ongoing for some 
time (months or even years). There is, however, no close correlation between the degree of contractile 
dysfunction and the severity of symptoms. 
 
Although no cause is apparent in many cases, dilated cardiomyopathy is probably the end result of 
myocardial damage produced by a variety of toxic, metabolic or infectious agents. Dilated cardiomyopathy 
may be the late sequel of acute viral myocarditis, possibly mediated through an immunologic mechanism. 
Although it may occur in any patient population, it is more common in African Americans than in whites. 
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The prevalence of this condition is increasing. A reversible form of dilated cardiomyopathy may be found 
with alcohol abuse, pregnancy, thyroid disease, cocaine abuse and chronic uncontrolled tachycardia (9).  
PPCM is therefore a form of primary cardiomyopathy that by definition occurs exclusively during the 
peripartum period. 82% of women with PPCM develop cardiac symptoms in the first three postpartum 
months and only 7% in the last month of pregnancy (10). Echocardiography reveals features of dilated 
cardiomyopathy with impaired ejection fraction, global dilatation and sometimes thinned out walls. 
Although it is still termed idiopathic a number of  mechanisms have been proposed as potential aetiological 
agents which include nutritional deficiencies, genetic disorders, viral or autoimmune aetiologies, hormonal 
problems, volume overload, alcohol, physiologic stress of pregnancy, or unmasking of latent idiopathic 
dilated cardiomyopathy (58).  
The rare incidence of PPCM and the difficulty to set up relevant animal models have limited research and 
understanding of the pathogenic mechanisms involved. With the above in mind, some have suggested that 
the aetiology of PPCM is dependent on the interaction of pregnancy associated factors, e.g. increased 
haemodynamic stress, vasoactive hormones and fetal microchimerism, that co-operate in the context of 
essential immune and genetic environments for disease progression (59).  
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1.5.2 A specific pathophysiological approach towards PPCM  
PPCM is defined as a disorder of unknown pathogenesis in which left ventricular dysfunction and symptoms 
of heart failure occur between the last month of pregnancy and the first five months postpartum. PPCM is an 
exclusion diagnosis based on the absence of an identifiable cause of heart failure or recognizable heart 
disease prior to the last month of pregnancy (1). It is a distinct entity of dilated cardiomyopathy (1, 2) and is 
incompletely characterized (3). Historically, PPCM has mainly been attributed to nutritional deficiencies. 
Recent publications focus on the role of inflammatory cytokines, cardiac myocyte apoptosis, infectious 
disease agents, myocarditis, auto-antibodies, hormones and genetic factors on the background of a 
pregnancy-specific immune-environment.  
 
1.5.2.1 Role of immune environment 
A physiologically normal immune response involves interplay of the innate and acquired immune system. 
Cytokines, chemokines and their natural ligands, expressed by cells of the innate and acquired immune 
system, regulate the quantity, quality and kinetics of such immune responses. Whereas chemokines create a 
biological gradient to attract haematopoietic cells into the immune environment, cytokines influence the 
quality of the immune response (4). Mosmann et al. described the differences between two types of helper T-
cells, defined primarily by differences in the pattern of lymphokines synthesized and their different functions 
(table 1.5.2.1). Patterns of lymphokines synthesized are convenient and explicit markers to describe T-cell 
subset differences. Evidence suggesting that many of the functions of helper T-cells are predicted by the 
functions of the lymphokines that they synthesize after activation by cognate antigen being processed and 
presented by antigen presenting cells is accumulating. Depending on the infectious agent, the immune 
response can be classified as belonging to either Th1 or Th2, Th3 or Th0 based on the cytokine profile and is 
reasoned to be important to consider when inducing therapeutic immune responses (60).  
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Lymphokine secretion patterns Cytokine gene expression 
Th1-like (pro-inflammatory) Synthesize IL-2, 3, IFN-gamma, GM-CSF, lymphotoxin, TNF, TY5, met-encephalin, 
Th2-like Synthesize IL-3,4,5 and 6, GM-CSF, TNF, TY5, met-encephalin, P600 
Th0 Synthesize Th1 and Th2-like cytokines 
Th3-like (possibly identical with CD4/CD25) 
Synthesize TGF-β, regulatory functions 
(inhibition of immune response, delivery of 
anti-apoptotic signals to T-cells) 
Table 1.2: Cytokine gene expression profile by Th1, Th2, Th0 and Th3 helper cells (60-62) 
 
 
Cerwenka et al. described the existence of the TGF-β-producing Th3 subset. TGF-β was recognized as an 
anti-apoptotic survival factor for T-lymphocytes and is thought to play an important regulatory role during 
an immune response. Th3-like cells might be identical with CD4/CD25 regulatory T-cells (62). This subset 
of CD4 T cells is highly potent in suppressing immune responses and its experimental depletion resulted in 
organ-specific autoimmunity. Changes in the frequencies of such immune cell subsets and the cytokine 
environment they create, can regulate the quantity and quality of the immune response (4). Ansari et al. 
performed a flow cytometric analysis of the frequency of CD25 among the CD4 T cells of PPCM patients 
and women with normal pregnancy. Frequency of CD25 increases in women with normal pregnancy during 
the third semester and returns to normal post delivery. In contrast all PPCM patients showed markedly lower 
frequency of this cell lineage. Furthermore those PPCM patients with the lowest values continued to 
demonstrate poor cardiac function (4).  
Immunoglobulin subclass profiles in PPCM patients from Haiti, South Africa and Mozambique differ from 
those with IDCM from the same countries. Warraich et al. documented a selective upregulation of the IgG3 
subclass, consisting of immunoglobulins with pro-inflammatory characteristics in IDCM patients. In 
contrast, PPCM patients had raised levels of all immunoglobulin subclasses. However, raised levels of the 
G3 subclass correlated with higher NYHA functional class. An increase in all the subclasses both in 
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frequency and in reactivity supports a relatively non-specific or a rather exaggerated humoral immune 
response. Whether a multitude of stimuli, differences in co-stimulatory factors or hyper-responsiveness to 
self-constituents following changes in host defence underlies these findings is currently not clear. Disparity 
in the distribution of subclass immunoglobulins in cardiomyopathies of distinct origins is suggestive of 
diversity in the regulatory components driving these responses in disease.  
 
1.5.2.2 Pregnancy specific immune environment 
As Peter Medawar stated in his Nobel lecture, "Immunological tolerance" may be described as a state of 
indifference or non-reactivity towards a substance that would normally be expected to excite an 
immunological response (63). The question how a semi-allogeneic fetus is protected from rejection by the 
mother is a subject of debate. Fetal cells have been shown to cross into the mother and maternal cells have 
been shown to cross into the fetus. 25% of adults carry long-lasting maternal haematopoietic cells. Both fetal 
and placental cells have also been shown to express detectable levels of major histocompatibility complex 
molecules. The regulatory role of such cells on the mother's immune status continues to be subject of study.  
Munn et al. demonstrated rapid T cell-induced rejection of all allogeneic conception when pregnant mice 
were treated with a pharmacologic inhibitor of indoleamine 2, 3-dioxygenase (IDO), a tryptophan-
catabolising enzyme expressed by trophoblasts and macrophages. Thus, by catabolising tryptophan, the 
mammalian conceptus suppresses T cell activity and defends itself against rejection (64). Ansari et al. 
described an abnormal increase if IL-2 synthesis by peripheral blood mononuclear cells from PPCM patients 
as compared to other normally pregnant women, providing support to the view of an abnormal immune 
environment as a contributing factor in human PPCM (4).  
Autoimmune diseases frequently develop after delivery due to the immune rebound mechanism. In a case 
report from Osaka, Japan, three patients had positive anti-heart antibody detected by indirect 
immunofluorescence assay, and one had antibody to heart myosin detected by enzyme-linked 
immunosorbent assay providing suggestive evidence that heart failure is induced by postpartum autoimmune 
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myocarditis (41). Multiple sclerosis and rheumatoid arthritis are thought to be Th1 cytokine related diseases 
and usually reduce severity during pregnancy that returns postpartum. In contrast SLE which is thought to be 
related to Th2 type immune response often exacerbates during pregnancy, suggesting connectivity between 
Th1/Th2 cytokines and autoimmune diseases (4).  
 
1.5.2.3 Microchimerism 
The exchange of blood or lymphoid tissues between individuals as a result of organ transplantation, blood 
transfusion and pregnancy leads to microchimerism describing the persistent presence of a minor population 
of semi-allogeneic lymphocytes or DNA in the peripheral circulation and / or tissues of organ transplant / 
blood transfusion recipients and following pregnancy (4).  Microchimeric cells are understood to play a vital 
role in tolerance-induction in humans for organ transplantation (65, 66). Male fetal CD34+ or CD34+CD38+ 
cells were detected in women up to 27 years after their last pregnancy. The prolonged persistence of fetal 
progenitor cells may have significance in development of tolerance of the fetus. Pregnancy may thus 
establish a long-term, low-grade chimeric state in the human female (67). In patients who have suffered 
recurrent spontaneous abortions of unknown cause, alloimmunization therapy using the partner's leukocytes 
has been reported to be effective in preventing the failure of pregnancy, proposing that alloimmunization 
establishes a state of microchimerism that would be the necessary allogeneic stimulus for T-cell activation, 
and the induction or maintenance of tolerance to the fetus during pregnancy (68). Chimerism has also been 
linked to autoimmune thyroid disease and systemic sclerosis (69, 70).  
Fetal cells can migrate to the mothers skin during gestation, where they seem to be associated with the 
development of cutaneous disorders of pregnancy (71). On the other hand, microchimeric cells have been 
aetiologically associated with severe graft versus host reactions post bone marrow transplantation or 
transfusion.  
Several reports have documented the occurrence of chimerism of the haematopoietic lineage cells from the 
fetus to the mother during pregnancy (72, 73). It is postulated that fetal cells may escape into the maternal 
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circulation and remain there without being rejected, due to weak immunogenicity of the paternal haplotype 
of the chimeric cells, or to the naturally occurring immunosuppressive state of the mother, or both. If 
chimeric haematopoietic cells take up residence in cardiac tissue during the immunosuppressed pregnant 
state and, following postpartum recovery of immune competence, are recognized as nonself by the maternal 
immune system, a pathologic autoimmune response may be triggered. Prior exposure to paternal major 
histocompatibility complex antigens expressed by spermatozoa or previous immunization from prior 
pregnancies may play a role in inducing local tissue inflammatory response. Cytokines and similar signaling 
molecules are then released, leading to non-specific bystander myocytotoxicity and myocarditis. Abnormal 
immunologic activity as a possible cause of PPCM is supported by high titers of autoantibodies against 
select cardiac tissue proteins (e.g., adenine nucleotide translocator, branched chain alpha-keto acid 
dehydrogenase) (74).   
A large foetomaternal transfusion occurs at the time of labour and delivery in all pregnant women. This may 
establish fetal cell microchimerism in the mother, which may be implicated in the subsequent development 
of diseases such as scleroderma that are more common in women (75). A similar mechanism could play a 
role in the pathogenesis of PPCM.  
 
1.5.2.4 Haemodynamic stress of pregnancy 
Gave et al. performed an echocardiographic assessment of the haemodynamics in normal pregnancies and 
demonstrated a 10% increase in left ventricular end-diastolic volume, a 45% increase in cardiac output, and 
a 26% to 28% decrease in end-systolic wall stress. In addition, the left ventricle remodels in response to the 
haemodynamics of pregnancy, resulting in transient hypertrophy (76).  
 
1.5.2.5 Hormones 
The profound effects of estrogen (53, 54), progesterone (55) and prolactin (56) on the cardiovascular system 
have been demonstrated in general, but no distinct hormonal disorder has been identified in PPCM. Coulson 
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et al. reported on abnormalities of relaxin, primarily an ovarian hormone produced during pregnancy, 
recently found in cardiac atria, shown to have positive inotropic and chronotropic properties and potentially 
involved in excessive relaxation of the cardiac skeleton (77). Sex steroid regulation of the production of  the 
lymphokine interferon-gamma as well as other cytokines may help explain the gender-specific differences in 
the immune system, including autoimmunity (78). The prevalence of autoimmune diseases in women may 
be the consequence of a bidirectional signaling network between hormones and the immune system that 
regulates female reproductive life. Certain estrogens have been thought to improve rheumatoid arthritis 
which is Th1-mediated and exacerbate Th2-mediated SLE (79).  
Estrogen and prolactin have a reciprocal endocrinologic relationship and both hormones have pleiotropic 
effects on the immune system. Despite the presence of a number of confounding variables, these hormones 
modulate autoimmunity. Estrogen appears to suppress cell-mediated and augment humoral-based immunity. 
Prolactin appears to stimulate both, cell and humoral-based immunity. Both hormones have been shown to 
modulate IFN-gamma secretion. These similar sets of data, derived from experimental models, human 
autoimmune disease and pregnant patients with autoimmune diseases suggests disparate effects of estrogen 
and prolactin on autoimmune responses and disease pathogenesis. The endocrinologic and immune effects of 
estrogen may directly or indirectly stimulate or inhibit immune responses. These dichotomous effects have 
limited its successful pharmacologic manipulation in human autoimmune disease with estrogen compounds, 
tamoxifen, oral contraceptives, anti-gonadotropic agents, or ovulation induction regimens. In contrast, 
reduction of immuno-stimulatory concentrations of prolactin with bromocriptine has successfully suppressed 
development or expression of murine and human autoimmune disease (80). Prolactin has been implicated in 
cardiac tissue injury, modulation of the autoimmune response and maintenance of pregnancy  (81, 82). 
Progesterone appears to promote Th2 cells and suppress the generation of Th1-like immune responses. 
Testosterone has been shown to regulate T cell cytokine secretion and possess anti-inflammatory properties 
associated with immunosuppression (83).  
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1.5.2.6 Inflammatory cytokines 
Stress-activated pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha) or interleukin-
1 have been implicated in the pathophysiology of idiopathic dilated cardiomyopathy (84). TNF-alpha is a 
pleiotropic inflammatory cytokine and serves a variety of functions, many of which are not yet fully 
understood. The cytokine possesses both growth stimulating and growth inhibitory properties and appears to 
have self-regulatory properties as well.  For instance, TNF-alpha induces neutrophil proliferation during 
inflammation, but it also induces neutrophil apoptosis upon binding to the TNF-R55 receptor (85). TNF-
alpha is a 26 kDa protein and is produced by many different cell types. The main sources in vivo are 
stimulated monocytes, fibroblasts, and endothelial cells. Macrophages, T-cells and B-lymphocytes, 
granulocytes, smooth muscle cells, eosinophils, chondrocytes, osteoblasts, mast cells, glial cells and 
keratinocytes also stimulate production of TNF-alpha. Glioblastoma cells constitutively produce TNF-alpha 
and the factor can be detected also in the cerebrospinal fluid. Human milk also contains TNF-alpha. 
Physiological stimuli for the synthesis of TNF-alpha are IL-1, bacterial endotoxins, PDGF and oncostatin M. 
In fibroblasts the synthesis of TNF-alpha is stimulated by IFN-β, TNF-alpha, PDGF and viral infections. In 
thymic stromal cells the synthesis of TNF-alpha can be induced by NGF. TNF-alpha can also stimulate or 
inhibits its own synthesis, depending upon the cell type. In epithelial, endothelial, and fibroblastic cells 
secretion of TNF-alpha is induced by IL-17. 
 
Beneficial functions of TNF-alpha include its role in the immune response to bacterial, and certain fungal, 
viral, and parasitic invasions as well as its role in the necrosis of specific tumors.  TNF-alpha acts as a key 
mediary during local inflammatory immune response. It is an acute phase protein which initiates a cascade 
of cytokines and increases vascular permeability, thereby recruiting macrophage and neutrophils to a site of 
infection. TNF-alpha secreted by the macrophage causes blood clotting which serves to contain the 
infection. Without TNF-alpha, mice infected with gram-negative bacteria experience septic shock (86). 
Tracey and Cerami suggest that low levels of TNF-alpha may aid in maintaining homeostasis by regulating 
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the body's circadian rhythm and that low levels of TNF-alpha promote the remodeling or replacement of 
injured and senescent tissue by stimulating fibroblast growth (87). The pathological activities of TNF-alpha 
include the promotion of growth of certain tumor cells, although it causes necrosis of other types of tumors. 
High levels of TNF-alpha correlate with increased risk of mortality (88). TNF-alpha participates in disorders 
of inflammatory and non-inflammatory origin (89). Originally, sepsis was believed to result directly from 
the invading bacteria itself, but it was later recognized that host system proteins, such as TNF-alpha induce 
sepsis in response. Exogenous and endogenous factors from bacteria, viruses, and parasites stimulate 
production of TNF-alpha and other cytokines. Lipopolysaccharide from bacteria cell walls are a potent 
stimulus for TNF-alpha synthesis (87). TNF-alpha exhibits acute and chronic effects. If TNF-alpha remains 
in the body for a long time, it loses its anti-tumor activity. This can occur due to cytokine polymerization, 
shedding of TNF-alpha receptors by tumor cells, excessive production of anti-TNF antibodies, found in 
patients with carcinomas or chronic infection, and disruptions in the alpha-2 macroglobulin proteinase 
system which may deregulate cytokines. Prolonged overproduction of TNF-alpha results in cachexia. 
Cachectin and TNF-alpha were once considered different proteins, but in 1985 researchers discovered that 
the two proteins were homologous (90).  
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Picture 1.1: A resolution structure of mouse tumor necrosis factor, towards modulation of its selectivity and 
trimerisation (91). 
 
All known members of the TNF-alpha cytokine family induce hepatic expression of acute phase proteins. 
Acute, high dose exposure to TNF-alpha causes shock and tissue damage, catabolic hormone release, 
vascular leakage syndrome, adult respiratory distress disorder, gastrointestinal necrosis, acute renal tube 
necrosis, adrenal hemorrhage, decreased muscle membrane potentials, disseminated intravascular 
coagulation and fever. Chronic, low dose exposure to TNF-alpha has been associated with subendocardial 
inflammation, endothelial activation, protein catabolism, lipid depletion, insulin resistance and enhanced 
tumor cell reproduction. Sliwa et al. reported significantly higher plasma levels of TNF-alpha and 
interleukin-6 in PPCM patients as compared to age-matched healthy controls (92).  
One hypothetical advantage of treatment with anti-TNF-alpha antibodies results from its role in multiple 
types of inflammation. It is often difficult to determine that inflammation in burn and trauma victims are of 
 43
infectious aetiology and warrant treatment with antibiotics; therefore another treatment strategy might 
involve anti-TNF-alpha therapy (89). Strategies for preventing TNF-alpha activity include neutralization of 
the cytokine via either anti-TNF-alpha antibodies, soluble receptors, or receptor fusion proteins; suppression 
of TNF-alpha synthesis via drugs such as cyclosporine A, glucocorticoides, or  cytokine IL-10 and by 
inhibition of secondary mediators such as IL-1, IL-6 or nitric oxide (87). 
 
The rationale for using immuno-modulating agents to treat patients with heart failure is based on the fact that 
excessive enhancement of pro-inflammatory cytokines appears to mimic many aspects of the heart failure 
phenotype (93). Inflammatory cytokines have been shown to play a key role in the pathogenesis of 
atherosclerosis and coronary artery disease (94) and it has been suggested that sustained TNF-alpha 
expression after myocardial infarction and in persistent ischemia may have detrimental effects on the 
remodeling process (95). However, recent trials with anticytokine agents such as etanercept and infliximab 
showed time- and dose-dependent worsening of heart failure (93, 96, 97). These rather discouraging results 
may be explained by the mechanisms of action of these agents. Infliximab exerts its effects by fixing 
complement in cells (93), which in the heart is reported to lead to cardiac myocyte lysis (98). Etanercept 
stabilizes TNF-alpha and hence leads to an accumulation of TNF-alpha in the peripheral circulation (93). In 
comparison, the effects of pentoxifylline are to reduce the synthesis of TNF-alpha by blocking 
transcriptional activation (99, 100). Furthermore, pentoxifylline has been shown to inhibit apoptosis in 
different human cell types in vitro (101, 102) and in vivo (102). Hence, pentoxifylline is likely to be a more 
promising anticytokine agent. Indeed, Sliwa et al. were able to report on improvements in cardiac function 
with pentoxifylline (103), which were associated with reductions of inflammatory marker levels. These 
results were in line with their previous work performed in patients with idiopathic dilated cardiomyopathy 
(104-106). Plasma levels of NT-pro BNP have been used in several clinical trials to assess the efficacy of 
medical therapy (107). Sliwa et al. also observed reductions in NT-pro BNP in patients treated with 
pentoxifylline in a randomized study of patients with ischaemic cardiomyopathy (103) and were able to 
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confirm the efficacy of pentoxifylline in ischaemic heart failure. While pentoxifylline did not abolish 
increments in circulating TNF-alpha concentrations in patients, experimental studies have suggested that 
physiological levels of TNF-alpha have cytoprotective effects on the heart during ischaemic events (108, 
109). Although we are not aware of any large-scale study that has evaluated the safety of pentoxifylline in 
patients with heart failure, this pharmacological agent has been in clinical use for more than 25 years for 
conditions such as peripheral and cerebrovascular disease (110). Furthermore, because patients with 
peripheral vascular disease frequently also have coronary artery disease and heart failure, it is important to 
note that large trials with more than 10000 such patients have not reported increases in mortality in patients 
treated with pentoxifylline (110).  
Furthermore, beneficial effects of pentoxifylline have been reported in HIV-positive patients. Apoptosis is a 
significant cause of CD4 T cell death. Wanchu et al. demonstrated a significant decline of caspase 1 and 
caspase 8 that are involved in Fas/Apo-1 and TNF-alpha facilitated apoptosis in HIV-positive patients and 
concluded that this might result in reduced apoptosis and improved CD4 lymphocyte survival (111). The 
same group described a reduction of nitric oxide in HIV-1 positive patients after administration of 
pentoxiphylline (112). Swords et al. described an association between enhanced HIV replication and 
increased production of TNF-alpha. They observed partial inhibition of HIV-1 induction using pentoxifylline 
and matrix metalloproteinase (MMP) inhibitor I (113).  
Data on the effects of pentoxifylline in patients with PPCM is only available from small, non-randomised 
studies. Furthermore the impact of HIV-1 infection in PPCM and the potential beneficial effects of 
pentoxifylline have not been studied yet.  
 
1.5.2.7 Cardiac myocyte apoptosis  
Loss of myocytes due to apoptosis occurs in patients with end-stage cardiomyopathy and may contribute to 
progressive myocardial dysfunction (114), but its importance in pathogenesis is unknown. Transgenic mice 
with cardiac-restricted overexpression of G alpha(q) exhibit a lethal PPCM accompanied by apoptosis. 
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Hayakawa et al. demonstrated a reduction in cardiac myocyte apoptosis by caspase inhibition through 
administration of the polycaspase inhibitor IDN-1965 and improved left ventricular function and survival in 
pregnant G alpha(q) mice, suggesting that cardiac myocyte apoptosis plays a causal role in the pathogenesis 
of cardiomyopathy (115). Fas/APO-1 is an apoptosis signaling surface receptor, known to trigger cell death 
in a variety of cell types (116). Sliwa et al. observed significantly higher plasma levels of Fas/APO-1 in 
PPCM patients compared with healthy volunteers (92). 
 
1.5.2.8 Myocarditis 
Several lines of evidence suggest that PPCM may be the result of myocarditis due to a viral illness or an 
autoimmune aetiology (52, 117, 118). On the background of a relatively immunosuppressed state during 
pregnancy, susceptibility to cardiotrophic viruses is relatively higher than normal (119). The role of 
endomyocardial biopsy remains controversial and is likely to be clinically useful only if performed early in 
the course of the disease (52).  
Bultmann et al. detected viral genomes in endomyocardial biopsy specimen in eight of 26 PPCM patients 
(30,7%) but also in 10 of 33 control subjects (30,3%) (49). The detected viruses (PVB 19, HHV 6, EBV, 
HCMV) have been related to inflammatory cardiomyopathy but also have a high prevalence in healthy 
populations (50, 51). In this regard, it is important to note that myocarditis was identified in 29% of patients 
with peripartum cardiomyopathy (48) and in a separate study cardiac biopsy analysis of patients with PPCM 
showed  a high incidence of myocarditis (47). Kuhl et al. amplified viral genomes in endomyocardial 
biopsies of 165 (67.4%) among 245 patients with idiopathic dilated cardiomyopathy and found a similar 
spectrum of viruses (EV=9.4%, ADV=1.6%, PVB19=51.4%, HHV-6=21.6%, EBV=52.0%, HCMV=0.8%), 
including 45 cases (27.3%) with multiple infections (120).  
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1.5.2.9 Autoantibodies 
A possible association with antimyocardial antibodies has been suggested, although their aetiologic role for 
PPCM has not been demonstrated (121, 122). It is difficult to conclude from current literature if the presence 
of autoantibodies (AAB) in sera of patients with cardiomyopathy is result of the disease process or a cause. 
In more than half of 30 Haitian PPCM mothers, plasma autoantibodies were found. The targets of such 
autoantibodies include human cardiac myosin heavy chain (200 kDa), putative cardiac transaldolase (37 
kDa), putative cardiac myosin light chain (27 kDa) and yet unidentified 25 and 33 kDa cardiac proteins. It is 
uncertain if these AAB are merely secondary epiphenomena or if they could be directly contributing to 
cardiomyocyte injury. These autoantibodies were unique to PPCM patients and could not be detected in sera 
from controls or patients with other forms of cardiomyopathies (4, 29, 59, 123).  In contrast, a study from 
Niamey, Niger demonstrates the absence of a humoral autoimmunity process in PPCM (44).  
Case report The presence of a high titer of antiactin antibodies 9 months after the delivery supports the 
theory that the peripartum cardiomyopathy was of autoimmune aetiology (43). 
Additional evidence for an immune hypothesis comes from the presence of antimyosin antibodies, adenine 
nucleotide translocator (ANT), and branched-chain [alpha]-ketoacid dehydrogenase in patients with 
peripartum cardiomyopathy, in comparison with control subjects (1).  
All immunoglobulins of the G subclass are up-regulated in peripartum cardiomyopathy. Immunoglobulin 
G3–positive patients have a higher New York Heart Association (NYHA) class and more advanced 
symptoms at initial presentation (124). 
 
Pregnancy leads to structural, physiological, hormonal and immunological changes in healthy mothers to 
accommodate a healthy fetus and the mechanisms involved in the pathogenesis of PPCM have to be viewed 
in this context. Ansari et al. proposed that the dynamic balance between pregnancy, immune environment, 
fetal microchimerism and genetics is critical in determining the progression toward PPCM. Increased 
haemodynamic stress during late stage pregnancy leads to pregnancy induced hypertension (PIH) that 
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triggers myocyte hypertrophy and cardiac remodeling. Increasing levels of hormones such as progesterone, 
relaxin and estradiol during normal pregnancy promote vasodilatation and have been reported to buffer such 
pregnancy induced hypertension. Preliminary data suggest that reduced plasma levels of these three 
hormones in PPCM patients and thus a decreased buffering capacity against PIH, could result in the cardiac 
tissue pathology of PPCM patients. As a response to reparative maternal cardiac remodeling, fetal cells in 
the maternal circulation may be selectively recruited because of their undifferentiated characteristics and 
their potential to integrate into the host cardiac tissue. Ansari et al demonstrated significant increase in the 
levels of male genomic chromosomal DNA in PPCM patients relative to normal pregnancies, which further 
supports the opportunity for fetal microchimerism to play a role in the development of PPCM. During the 
cardiac remodeling process, fetal microchimeric stem cells under the influence of local cytokines and growth 
factors may differentiate into fetal dendritic cells (DCs). These would process maternal cardiac antigens and 
then migrate to regional lymph nodes where they present these self-antigens to maternal B- and T-helper 
cells in a different semi-allogeneic MHC context. As outlined above, plasma of PPCM patients contains 
autoantibodies that recognize unique cardiac antigens. The role of an abnormal immune environment in the 
development of autoimmune mediated PPCM is supported by significant differences in the cytokine 
potential and decrease in frequency of CD4/CD25 regulatory cells in the peripheral blood of PPCM patients 
(4).  
Wallukat et al. described the presence of agonist-like autoantibodies directed against the β 1-adrenoceptor 
and/or the muscarinic M2-receptor in sera of patients with idiopathic dilated cardiomyopathy and Chagas' 
disease. In patients with dilated cardiomyopathy the first as well as the second extracellular loop was 
identified as an antibody epitope. In Chagas' disease the anti-β 1-adrenoceptor antibody recognizes only one 
epitope on the second extracellular loop. The anti-β 1-adrenoceptor antibodies acting like the β-adrenergic 
agonist isoprenaline and exert a positive chronotropic effect in cultured rat cardiomyocytes. In contrast to 
isoprenaline the antibody caused no downregulation of the β-adrenergic signal transduction cascade within 
six hours. The anti-M2 receptor antibodies recognize in both diseases an epitope on the second extracellular 
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loop. The anti-M2-receptor antibody exerts a negative chronotropic response in cultured cardiomyocytes. 
This antibody induced no downregulation of the muscarinic M2-receptor. The negative chronotropic effect 
was unabated for 6 hours. Based on these findings it is believed that the agonist-like autoantibodies acting 
against the β 1-adrenoceptor and the muscarinic M2-receptor may play a role in the pathogenesis of dilated 
cardiomyopathy and Chagas' disease (125).  
We therefore analysed serum of PPCM patients for agonist-like autoantibodies directed against the β 1-
adrenoceptor and correlated these with the kinetics of clinical improvement or lack thereof in chapter six of 
this thesis.  
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1.5.2.10 Infectious disease agents 
A number of infectious disease agents have long been suspected to be involved in the pathogenesis of 
PPCM. This includes  a  study from Niamey, Niger that reported  a relationship between enterovirus 
infection and PPCM (32). It has been suggested that such patients might be suffering from a quiescent heart 
muscle disease from a previous viral myocarditis and that stress induced volume overload was sufficient to 
trigger the disease process  (35). Others have reported a correlation of PPCM with sexually transmitted 
diseases (36) including Chlamydia pneumoniae (37). Latent viral myocarditis has been reported as a risk 
factor for PPCM in a study from Sahelian Africa (11). In light of such a view, Sainani et al. reported a virus 
aetiology of heart disease that was supported  by the successful isolation of one of the subtypes of Coxsackie 
B virus in 19 out of 55 patients (126). However, only one of these patients had PPCM.  
Ansari et al. performed extensive polymerase chain reaction and in situ hybridization studies of cardiac 
tissues explanted from PPCM, IDCM and non-PPCM, non-IDCM patients trauma cases and found similar 
transcripts in about the same frequency in all patients. In another effort by the same investigators no 
significant evidence of mycobacteria, helicobacter, archaeobacter or eubacteria was detected in cardiac 
tissues of PPCM patients.  
Ansari et al. hypothesized that immune responses against virus infected cardiomyocytes prompt lysis of such 
cells, leading to exposure of the immune system to intracellular cardiac tissue proteins. These are normally 
sequestered from the immune system against which self-tolerance was not achieved and hence such proteins 
now serve as neo-antigens and the autoimmune process becomes initiated, explaining the presence of 
antibodies against intracellular cardiac tissue proteins in sera of patients with PPCM (4).  
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1.5.2.11 Genetic factors 
Genetic factors have been implicated to play a role in a number of autoimmune diseases. This was 
underlined by the documentation of a significantly higher incidence of diseases such as primary biliary 
cirrhosis in monozygotic twins than expected in the population in which the study was performed. Individual 
familial cases of PPCM have been reported (8), but altogether there are few reports on familial occurrence of 
PPCM (46). It has been suggested that PPCM is due to familial DCM  which becomes unmasked by 
pregnancy (4). Fett et al. have reported a case of PPCM in a mother and her daughter in Haiti (29). Most of 
the attention has been paid to a role for MHC genes and susceptibility to autoimmune diseases, including 
experimental autoimmune encephalomyelitis, IDDM and rheumatoid arthritis. It appears that not only MHC 
but also sets of other non-MHC genes likely play a role. This includes genes encoded by 6p21, genes 
encoded by chromosomes 5 and 19 and polymorphisms for genes encoding for a number of cytokines, 
chemokines and/or promoters of such cytokines and chemokines (4).  
 
STAT3 (one of a family of signal transducer and activators of transcription) was initially identified as APRF 
(acute-phase response factor), an intracellular DNA-binding protein that binds to interleukin 6 (IL-6)-
responsive elements. Subsequently, it has been shown that STAT3 is activated by the entire family of IL-6–
related cytokines, peptide growth factors, and hormones (127-129). Although initially considered to be a 
mere target gene of the IL-6–mediated inflammatory response, STAT3 is by now known to direct a wide 
variety of biologic processes, such as cell survival and apoptosis, inflammation, angiogenesis, and cardiac 
hypertrophy (129-131).  
Experimental studies indicate that IL-6-related cytokines, signaling via the shared receptor gp130, and the 
Janus kinase (JAKs) - STAT pathway, provide a critical cardiomyocyte survival pathway in vivo in normal 
healthy conditions. Podewski et al. found that signaling via gp130 and JAK-STAT is profoundly altered in 
DCM. Importantly, tyrosine-phosphorylation of JAK2 is reduced in the face of increased gp130 
phosphorylation, indicating impaired downstream activation of this critical pathway in DCM  (132).  
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 STAT-3 participates in a wide variety of physiological processes and directs seemingly contradictory 
responses such as proliferation and apoptosis (133). The constitutive activation of STAT3 promotes tumor 
growth and angiogenesis and is associated with drug resistance in cancer therapy. In contrast, in the heart, 
the down-regulation of STAT3 has been associated with end-stage heart failure in patients (132).  
Osugi et al. provided the first evidence that activation of STAT3 controls vessel growth in vivo and suggests 
that STAT3 contributes to cardiac adaptation by regulating vascular function under the conditions of stress 
(134). Giordano et al. established the critical importance of cardiac myocyte-derived vascular endothelial 
growth factor in cardiac morphogenesis and determination of heart function (135), suggesting that VEGF 
may be an important target gene mediating pro-angiogenic effects of STAT3. To elucidate the role of 
STAT3 in cardiac muscle and in particular for cardiac protection against physiological and 
pathophysiological stresses, Hilfiker-Kleiner et al. generated mice harbouring a cardiomyocyte-restricted 
knockout of STAT3 using the standard Cre/loxP-regulated gene knock out ( KO ) system. STAT3-deficient 
mice developed reduced myocardial capillary density and increased interstitial fibrosis within the first four 
postnatal months, followed by dilated cardiomyopathy with impaired cardiac function and premature death. 
Conditioned medium from STAT3-deficient cardiomyocytes generated in vitro inhibited endothelial cell 
proliferation and increased fibroblast proliferation, suggesting the presence of paracrine factors attenuating 
angiogenesis and promoting fibrosis in vitro. Hilfiker-Kleiner et al. thus established a novel role for STAT3 
in controlling paracrine circuits in the heart, essential for postnatal capillary vasculature maintenance, 
interstitial matrix deposition balance, and protection from ischaemic injury and heart failure (133, 136).  
STAT3 KO mice displayed an upregulation of CTGF, an endogenous inhibitor of VEGF activity (137) and 
increased expression levels of  TSP1, which suppresses capillary formation by inhibiting VEGF release and 
inducing endothelial cell apoptosis (133, 138, 139). Moreover expression of the potent anti-angiogenic factor 
TIMP1 was augmented in STAT3 KO hearts (133, 140). In short, one could say that STAT3 suppresses an 
anti-angiogenic gene program in the adult heart (141).  
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While studying the STAT-3 KO mice, Hilfiker et al. not only observed the upregulation of CTGF, TSP1 and 
TIMP1, but also OPN, TNC and PAI-1. These antiangiogenic factors are also involved in the formation of 
interstitial matrix (142, 143), which is consistent with the profibrotic state in these animals. Vice versa there 
is evidence that enhanced interstitial matrix formation inhibits angiogenesis (144). This supports the concept 
that the anti-angiogenic and profibrotic cardiac phenotypes of KO mice are mediated, at least in part, by 
overlapping paracrine mechanisms. Alternative explanations for the enhanced fibrosis in the STAT-3 KO 
myocardium, such as replacement fibrosis caused by myocyte loss as a result of decreased myocardial blood 
supply or oxidative stress secondary to tissue hypoxia / ischaemia driving fibrosis have also been forwarded 
(133). In this regard, it is important to note that the development of severe cardiac fibrosis in aging STAT-3 
KO mice was shown to be associated with impaired cardiac function, increased apoptosis, ventricular 
remodeling, and heart failure with generalized oedema and enhanced mortality (i.e. typical features noted in 
patients with dilated cardiomyopathy and end-stage heart failure). Hilfiker et al. have shown that the 
expression of both, total and phosphorylated STAT3 protein, are markedly reduced in failing human hearts. 
Therefore it is conceivable that reduced STAT3 expression and activation in patients with heart failure 
adversely affects fundamental cardioprotective mechanisms (in analogy to what is observed in KO mice), 
thereby contributing to the progression of heart failure (133). It is therefore not an unexpected finding that 
cardiomyocyte specific deletion of STAT3 impairs cardiac response to neurohormonal activation, ischaemia, 
doxorubicin treatment and bacterial toxins, functioning to interfere directly with pathways involved with 
cytoprotective effects (133).  
In summary, the extent of angiogenesis in vivo depends on the local balance between proangiogenic and 
antiangiogenic molecules, whereby paracrine and autocrine circuits in cardiomyocytes and endothelial cells 
play a crucial role. In this setting, STAT3, in its function as a signaling molecule and an enhancer or 
repressor of gene transcription, appears to play a central role in regulating angiogenesis in the postnatal heart 
under physiologic and pathophysiological conditions (141).  
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1.5.2.12 Nutritional deficiencies 
Walsh described the nutritional background of his patients as being extremely deficient, particularly in 
conjunction with multiparity and in most cases sequential pregnancies (8).  
A role of nutritional deficiency in PPCM was supported by a study conducted in Niamey (Republic of 
Niger): Plasma albumin and pre-albumin levels were lower in patients with PPCM than they were in controls 
(P < 0.001). For retinol binding protein, the difference was not statistically significant. The plasma 
concentrations of selenium and zinc were lower in patients than they were in controls (48±25 versus 77±16 
ng/ml and 0.90±0.21 versus 1.17±0.25 micrograms/ml, respectively, P < 0.001) whereas that of copper was 
higher (2.03±0.37 versus 1.23±0.20 micrograms/ml, P < 0.001). The mean plasma zinc: copper ratio was 
lower in patients than controls (0.44 versus 0.95). It was concluded from these studies that such differences 
might be aetiological factors or biological consequences of the peripartum cardiac failure due to 
cardiomyopathy. Nutritional abnormalities were thus reasoned to  play a role in the pathophysiology of the 
disease (145). 
In a more recent study from Haiti on the other hand, Fett et al. report that neither a macronutrient deficiency 
(protein and iron) nor a micro-nutrient deficiency (vitamin A, vitamin B-12, vitamin C, vitamin E, β-
carotene or selenium) played a significant role in the high incidence and prevalence of PPCM in the Haitian 
population, concluding that future studies of PPCM in this population should focus on other potential 
aetiologic and risk factors (29, 146). 
Thus while poor nutrition was initially thought to be associated with the development of PPCM (24),  
several more recent reports suggest caution in the interpretation of these data  (29, 30). Differences in the 
nutritional status based on the geographical location of the population needs to be considered within this 
context. 
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1.6 Clinical Presentation and Diagnosis 
1.6.1 Physiologic features 
Normal pregnancy is associated with an expansion of blood volume, an increase in metabolic demands, 
relative anaemia and changes in vascular resistance that are associated with ventricular dilatation and 
increase in cardiac output. These physiologic changes are due to an increase in preload and heart rate 
accompanied by a decrease in afterload, peaking during the second trimester of pregnancy. Decompensation 
of patients with subclinical valvular, ischaemic or myopathic heart disease usually occurs during this time. 
The early stage of PPCM can easily be missed, because many symptoms and signs of pregnancy are similar 
to those of early congestive heart failure (e.g. dyspnoea, abdominal discomfort, fatigue) (6, 147). Elkayam et 
al. report that 7% of their US patients were diagnosed within one month before delivery and 75% of patients 
were diagnosed during the first month postpartum (5) while Sliwa et al. observed onset of symptoms in 
South African patients primarily during the postpartum period (92, 148), which is in accordance with 
findings by Fett et al. in Haitian patients (14, 149). The symptoms and signs are similar to those in patients 
with idiopathic dilated cardiomyopathy (9) and can be complicated by thromboembolic events and 
arrhythmia. Echocardiography usually demonstrates features of dilated cardiomyopathy (DCM) with 
impaired ejection fraction, global dilatation and sometimes thinned out walls.   
 
1.6.2 Symptoms and signs 
The symptoms and signs are similar to those in patients with idiopathic dilated cardiomyopathy (9). Patients 
uniformly present with signs and symptoms of left heart failure (8). On physical examination one usually 
finds a young woman in moderate to severe respiratory distress and elevated jugular venous pressure. The 
heart is enlarged and there is an active left ventricular impulse. A left parasternal impulse due to an enlarged 
right ventricle may also be present. On auscultation a holosystolic murmur representing mitral and 
sometimes also tricuspid incompetence may be present. The murmur usually disappears as cardiac function 
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improves. In some patients mitral regurgitation persists and may be due to cardiomyopathic involvement of 
the papillary muscles (150).  
Peripheral oedema and upper abdominal discomfort (congested liver) are present in 50% of the cases. Chest 
pain occurs in half of the women and might in some instances be due to pulmonary embolism (151). As a 
rule, the presence of ascites has not been noted during the earlier phases of the initial episode of cardiac 
insufficiency (8). Patients are usually in regular sinus rhythm although some complain of palpitations. 
Haemoptysis may be the presenting feature of pulmonary embolus, to which these patients are particularly 
predisposed (23).  
Walsh et al. observed a high incidence of colicky, severe, persistent abdominal pain. With return of cardiac 
compensation these symptoms generally subsided, although they tended to persist to a mild degree for many 
months without demonstrable congestive heart failure or intrinsic gastrointestinal disease (8).  
Non-specific palpitations, chest pain and abdominal pain are common and tend to contribute to some 
confusion during the initial clinical evaluation. The use of the New York Heart Association functional 
classification is confounded by simultaneously occurring signs and symptoms of normal pregnancy and may 
not reflect the severity of underlying cardiac dysfunction (152). Table 1.6.2 provides a summary of the 
frequency by which some of these symptoms are noted in PPCM patients.  
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Symptoms Signs Percentage of patients 
Dyspnoea Increased jugular venous 
pressure 
60% 
Cough Cardiomegaly 100% 
Orthopnea Third heart sound 100% 
Oedema Pulmonary rales 60% 
Paroxysmal nocturnal 
dyspnoea 
Loud pulmonic valve 
component of second heart 
sound 
93% 
Fatigue Mitral and/or tricuspid 
regurgitation, peripheral 
oedema 
60% 
Palpitations Arrhythmias 7% 
Haemoptysis Embolic phenomena,  26% 
Chest pain Embolic phenomena 50% 
Abdominal pain Hepatomegaly,  
Ascites 
67% 
47% 
Table 1.3: Symptoms and signs in patients with PPCM (6, 8, 10, 23) 
 
The chest X-ray usually shows cardiomegaly (23). The left ventricle is consistently enlarged and there may 
be left atrial enlargement as well (10). Pulmonary venous congestion and bibasilar infiltrates are commonly 
seen (8, 18, 23, 151). Serial thoracic teleroentgenograms with barium in the oesophagus in all patients 
initially show generalized cardiomegaly involving all four chambers. In 1/3 of the  patients a double shadow 
ascribable to left atrial enlargement  has been  noted on postero-anterior views of the chest (8).  
The electrocardiogram (ECG) usually does not demonstrate any major abnormalities (30). The ECG often 
shows non-specific findings such as tachycardia and non-specific ST-T wave changes.  
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1.6.3 Echocardiographic studies 
Geva et al. performed systematic echocardiographic assessment of the haemodynamics in normal 
pregnancies and demonstrated a 10% increase in left ventricular end-diastolic volume, a 45% increase in 
cardiac output, and a 26% to 28% decrease in end-systolic wall stress. In addition, the left ventricle remodels 
in response to the haemodynamics of pregnancy, resulting in transient hypertrophy (76).  
The echocardiogram usually shows a dilated left ventricle with marked impairment of overall systolic 
performance (30, 45). Sliwa et al. observed a diastolic restrictive pattern in 21 of 29 patients at presentation 
(92). In addition, regional heterogeneities in systolic wall thickening, a B notch on M-mode tracing, mitral 
regurgitation, atrial enlargement and a small haemodynamically insignificant pericardial effusion may be 
noted. In approx. 25% of patients left ventricular thrombi were diagnosed by echocardiography (92). A 
fractional shortening value less than 20% and a left ventricular end diastolic dimension 6 cm or greater at the 
time of diagnosis was associated with a more than 3-fold higher risk for persistent left ventricular 
dysfunction. Along with being an important diagnostic tool in PPCM, echocardiography may provide 
significant prognostic information with regards to recovery of cardiac function (153). 
In patients presenting with PPCM, inotropic contractile reserve during dobutamine stress echocardiography 
accurately correlates with subsequent recovery of LV function and confers a benign prognosis (154). 
 
1.6.4 Tissue studies 
During autopsy the heart of PPCM patients is usually soft and grossly enlarged (350-650g) with dilatation of 
all four chambers (8, 10). Specimens demonstrate paleness of the myocardium. Although ventricular mural 
thrombi are often seen, there is no evidence of detectable coronary artery, valvular or pericardial disease. 
Endocardial thickening and pericardial fluid have been noted occasionally (8, 10, 23, 24, 151, 152, 155). No 
vascular changes of hypertension have so far been seen (23).  
In 1971 Demakis et al. performed thoracotomy for myocardial and pericardial biopsies. Results of these 
studies showed that the pericardium appeared normal. The most prominent findings in these myocardial 
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biopsies were hypertrophy of myocardial fibers and varying degrees of fibrosis (23). Other authors 
demonstrated non-specific myofiber hypertrophy, myofiber degeneration, fibrosis, interstitial oedema and 
occasionally lymphocytic infiltration in antemortem biopsy specimens (18, 156, 157).  
Electron microscopic studies of sections of the myocardium in congestive cardiomyopathy show an increase 
in the number and size of mitochondria, presence of dense intra-mitochondrial inclusions, fragmentation of 
the cristae, varying degrees of myofibrillar destruction, fragmentation of sarcoplasmatic reticulum, increased 
number of lipofuscin granules and increased glycogen deposition. Electron microscopic studies of 
myocardial sections from a patient with PPCM showed essentially similar results (158, 159). Histochemical 
studies have shown an increased deposition of neutral lipid deposits in the myofibrils and a decrease in 
myocardial oxidative enzymes, especially succinic dehydrogenase activity. Variable areas of interstitial 
fibrosis and areas of muscle degeneration were seen dispersed throughout the myocardium (8). 
All patients exhibited severe chronic passive congestion of the lungs and intraabdominal organs. 
Microscopically all hearts demonstrated significant variation in fiber size and oedematous and partially 
hyalinised fibers which were interspersed irregularly. Variable areas of fibrosis were seen throughout. The 
presence of inflammatory cells was highly variable. The amount of lipofuscin granules was within normal 
limits. The number of mast cells per unit area of PPCM tissue examined appeared to be similar to that seen 
in similar tissues from otherwise normal donors using cresyl violet stain. No detectable levels of 
metachromasia or accumulation of PAS-positive material was found. There was little fatty acid change 
except in areas with heavy deposition of relatively large fat droplets. Such areas correspond to those with 
diminished or absent succinic dehydrogenase and cytochrome oxidase activity. Walsh et al. interpreted these 
changes as evidence of mitochondrial damage with resulting impairment of oxidation of lipids which 
therefore accumulate. There were individual fibers with diminished succinic dehydrogenase reaction and no 
lipid droplets as well as others with normal enzymatic reactions and small lipid droplets. All fibers 
containing fat droplets demonstrated a very reduced response for both oxidative enzymes. These changes 
were strikingly different from those seen in alcoholic cardiomyopathy (8).  
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Other authors found that pathologic studies of cardiac tissues have so far failed to identify any significant 
difference between PPCM and other forms of primary congestive cardiomyopathy. However, it should be 
stressed that specimens of myocardium that have been studied were obtained several months to several years 
after the onset of the disease (10). It is important to note, however, that a case for the presence of 
inflammation within cardiac tissues of PPCM patients has been made by a number of studies. Thus, a study 
of cardiac tissues obtained at autopsy from three PPCM patients from Haiti, demonstrated  an inflammatory 
infiltrate consisting of mononuclear cells including T-lymphocytes (CD 8) and monocyte/macrophage 
lineage cells (CD 68) in one patient. Cardiac tissues from the second patient showed non-specific changes in 
the myocardium similar to those that may be seen in dilated cardiomyopathy of various aetiologies, 
including PPCM. The third patients cardiac tissue additionally showed areas of interstitial fibrosis, 
highlighting the difficulty of finding focal myocarditis in limited autopsy tissue (123).  
Similarly several additional studies have reported an inflammation of the myocardium which was shown to 
be sometimes associated with pericarditis and demonstrated histological evidence of myocarditis on 
endomyocardial biopsy samples (52, 118, 160).  
One of these studies reported from the Stanford University Medical Centre which involved a  retrospective 
review of endomyocardial biopsy specimens from 34 patients with PPCM reported an incidence comparable 
to that found in age- and sex-matched controls (118).  
Bultmann et al. detected viral genomes in endomyocardial biopsy specimen in eight of 26 PPCM patients 
(30.7%) but also in 10 of 33 control subjects (30.3%) (49). The detected viruses (PVB 19, HHV 6, EBV, 
HCMV) have been related to inflammatory cardiomyopathy but also have a high prevalence in healthy 
populations (50, 51). A study by Sanderson et al. of EMB in 11 African women with PPCM in Nairobi were 
consistent with healing myocarditis in 5 patients (161).  
In a study from Johns Hopkins Hospital myocarditis was demonstrated in EMB specimens in 14 of 18 
patients with newly diagnosed PPCM. Of these, 10 were treated with immunosuppressive therapy. Nine of 
the 10 treated patients with myocarditis had subjective and objective improvement. Follow-up 
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endomyocardial biopsies in these patients showed resolution or substantial improvement in myocarditis. 
Four patients with myocarditis not treated with immunosuppressives also improved. The role of 
endomyocardial biopsy remains controversial and is likely to be clinically useful only if performed early in 
the course of the disease (52).  
 
Picture 1.2: Exterior aspect of the globally dilated heart of a patient with PPCM (162) 
 
Picture 1.3: Interior aspect of the globally dilated heart of a patient with PPCM (163) 
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1.7 Current therapeutic approaches towards heart failure in PPCM 
1.7.1 Treatment of acute heart failure in PPCM 
Treatment is directed toward symptomatic relief and improvement of cardiac function and similar to other 
forms of congestive heart failure. The maintenance of a SaO2 within the normal range (95-98%) is important 
to maximize oxygen delivery to the tissues and tissue oxygenation, thus helping to prevent end-organ 
dysfunction and multiple organ failure. This is best achieved by first ensuring that there is a patent airway 
and then by administration of an increased FiO2. Endotracheal intubation is indicated if these measures fail 
to improve tissue oxygenation. The use of CPAP and NIPPV in acute cardiogenic pulmonary oedema is 
associated with a significant reduction in the need for tracheal intubation and mechanical ventilation. 
Respiratory muscle fatigue is the most frequent reason for endotracheal intubation and mechanical 
ventilation in AHF. It may be diagnosed by decreased respiratory rate associated with hypercapnia and a 
confused state of mind. Invasive mechanical ventilation should only be used if acute respiratory failure does 
not respond to vasodilators, oxygen therapy and/or CPAP or NIPPV (164).  
Morphine is indicated in the early stage of treatment of patients with severe AHF, especially if associated 
with restlessness and dyspnoea. Morphine induces venodilation and mild arterial dilatation and reduces heart 
rate. Anticoagulation should be initiated unless contraindicated to avoid both, venous and arterial 
thromboembolic events. Careful monitoring of INR and PTT is advised since autoanticoagulation due to 
hepatic congestion may be present.  
Vasodilators are indicated as first line therapy if hypoperfusion is associated with an adequate blood pressure 
and signs of congestion with low diuresis, to open the peripheral circulation and to lower pre-load.  
Angiotensin converting enzyme (87)-inhibitors are not indicated in the early stabilization of patients with 
HF. Administration of diuretics is indicated in the presence of symptoms secondary to fluid retention. There 
has been no study with β-blocker therapy in AHF targeted to acutely improve the condition. On the contrary 
AHF has been considered a contraindication for this treatment.  
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It is important to note that management will differ in women who are still pregnant since the threshold to 
perform X-rays or a CT scan will be much higher. Before the administration of drugs, contra-indications 
during pregnancy need to be observed.  
In patients with chronic heart failure, β-blockers should be initiated when the patient has stabilized after the 
acute episode (usually after 4 days). Inotropic agents are indicated in the presence of peripheral 
hypoperfusion (hypotension, decreased renal function) with or without congestion or pulmonary oedema 
refractory to diuretics and vasodilators.  
Temporary mechanical circulatory assistance may be indicated in patients with AHF who are not responding 
to conventional therapy and where there is a potential for myocardial recovery or as a bridge to heart 
transplantation or interventions that may result in significant recovery of the heart function (intra-aortic 
balloon pump, left ventricular assist device) (164). In clinical experience, PPCM often shows remarkable 
spontaneous improvement. The decision for heart transplantation should therefore only be made very 
carefully, after all other options have been exhausted and sufficient time for recovery has been allowed.  
Cardiac transplantation has been performed successfully in PPCM patients. Favourable outcomes have been 
attributed to the young age of the recipients and to the recent onset of heart failure, resulting in minimal end-
organ damage. In view of the success that has been achieved by transplantation in these young and otherwise 
healthy mothers, aggressive measures such as temporary life support in form of cardiopulmonary bypass or a 
left ventricular assist device until availability of transplant (165) have been advocated. 
 
1.7.2 Treatment of chronic heart failure in PPCM 
Angiotensin-converting enzyme-inhibitors are recommended as first-line therapy in patients with a reduced 
left ventricular systolic function less than 40-45% with or without symptoms (166), but are contraindicated 
during pregnancy because of teratogenicity (1). Vasodilator therapy reduces afterload and improves cardiac 
output, resulting in a reduction in left ventricular end-diastolic pressure and a decrease in pulmonary and 
systemic vascular resistances. Godsel et al. view an ACE-inhibitor as the most valuable medication, not only 
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because of it's direct beneficial effects on the heart but also because of it's potential benefit to interrupt the 
chain of events in the pathobiology of PPCM (167). ACE-inhibitors should be uptitrated to dosages shown to 
be effective in the large controlled trials in heart failure and not on symptomatic improvement alone.  
Diuretics are essential for symptomatic treatment when fluid overload is present and manifest as pulmonary 
congestion or peripheral oedema, but their use should be carefully considered during pregnancy. In patients 
with chronic heart failure diuretics should be administered in combination with ACE-inhibitors and β-
blockers if tolerated.  
Β-blockers should be considered for treatment of all patients with stable, mild, moderate and severe heart 
failure, unless there is a contraindication. Β-blocker therapy reduces hospitalizations, improves the NYHA 
functional class and leads to less worsening of heart failure. The initial dose should be low and increased 
slowly and progressively to the target dose used in  the large clinical trials (166). Carvedilol reduces the risk 
of death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure. 
Vasodilating β-blockers such as carvedilol also reduce afterload through alpha-1 adrenergic blockade. Lowes 
et a. reported functional improvement in IDCM patients related to treatment with β-blockers and an 
association with changes in myocardial gene expression. Β-blocker treated patients who improved left 
ventricular ejection fraction had an increase in sarcoplasmatic reticulum calcium ATPase mRNA and alpha-
myosin heavy chain mRNA and a decrease in β-myosin heavy chain mRNA (168). Up-titration should be 
adapted to individual responses. Aldosterone receptor antagonists are recommended in addition to ACE-
inhibitors, β-blockers and diuretics in advanced heart failure (NYHA III-VI) with systolic dysfunction to 
improve survival and morbidity. In the RALES study, low doses of aldactone, added to standard of care for 
severe heart failure, improved survival by 30% and lowered hospitalization by 35% (169). Angiotensin II 
receptor blockers (ARB) can be used as an alternative to ACE-inhibition in symptomatic patients intolerant 
to ACE-inhibitors to improve morbidity and mortality, but are also contra-indicated during pregnancy.  
Digoxin therapy is associated with an increased risk of death from any cause among women with heart 
failure and depressed left ventricular systolic function (170).  Retrospective analysis of data from the DIG 
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trial indicates a beneficial effect of digoxin on morbidity and no excess mortality in women at serum 
concentrations from 0.5 to 0.9 ng/ml, whereas serum concentrations > or =1.2 ng/ml seem harmful (171). 
Ahmed et al. found lower hospitalisation rates without increasing odds for death among women with heart 
failure and left ventricular ejection fraction below 35% with serum digoxin concentrations between 05 – 1.1 
ng/ml. Negative outcome was documented in women with higher serum digoxin concentrations or higher 
LVEF (172).  
Digoxin is a class C drug and should be avoided during pregnancy. While ACE-inhibitors and ARB's are 
contra-indicated during pregnancy, hydralazine might be the vasodilator of choice although controversy 
exists (173). Among the vasodilators, nitrates are another alternative during pregnancy. It is important to 
note that venous therapeutic modalities mentioned in the article have never been studied specifically in 
PPCM patients but in DCM patients.  
Thromboembolic phenomena have been reported in PPCM patients.  Pregnant patients are at increased risk 
of thromboembolic complications due to the hypercoagulable state of late pregnancy that may persist up to 
six weeks postpartum. Left ventricular systolic dysfunction resulting in blood stasis, additionally predisposes 
patients to develop left ventricular, pulmonary and cerebral thrombemboli. The decision for anticoagulation 
should be made after careful consideration, that should include dilated left ventricular dimensions and low 
ejection fraction. It is important to stress that not all PPCM patients need to be anticoagulated. During the 
last weeks of pregnancy low-molecular heparin is the agent of choice while warfarin is preferred postpartum.  
The need for early delivery and the mode of delivery should be assessed through collaboration between 
obstetricians, cardiologists and anesthesiologists (1). If possible, pregnancy should be permitted to continue 
to term in PPCM patients diagnosed during the last month of gestation. Urgent delivery of the fetus may be 
considered for patients who present with advanced heart failure with haemodynamic instability. Patients 
with adequate cardiac output may tolerate induction and vaginal delivery. Critically ill patients who require 
inotropic therapy or mechanical support should undergo caesarean delivery 
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1.7.3 Immunomodulatory therapy  
Stress-activated pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) or interleukin 
1 (IL-1) have been implicated in the pathophysiology of idiopathic dilated cardiomyopathy (84). TNF-alpha 
is a pleiotropic inflammatory cytokine and serves a variety of functions, many of which are not yet fully 
understood. The cytokine possesses both growth stimulating properties and growth inhibitory processes, and 
it appears to have self regulatory properties as well. For instance, TNF-alpha induces neutrophil proliferation 
during inflammation, but it also induces neutrophil apoptosis upon binding to the TNF-R55 receptor (85). 
TNF-alpha is a 26 kDa protein and is produced by many different cell types. The main sources in vivo are 
stimulated monocytes, fibroblasts, and endothelial cells. Macrophages, T-cells and B-lymphocytes, 
granulocytes, smooth muscle cells, eosinophils, chondrocytes, osteoblasts, mast cells, glial cells and 
keratinocytes also stimulate production of TNF-alpha. Glioblastoma cells constitutively produce TNF-alpha 
and the factor can be detected also in the cerebrospinal fluid. Human milk also contains TNF-alpha. 
Physiological stimuli for the synthesis of TNF-alpha are IL-1, bacterial endotoxins, PDGF and Oncostatin 
M. In fibroblasts the synthesis of TNF-alpha is stimulated by IFN-β, TNF-alpha, PDGF and viral infections. 
In thymic stromal cells the synthesis of TNF-alpha can be induced by NGF. TNF-alpha can also stimulate or 
inhibits its own synthesis, depending upon the cell type. In epithelial, endothelial, and fibroblastic cells 
secretion of TNF-alpha is induced by IL-17. 
 
Beneficial functions of TNF-alpha include its role in the immune response to bacterial, and certain fungal, 
viral, and parasitic invasions as well as its role in the necrosis of specific tumors.  TNF-alpha acts as a key 
mediary during local inflammatory immune response. It is an acute phase protein which initiates a cascade 
of cytokines and increases vascular permeability, thereby recruiting macrophage and neutrophils to a site of 
infection.  TNF-alpha secreted by the macrophage causes blood clotting which serves to contain the 
infection.  Without TNF-alpha, mice infected with gram-negative bacteria experience septic shock (86). 
Tracey and Cerami suggest that low levels of TNF-alpha may aid in maintaining homeostasis by regulating 
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the body's circadian rhythm and that low levels of TNF-alpha promote the remodeling or replacement of 
injured and senescent tissue by stimulating fibroblast growth (87). The pathological activities of TNF-alpha 
include the promotion of growth of certain tumor cells, although it causes necrosis of other types of tumors.  
High levels of TNF-alpha correlate with increased risk of mortality (88). TNF-alpha participates in disorders 
of inflammatory and non-inflammatory origin (89). Originally sepsis was believed to result directly from the 
invading bacteria itself, but it was later recognized that host system proteins, such as TNF-alpha induce 
sepsis in response. Exogenous and endogenous factors from bacteria, viruses, and parasites stimulate 
production of TNF-alpha and other cytokines. Lipopolysaccharide from bacteria cell walls are a potent 
stimulus for TNF-alpha synthesis (87). TNF-alpha exhibits acute and chronic effects. If TNF-alpha remains 
in the body for a long time, it loses its anti tumor activity.  This can occur due to cytokine polymerization, 
shedding of TNF-alpha receptors by tumor cells, excessive production of anti-TNF antibodies, found in 
patients with carcinomas or chronic infection, and disruptions in the alpha-2 macroglobulin proteinase 
system which may deregulate cytokines. Prolonged overproduction of TNF-alpha results in cachexia. 
Cachectin and TNF-alpha were once considered different proteins, but in 1985 researchers discovered that 
the two proteins were homologous (90).  
All known members of the TNF-alpha cytokine family induce hepatic expression of acute phase proteins. 
Acute, high dose exposure to TNF-alpha causes shock and tissue damage, catabolic hormone release, 
vascular leakage syndrome, adult respiratory distress disorder, gastrointestinal necrosis, acute renal tube 
necrosis, adrenal hemorrhage, decreased muscle membrane potentials, disseminated intravascular 
coagulation, fever. Chronic, low dose exposure to TNF-alpha has been associated with subendocardial 
inflammation, endothelial activation, protein catabolism, lipid depletion, insulin resistance and enhanced 
tumor cell reproduction.  
Sliwa et al. reported significantly higher plasma levels of TNF-alpha and interleukin-6  in PPCM patients as 
compared to age matched healthy controls (92). One hypothetical advantage of treatment with anti-TNF-
alpha antibodies results from its role in multiple types of inflammation. It is often difficult to determine that 
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inflammation in burn and trauma victims are of infectious aetiology and warrant treatment with antibiotics. 
Therefore another treatment strategy might involve anti-TNF-alpha therapy (89). Strategies for preventing 
TNF-alpha activity include neutralization of the cytokine via either anti-TNF antibodies, soluble receptors, 
or receptor fusion proteins, suppression of TNF-alpha synthesis via drugs such as cyclosporine A, 
glucocorticoides, or  cytokine IL-10 and by inhibition of secondary mediators such as IL-1, IL-6 or nitric 
oxide (87). 
 
The rationale for using immunomodulating agents to treat patients with heart failure is based on the fact that 
excessive enhancement of pro-inflammatory cytokines appears to mimic many aspects of the heart failure 
phenotype (93). In addition, inflammatory cytokines have been shown to play a key role in the pathogenesis 
of atherosclerosis and coronary artery disease (94) and it has been suggested that sustained TNF-alpha 
expression after myocardial infarction and in persistent ischemia may have detrimental effects on the 
remodeling process (95). However, recent trials with anticytokine agents such as etanercept and infliximab 
showed time- and dose-dependent worsening of heart failure (93, 96, 97). These rather discouraging results 
may be explained by the mechanisms of action of these agents. Infliximab exerts its effects by fixing 
complement in cells (93), which in the heart is reported to lead to cardiac myocyte lysis (98). Etanercept 
stabilizes TNF-alpha and hence leads to an accumulation of TNF-alpha in the peripheral circulation (93).  
In comparison, the effects of pentoxifylline are to reduce the synthesis of TNF-alpha by blocking 
transcriptional activation (99, 100). Furthermore, pentoxifylline has been shown to inhibit apoptosis in 
different human cell types in vitro (101, 102) and in vivo (102). Hence, pentoxifylline is likely to be a more 
promising anticytokine agent. Indeed, Sliwa et al. were able to demonstrate improved outcome in PPCM 
patients who received pentoxifylline in addition to standard heart failure therapy. In a non-randomised, 
single-centre study with 59 prospectively enrolled PPCM patients the composite end-point of poor outcome 
(either death, NYHA FC III or IV at latest follow-up and/or failure to improve LVEF by 10 absolute units) 
occurred in 52% of patients on standard heart failure therapy alone and in 27% of patients who received 
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additional pentoxifylline. From all baseline characteristics analysed between the two groups, treatment with 
pentoxifylline was the only independent predictor of outcome (p=0.04) using logistic regression analysis 
(148). These results are in line with Sliwa et al.'s previous work on patients with idiopathic dilated 
cardiomyopathy (104-106). However, the effects of additional pentoxifylline in the treatment of PPCM need 
to be interpreted carefully since PPCM is a rare disorder, limiting studies to small numbers of patients and 
because PPCM has a spontaneous recovery rate of approximately 30%, making statistical interpretation 
difficult.  
The beneficial effects of pentoxifylline observed in PPCM patients are likely to have been mediated by 
several mechanisms. Patients treated with pentoxifylline showed a marginal decrease in plasma TNF-alpha 
concentrations but significant reductions in plasma Fas/Apo-1 concentrations. Because programmed cell 
death has been recognized as a contributing cause of myocyte loss in myocardial infarction (174) and TNF-
alpha augments this process through the stimulation of apoptosis (175), the combined reduction of TNF-
alpha and Fas/Apo-1 concentrations in PPCM patients may explain the clinical benefits observed with 
pentoxifylline therapy. In addition, the acute-phase protein CRP was reduced in those patients who were 
treated with pentoxifylline. CRP has direct pro-inflammatory effects on endothelial cells, including the 
expression of adhesion molecules and monocyte chemotactic protein-1 (176). Furthermore, CRP is 
implicated in the synthesis of TNF-alpha (177). Hence, a reduction in serum CRP concentrations could have 
beneficial effects on the progression of cardiac dysfunction. Plasma levels of NT-pro BNP have been used in 
several clinical trials to assess the efficacy of medical therapy (107). Sliwa et al. also observed reductions in 
NT-pro BNP in patients treated with pentoxifylline in a randomized study of patients with ischaemic 
cardiomyopathy (103) and were able to confirm the efficacy of pentoxifylline in ischaemic heart failure. 
While pentoxifylline did not abolish increments in circulating TNF-alpha concentrations in patients, 
experimental studies have suggested that physiological levels of TNF-alpha have cytoprotective effects on 
the heart during ischaemic events (108, 109). Although we are not aware of any large-scale study that has 
evaluated the safety of pentoxifylline in patients with heart failure, this pharmacological agent has been in 
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clinical use for more than 25 years for conditions such as peripheral and cerebrovascular disease (110). 
Patients with peripheral vascular disease frequently also have coronary artery disease and heart failure. It is 
therefore important to note that large trials with more than 10000 such patients have not reported increases in 
mortality in patients treated with pentoxifylline (110).  
Furthermore beneficial effects of pentoxifylline have been reported in HIV-positive patients. Apoptosis is a 
significant cause of CD4 T cell death. Wanchu et al. demonstrated a significant decline of caspase 1 and 
caspase 8 that are involved in Fas/Apo-1 and TNF-alpha facilitated apoptosis in HIV-positive patients and 
concluded that this might result in reduced apoptosis and improved CD4 lymphocyte survival (111). The 
same group described a reduction of nitric oxide in HIV-1 positive patients after administration of 
pentoxiphylline (112). Swords et al. described an association between enhanced HIV replication and 
increased production of TNF-alpha. They observed partial inhibition of HIV-1 induction using pentoxifylline 
and matrix metalloproteinase (MMP) inhibitor I (113).  
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1.7.4 Anticoagulatory drugs 
Thromboembolic phenomena have been reported in up to 53% of PPCM patients (8, 178).  Because of the 
high incidence, Demakis et al. recommend anticoagulants for the duration of cardiomegaly (10). In general, 
pregnant patients are at an increased risk of thromboembolic complications due to a hypercoagulable state of 
late pregnancy, which is associated with increased concentrations of coagulation factors II, VII, VIII, X and 
of plasma fibrinogen as well as augmented platelet adhesiveness (179). These changes may persist up to six 
weeks postpartum (180, 181). Left ventricular dysfunction results in partial blood stasis, which predisposes 
additionally to the formation of left ventricular, pulmonary and cerebral thrombemboli. During the last 
weeks of pregnancy low-molecular weight heparin is the agent of choice while warfarin is preferred 
postpartum.  
 
1.7.5 Immunosuppressive therapy 
A case report by Rached et al. from Argentina described good results of immunosuppressive therapy in one 
patient with PPCM (182). Immunosuppression has been attempted in PPCM patients with biopsy-proven 
myocarditis (117). However, most EMB studies in PPCM patients did not reveal conclusive results. 
Although Maisch et al. recommend heart catheterization with endomyocardial biopsy to allow for the exact 
diagnosis of the underlying cardiac process (inflammatory and/or viral vs. autoreactive myocarditis or non-
inflammatory or nonviral forms) (160) this is not an established routine procedure. Until a link between 
immunosuppressive therapy and resolution of myocarditis can be established in PPCM patients, the use of 
immunosuppressive agents is not recommended (6).  In fact the benefit of immunosuppressive and antiviral 
therapy is discussed controversially (183).  
In a small retrospective study Bozkurt et al. treated women with PPCM with intravenous  immunoglobulin 
and reported a greater improvement in ejection fraction during early follow-up than patients treated 
conventionally (184).  
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1.7.6 Cardiac transplantation 
Cardiac transplantation has been performed successfully in PPCM patients (165, 185). Favourable outcomes 
have been attributed to the young age of the recipients and to the recent onset of heart failure, resulting in 
minimal end-organ damage. In view of the successful transplantation in these young and otherwise healthy 
mothers, aggressive measures such as temporary life support in form of cardiopulmonary bypass or a left 
ventricular assist device until availability of transplant (165) have been advocated. Tubal ligation has been 
recommended for women who have received heart transplants due to the mother's reduced life expectancy 
and teratogenicity of immunosuppressive drugs (186). But Carvalho et al. even reported on a successful 
subsequent pregnancy in a PPCM patient post-transplant (187). Data on the outcome of pregnancies among 
heart transplant recipients demonstrates that despite frequent complications these pregnancies can be 
managed as high-risk cases (188). 
 
1.7.7 Other forms of treatment 
1.7.7.1 Salt and water restriction 
Salt and water restriction are important in patient management, particularly in women with symptoms and 
signs of heart failure. Once heart failure symptoms have been controlled, modest exercise may improve 
symptoms as well as peripheral muscular and arterial tone (1).  
 
1.7.7.2 Prolonged bed rest 
Burch et al. stressed the value of prolonged bed rest in altering the course of PPCM and advocate bed rest for 
three months after the heart size has returned to normal (20). Also Walsh et al. advocated prolonged, 
complete bed rest for periods in excess of one year in some instances or until the heart had returned to 
normal size (8).  
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1.7.7.3 Herbal medicine 
Bark extracts prepared from Terminalia Arjuna, an Indian medicinal plant, when administered at a dose of 
500 mg  qid  for a 2 week period, patients with idiopathic dilated cardiomyopathy and PPCM showed 
continued improvement in symptoms, signs, effort tolerance and NYHA Class as compared with patients 
administered placebo using the same dosage scheme (189). The significance of this finding remains to be 
established as is the case with studies utilizing unconventional forms of alternative medicines from natural 
sources.  
 
1.7.8 Recommended contraceptive methods for PPCM patients 
Appropriate birth-control measures are recommended for patients with enlarged hearts. Oral contraceptives 
should be avoided due to the increased incidence of thromboembolism. However, the use of quarterly 
injections of depot hormone or other methods of preventive family planning need to be encouraged.  
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1.8 Prognosis 
1.8.1 Maternal outcome 
 
Before the routine application of ACE-inhibitors and β-blockers in patients with heart failure, Demakis et al. 
reported in 1971 that the clinical course of PPCM is related to the return of heart size to normal within six 
months which occurred in approximately half of their patients. The mortality of patients whose heart size 
returned to normal was 14%. Of those who maintained cardiomegaly beyond six months, 85%  died, all as a 
result of myocardial failure (23). The most common cause of death was congestive heart failure, which was 
frequently exacerbated by pulmonary emboli, subsequent pregnancies or supraventricular arrhythmias such 
as atrial fibrillation and atrial flutter (10). Patients in whom left ventricular function recovers have 
significantly improved survival (19, 190, 191). 
More recent studies confirm the importance of the recovery of cardiac dimensions. Echocardiography is an 
important diagnostic tool in PPCM and may provide significant prognostic information with regards to 
recovery of cardiac function. End diastolic dimensions of 6 cm or greater at the time of diagnosis were 
associated with a more than 3-fold higher risk for persistent left ventricular dysfunction (153). Dorbala et al. 
studied the left ventricular contractile reserve in seven PPCM patients during dobutamine stress 
echocardiography and documented a correlation (r=0.79) with subsequent recovery of LV function (154).  
In a cohort of 100 patients from South Africa, Sliwa et al. reported a mortality of 15% within a six months 
period. Baseline plasma levels of Fas/Apo-1 (OR=1.30, CI 95%=1.11-1.54) and NYHA FC (OR=2.88, CI 
95%=1.10-7.53) were identified as independent predictors of death (192). Sliwa et al. did not confirm 
variables previously reported by others, such as age above 30 years, higher parity, later onset of symptoms 
after delivery and twin deliveries as predictors of outcome (92).  
In a study from the US, Elkayam et al. report a maternal mortality of 9% within a period of 2.2 years. Death 
was described as sudden in four patients and as a result of complications from heart transplantation in two 
patients. Heart transplantation was performed in 4% of the patients. Three percent of the patients required 
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implantation of an automatic implantable cardioverter-defibrillator, and 2% required implantation of a 
permanent pacemaker during the follow-up period. LVEF at the time of diagnosis was 29±11% and 
improved to 46±14% (5) at follow-up. Normalization of LVEF occurred in 54% and was more likely in 
patients with LVEF >30% at diagnosis. (5).  
Felker et al. found better survival rates in 51 PPCM patients than in patients with other causes of 
cardiomyopathy (n=1230) (193). In a study from Haiti, the ratio of PPCM deaths for the 5-year period was 
47.1 per 100,000 births compared with the US ratio of 0.62 per 100,000 births. The mortality rate was 15.3% 
during a mean follow-up period of 2.2 years. 28% of patients who were observed for at least six months, 
regained normal left ventricular function. The difference in left ventricular echocardiographic features at 
diagnosis between deceased patients and survivors was not statistically significant, but a statistically 
significant difference occurred at diagnosis between the recovered and the non-recovered group for mean 
ejection fraction (28% vs. 23%; P<0.001) and fractional shortening (17% vs. 14%; P=0.004) (14).  
 
1.8.2 Neonatal outcome 
There is little systematic evidence that infants born to women with PPCM are adversely affected, although 
one study did report a premature delivery rate of 21% in 14 women. Results of a more recent study from the 
USA that described neonatal outcome in PPCM mothers is also of interest. However, this study requires 
careful interpretation since pregnancy related hypertension was reported in 43% of these patients who would 
otherwise be excluded from the analysis of these data since the diagnosis utilized for the inclusion of these 
patients did not follow a strict and generally acceptable diagnosis of PPCM as appreciated at our institution. 
The mode of delivery was a by cesarean section in 40 patients, which was performed for obstetrical reasons 
in 70% of the patients, cardiac reasons in 10% and unknown reasons in 20% of the patients. The duration of 
pregnancy (56 patients) ranged from 24 to 42 weeks, with an average of 37.7±3.5 weeks. Premature delivery 
(<37 weeks) was reported in 25% of these patients. Birth weight (51 patients) ranged between 1350 and 
5000 g, with a mean of 3092±745 g. The incidence of small-for-date infants was 5.9%. There were two 
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stillbirths and one neonatal death. Congenital anomalies in the newborn were reported in four cases and 
included hypospadias, coarctation of the aorta, dysmorphogenesis, and macrosomia. Neonatal complications 
were reported in six cases and included one case each of hypothermia, poor suckling, apnea with seizure 
requiring intubation, hypoglycemia and death and two cases of pulmonary oedema (5). As stated above, 
while these are interesting data, their interpretation with reference to a strict diagnosis of PPCM remains a 
problem.
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1.9 Subsequent pregnancy in PPCM 
One of the most common issues for women surviving an episode of PPCM is whether it is safe to become 
pregnant again (13). If cardiac failure recurs in subsequent pregnancies, it once again manifests clinically in 
the peripartum period (155). The mechanism of recurrent symptomatic heart failure in patients with a history 
of PPCM and recovered left ventricular function has been attributed to a significant physiological increase in 
blood volume, stroke volume and heart rate during pregnancy (194).  
Women with a history of peripartum cardiomyopathy who have regained normal resting left ventricular size 
and performance have decreased contractile reserve revealed by the use of a dobutamine challenge test. 
Ventricles of these women may respond suboptimal to haemodynamic stress in spite of evidence of recovery 
by routine echocardiographic evaluation (195). These haemodynamic changes are expected to cause 
symptomatic deterioration in patients with persistent unmasked subclinical myocardial dysfunction, which 
may exist even in patients who seem to recover their left ventricular function (195). At the same time the 
findings of a significant depression in left ventricular function associated with subsequent pregnancy suggest 
that worsening of symptoms are also due to reactivation of the underlying idiopathic process responsible for 
the development of the cardiomyopathy  during a   previous pregnancy (13).  
If a subsequent pregnancy occurs, it should be managed in close collaboration between an obstetrician and a 
cardiologist (1). The prognosis of a subsequent pregnancy in known PPCM appears to be related to left 
ventricular dimensions at onset of subsequent pregnancy.  
Elkayam et al. conducted a record review among members of the American College of Cardiology in the 
United States and Chris Hani Baragwanath Hospital and described the outcome of 60 subsequent 
pregnancies in 44 women with a history of PPCM. Among the first subsequent pregnancies in the 44 
women, 28 occurred among women, in whom left ventricular function had returned to normal (group 1) and 
16 occurred in women with persistent left ventricular dysfunction (group 2). The pregnancies were 
associated with a reduction in mean left ventricular ejection fraction in each group (from 56 ±7 % to 49 ±10 
% in group 1, p=0.002 and from 36±9 % to 32±11 % in group 2, p=0.08). During these pregnancies, a 
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decrease of more than 20 % in left ventricular ejection fraction occurred in 21 % of women in group 1 and 
25 % of those in group 2, and symptoms of heart failure occurred in 21 % of women in group 1 and 44 % of 
those in group 2. The mortality rate was 0% in group 1 and 19% in group 2 (p=0.06) (196). Although the 
likelihood of maternal death seems to be very low in women who recover their left ventricular function 
before a subsequent pregnancy, the fact that a reduction in left ventricular ejection fraction and symptomatic 
heart failure may occur during subsequent pregnancy needs to be considered (13).  
 
Results from other studies of subsequent pregnancies are important to summarize. Thus, a study conducted 
by Walsh et al. concerned observations on six subsequent full-term pregnancies in six patients with 
previously documented PPCM. At least two were complicated by the appearance of congestive heart failure 
in spite of digitalis.  Subsequent to each of the six pregnancies cardiac insufficiency became worse 
postpartum. Moreover these six patients experienced four additional pregnancies that did not go to term. 
Existing congestive heart failure may have become more severe following abortion of a three month fetus. 
The remaining three pregnancies terminating at six, six and seven months respectively were neither 
complicated by congestive heart failure nor followed by recurrence of PPCM  (8).  
In the experience of Demakis et al. the influence of a subsequent pregnancy was related to whether the heart 
size had returned to normal. 21 subsequent pregnancies occurred in 8 patients whose heart size had returned 
to normal (group A). There was a temporary recurrence of postpartum cardiac failure following three 
pregnancies in two of these patients. In each case the patient responded promptly to therapy. Six patients 
whose heart size did not return to normal (group B) had subsequent pregnancies. Although these six patients 
maintained cardiomegaly, they were not in clinical cardiac failure before onset of the subsequent pregnancy.   
There was no change in cardiac function in 3 of these patients. The other three patients experienced marked 
increase in cardiac symptoms in the last trimester or in the early postpartum period. In each case this 
initiated a permanent deterioration in cardiac function that resulted in death. This experience would strongly 
suggest that patients whose heart size has not returned to normal should avoid becoming pregnant (23).  
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Sutton et al. conclude that PPCM patients whose left ventricular function returns to normal may undertake 
further pregnancy with a normal fetal outcome and a low risk of recurrent left ventricular dysfunction (197). 
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2. METHODS 
The low incidence of PPCM in the northern hemisphere is one of the reasons why previous studies of this 
disease have relied to a great extent on case reports,  studies with small numbers of patients or a review of 
medical records from many hospitals for defining the potential aetio-pathogenesis of human PPCM. The 
high incidence of PPCM in a single centre in South Africa provides therefore a unique opportunity to initiate 
studies of the mechanism of pathogenesis, clinical features and prognostic markers in this disease.  
 
 
2.1 Study objectives 
• To describe the clinical profile of 100 patients diagnosed with PPCM 
• To document the kinetics of cardiac function biomarkers, pro-inflammatory cytokines, markers of re-
modeling and prolactin in 40 PPCM patients over a six months period 
• To study the presence of autoantibodies in PPCM 
• To document the outcome of subsequent pregnancy in PPCM 
 
2.2 Informed consent 
This study was approved by the Human Research Ethics Committee (HREC) of the University of the 
Witwatersrand, Johannesburg, South Africa (PRC 990409) and complies with the Declaration of Helsinki. 
All patients and controls gave written informed consent before study entry. As data developed during the 
course of this study and new aspects of the pathogenesis of PPCM emerged, several amendments to the 
original protocol became necessary and were also approved by the HREC. The nature of this study was 
explained to all patients in their native language by an interpreter and each patient was provided sufficient 
time to consider entry into the study and ask questions. Informed consent was signed before entry into the 
study and performance of any study related procedures. Please find the relevant documents attached in the 
appendix. 
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2.3 Methods   
The general methods are outlined in this chapter, while the methods specific to each section of the results are 
described in the methods section of the respective chapters. 
 
2.3.2 Recruitment of patients 
We enrolled 100 African women with PPCM attending the Cardiac Clinic at Chris Hani Baragwanath 
Hospital. All patients received standard therapy for PPCM (β-blocker, angiotensin-converting enzyme 
inhibitors, diuretics and if indicated digoxin). Patients with an ejection fraction < 25% or LV thrombus 
additionally received anticoagulation therapy. All patients were followed up at the Cardiac Clinic, Chris 
Hani Baragwanath Hospital every month. Reassessments of the initial examinations were performed after six 
and 12 months or at anytime in between when clinically indicated.  
 
2.3.3.1 Inclusion criteria 
At the time of entry into the study each patient had to meet the following criteria: 
• Symptoms of congestive heart failure that developed in the last month of pregnancy or in the first 5 
months postpartum 
• No other identifiable cause for heart failure and no demonstrable cardiac disease in the last three months 
of pregnancy 
• Left ventricular ejection fraction less than 40% by transthoracic echocardiography 
• New York Heart Association functional class II - IV 
• Sinus rhythm documented on ECG 
• Eligible patients in whom high-quality echocardiographic images could be obtained 
 
2.3.3.2 Exclusion criteria 
• Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg 
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• Significant organic valvular heart disease 
• Clinical conditions other than cardiomyopathy that could increase inflammatory markers i.e. active 
tuberculosis, sepsis, rheumatoid arthritis, allergy 
• Significant liver disease (defined as enzymes > 2 times the upper limit of normal) and severe anaemia 
(haemoglobin concentration < 9.0 g/dl) 
• Any clinical condition that according to the investigators preclude inclusion in the study or are a 
contraindication for the study medication pentoxifylline (malignancy, cachexia, COPD, recent retinal 
haemorrhage, recent cerebral bleed) 
 
2.3.4 Study visits 
Following the initial screening and baseline visits, monthly outpatient visits were scheduled for clinical 
assessment and evaluation of medication compliance. All baseline examinations were repeated after six 
months. After completing six months of therapy, patients were given a choice to extend their participation in 
the study to twelve months and continue monthly outpatient visits with another assessment of all baseline 
examinations after twelve months.  
 At the time of enrolment, and at six and twelve months following enrolment, physical and 
echocardiographic examinations were performed. In addition an ECG was done and blood pressure and heart 
rate were measured as described in the methods section. Echocardiography was taped on video and stored at 
the Division of Cardiology at Chris Hani Baragwanath Hospital for further reference and audit purposes.   
• Follow up visit 2  (after 1 month):   Check up 
• Follow up visit 3  (after 2 months):  Check up 
• Follow up visit 4  (after 3 months):  Check up 
• Follow up visit 5  (after 4 months):  Check up 
• Follow up visit 6  (after 5 months):  Check up 
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Follow up visit 7 (after 6 months): A physical examination was performed, blood pressure and heart rate 
measured, blood samples taken. Echocardiography was done, taped on video and stored at the Division of 
Cardiology at Chris Hani Baragwanath Hospital for further reference and audit purposes.  
 
After completing six months the patients were informed that they could decide to either continue 
participating in this study for an additional 6 months to complete 12 months of study or no longer participate 
in the study without any change in the clinical care they would receive if they did decide to terminate their 
participation. The ones who elected to continue participating in the study were subjected to the protocol 
below :  
• Follow up visit 8  (after 7 months):   Check up 
• Follow up visit 9  (after 8 months):  Check up 
• Follow up visit 10  (after 9 months):  Check up 
• Follow up visit 11  (after 10 months):  Check up 
• Follow up visit 12  (after 11 months):  Check up 
 
Follow up visit 13 (after 12 months): A physical examination was performed, blood pressure and heart rate 
measured, blood samples taken. Echocardiography was done, taped on video and stored at the Division of 
Cardiology at Chris Hani Baragwanath Hospital for further reference and audit purposes.  
 
2.3.5 Echocardiographic studies 
All studies were performed and interpreted by the same operator who was blinded to the protocol. Two-
dimensional targeted M-mode echocardiography with Doppler color flow mapping was performed using a 
Hewlett Packard Sonos 5500 (Philips, Bothell, Washington) echocardiograph attached to a 2.5 or 3.5 MHz 
transducer. Left ventricular dimensions were measured according to the American Society of 
Echocardiography guidelines (198). Measurements of LV dimensions and function were determined on an 
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average of ≥ 3 beats. Diastolic mitral flow was assessed by pulsed-wave Doppler echocardiography from the 
apical four-chamber view. E-wave deceleration time was measured as the interval between the early peak 
diastolic velocity and the point at which the steepest deceleration slope was extrapolated to the zero line. All 
studies were recorded on videotape. 
 
2.3.6 Assessment New York Heart Association functional class 
A physician who was provided with the clinical data, but blinded to the study protocol and unaware 
of the results of the laboratory tests assigned each patient to the NYHA FC during baseline and 
follow-up visits.  
 
2.3.7 Blood pressure measurements 
Non-invasive blood pressure measurements were performed by use of a Critikon Dinamap vital signs 
monitor 1846. Resting heart rate, systolic and diastolic blood pressures were calculated as mean values from 
5 readings. Measurements were made after a 30 minute rest period in sitting position with 2 minute intervals 
between successive measurements.  
 
 
2.3.8 Research specific blood tests 
A small research laboratory has been established at the Division of Cardiology at Chris Hani Baragwanath 
Hospital adjacent to the clinic. A volume of 21 ml of blood was withdrawn from an antecubital vein and 
collected in prechilled vacutainer tubes containing ethylenediaminetetraacetic acid and mixed rapidly. 
Plasma was separated by centrifugation at 2500 rpm for 12 minutes within 15 minutes of collection. Aliquots 
were stored at minus 70 degree Celsius. All plasma or serum samples used in this study were thawed only 
once for the measurement of biomarkers by commercially available enzyme linked immunosorbent assays 
(ELISA). The average of 2 measurements in undiluted plasma or serum was calculated. In order to obtain 
reference values for the population studied, plasma and serum was obtained from 20 female, age and HIV-
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status matched volunteers who were in the peripartum period. All volunteers were physically examined and 
clinically had no concomitant infections that would influence biomarker levels. None of the patients or 
volunteers received anti-inflammatory drugs during the four weeks preceding the sample they donated for 
the determination of inflammatory cytokines.  
All blood specimens were collected at Chris Hani Baragwanath Hospital and the plasma and serum obtained 
stored on site at minus 70 degrees Celsius. The aliquotted samples were then transferred on dry ice to the 
three different institutions as stated below, where the respective laboratory measurements were performed. 
Detailed protocols for each test are included in the appendix: 
 
Emory University School of Medicine 
Department of Pathology & Laboratory Medicine 
Room 2309 WMB 
1639 Pierce Drive, NE 
Atlanta, GA  30322 
Î  Pro-inflammatory biomarkers: CRP, TNF-alpha, IL-6 and IFN-gamma (measured at baseline, after 
six and twelve months) 
Î  Markers of remodeling: MMP-2, MMP-9, TGF-β and VEGF (measured at baseline, after six and 
twelve months) 
Î  Markers of cardiac function: ACE, NT-proBNP and Fas/APO-1 (measured at baseline, after six and 
twelve months) 
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Humboldt University 
Max Delbrück Center for Molecular Medicine (MDC) 
Franz Volhard Clinic Cardiovascular Disease 
Berlin, Germany 
Î  Identification and quantification of agonistic autoantibodies against β1-adrenergic receptor 
(measured at baseline and after six months) 
 
Medizinische Hochschule Hannover 
Molecular Cardiology 
Gebaeude K5, Ebene 2, Raum 3100 
Carl Neuberg Str. 1 
Î 16-kDa Prolaction (post-delivery) 
Î 23-kDa Prolactin (post-delivery) 
Î Cathepsin D 
 
In contrast to the original protocol, selenium levels were not measured since Fett et al ruled out a role for the 
effect of selenium levels and described the presence of  normal selenium levels in a cohort of PPCM patients 
from Haiti (29).  
 
2.4 Statistical analysis 
The applied statistical methods are outlined in the individual chapters.  
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 FIRST SECTION OF RESULTS 
 
3.0 CLINICAL PROFILE OF 100 PATIENTS DIAGNOSED WITH PPCM 
3.1 Introduction 
As outlined in the introductory chapter one, a low incidence of PPCM in the northern hemisphere (1:15000) 
as compared to countries like Nigeria, Haiti and South Africa with an incidence between 1:100 to 1:1000 
respectively, is one of the reasons why numerous previous studies on PPCM relied on case reports, small 
numbers of patients, a review of medical records or even a survey among 15000 members of the American 
College of Cardiology (199) by mail in an effort to obtain basic information that totaled 123 patients (5). 
Only patients in Haiti were studied prospectively by the same group of doctors, but given the political 
situation, researchers were faced with practical and logistical difficulties.    
Many reports on PPCM were written before the advent of echocardiography that is essential in the diagnosis 
of PPCM. As a result previous reports and studies most likely included a significant percentage of patients 
with a non-PPCM cause of cardiac malfunction that clinically mimic heart failure. The criteria for PPCM 
were re-defined in 1997 (1) emphasizing the absence of other underlying cardiac conditions to help refine 
the diagnosis of human PPCM. This problem of inaccurate diagnosis is reflected by the fact that select 
studies of human PPCM included a high percentage of patients with other cardiac conditions, e.g. a history 
of hypertension during pregnancy in 43% of patients (5). Furthermore, ACE-inhibitors or β-blockers were 
not available during many of the early studies, impacting negatively on outcome.  
In view of the above, systematic data collection to study the aetiology and the potential pathogenic 
mechanisms of PPCM was deemed difficult. The high incidence of PPCM in a single tertiary centre in South 
Africa provides therefore an unique opportunity to conduct a prospective study of the mechanism of the 
pathogenesis and clinical features of this disease in a significant number of these clinically well 
characterized patients that have a high probability to provide data that can withstand objective statistical 
analysis which have been heretofore not possible.  
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3.2 Patients and methods 
3.2.1 Study design and patient enrolment 
The protocol was approved by the Committee for Research on Human Subjects of the University of the 
Witwatersrand, Johannesburg, South Africa and complies with the Declaration of Helsinki. All patients and 
controls gave written informed consent before study entry. The objective of the study was to recruit a total of 
100 consecutive patients (who happened to be black and who represent the population being seen at that 
clinic) with PPCM which required screening of a total of 144 patients, 44 of whom did not fit the inclusion 
criteria of the study. The study was conducted at the Chris Hani Baragwanath Hospital, a tertiary hospital 
linked to the University of the Witwatersrand, located in Soweto, South Africa, which is the sole tertiary 
medical facility for this community. Patients were referred form local clinics, secondary hospitals, and the 
Department of Obstetrics at Chris Hani Baragwanath Hospital. History of pre-eclampsia and mode of 
delivery were obtained from the patient and confirmed by examining the obstetric card carried by each 
patient. The history of onset of symptoms and signs were recorded at the first presentation of the patients at 
the Chris Hani Baragwanath Hospital cardiac clinic (baseline) and after a follow-up period of 6 months (6 
months visit). These were the two time points of the study.   
Clinical assessment, echocardiography, and blood analysis were done at baseline and after 6 months of 
standard therapy. Inflammatory markers were measured at baseline only. All patients received treatment 
with diuretics and the angiotensin-converting enzyme inhibitor accupril. Patients with an EF ≤ 25% or LV 
thrombus received anti-coagulation therapy. Carvedilol was added after resolution of overt heart failure, and 
the dose was slowly titrated up to a target of 25 mg twice daily as long as SBP was ≥ 100 mmHg or 
symptoms such as dizziness did not occur. Patients attended the cardiac clinic at least once a month for 
routine follow-up. 
Inclusion and exclusion criteria are outlined in chapter 2. In addition 20 healthy, age, sex, body mass index 
and parity matched females were recruited from the local population for purposes of control.  
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Plasma levels of CRP were measured as part of routine investigation by the hospital laboratory utilizing a 
commercially available enzyme-linked immunosorbent assay (Roche Diagnostics GmbH, Mannheim, 
Germany). The assay utilized had a sensitivity of 0.1-10 mg/l and included standards which were run in 
parallel. Obtained values were used to calculate plasma levels in patient and control samples.  
  
3.2.2 TNF-alpha and Fas/APO-1 levels 
Fifteen milliliters of blood were drawn from each patient and controls during day time (10.00 to 12.00 a.m.) 
from the antecubital vein and collected into pre-chilled vacutainer tubes containing 
ethylenediaminetetraacetic acid. Plasma was separated by centrifugation at 2500 r.p.m. for 12 min within 15 
min of collection. Aliquots were stored at minus 80 degrees Celsius. Plasma levels of TNF-alpha and 
Fas/Apo-1 were measured using commercially available enzyme-linked immunoassays (Amersham, 
Maidstone, USA and Calbiochem, San Diego, CA, USA, respectively) and performed according to 
manufacturers’ instructions. The manufacturer supplied a reference range for normal values. However, as 
those values are obtained in samples from western population groups, we collected blood from 20 otherwise 
healthy, age, race, sex, body mass index, and parity comparable controls recruited from the local population. 
 
3.2.3 Functional class, echocardiography and cardiac scintigraphy 
A physician who was provided the clinical data, but was blinded to the protocol and unaware of the results 
of the laboratory tests, performed the assignments of each patient to the NYHA FC during baseline and 
follow-up visits. The same physician evaluated all patients. A multiple-gated equilibrium cardiac blood pool 
scintigraphic technique (MUGA) was used to measure LVEF (Elscint Apex 409, Chicago, IL, USA), and 
calculations of LV performance were made as previously described (200). Two-dimensional targeted M-
mode echocardiography with Doppler color flow mapping was performed using a Hewlett Packard Sonos 
5500 (Philips, Bothell, WA, USA) echocardiograph attached to a 2.5 or 3.5 MHz transducer. All studies 
were performed and interpreted by the same operator who was unaware of the other parameters investigated. 
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All studies were recorded on videotape. LV dimensions were measured according to the American Society 
of Echocardiography Guidelines (198). Measurements of LV dimensions and function were determined on 
an average of ≥ 3 beats. 
 
3.2.4 Statistical analysis 
Data were analysed using the SAS version 9.1 statistical program (SAS, Cary, NC, USA). Results are 
expressed as mean±SD or median (201). The paired t-test was used for the comparison of baseline data with 
the 6 months data, whereas the Wilcoxon matched pair test was used for variables measured in a continuous 
scale and with a non-normal distribution. The McNemar test was used for calculating the differences on the 
basis of the NYHA FC by grouping the patients into two classes (I + II and III + IV). Comparison of 
numerical data between groups of patients was carried out using non-parametric Mann–Whitney–Wilcoxon 
test. Significance was assumed at a two-tailed value of P< 0.05. Spearman correlation coefficients were 
calculated for continuous data. Univariate logistic regression was used to select possible predictors of 
mortality. Continuous variables were tested for linearity generating partial residual plots. As non-linear 
effects were detected for all the variables, 
they were transformed into an ordinal scale by tertiles. The multiple logistic regression was performed 
including predictor variables [NYHA FC, end-diastolic diameter (EDD), end-systolic diameter (ESD), EF, 
Fas/Apo1, aspartate amino transferase (AST) and SBP] that 
had a P-value less than 0.15 from the univariate analysis. A good fitting model was indicated in stepwise, 
forward, and backward logistic regression. The resulting model for mortality selected Fas/APO-1 and 
NYHA FC as explanatory variables with a P-value less than 0.05 being considered significant.  
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3.3 Results 
3.3.1 Characteristics of study patients 
The characteristics of the study population at time of first presentation to the cardiac clinic (baseline) are 
shown in Table 3.1. Although 91% of the study patients were diagnosed as PPCM patients for the first time, 
the remaining 9 (9%) PPCM patients had been diagnosed at a previous pregnancy. These nine patients had 
recovered their LV function and experienced a subsequent episode of PPCM. None of the patients had 
identifiable causes for heart failure. There was no association between history of hypertension and eclampsia 
during pregnancy or use of tocolytic agents (9%). At the day of first presentation at the clinic (baseline), 26 
patients were in NYHA FC II, 49 were in FC III, and 25 were in FC IV. LV thrombi were detected on 
echocardiography in 16% of the patients.  
 
Parameter Mean value 
Age (years) 31.6±6.6 
Body Mass Index (kg/cm 2) 25.6±5.1 
Blood pressure (mmHg) systolic 111.1±17.4 
Blood pressure (mmHg) diastolic 70.4±13.5 
Heart rate (beats/min) 93.5±18.5 
Left ventricular EDD (mm) 61.6±7.1 
Left ventricular ESD (mm) 53.1±7 
Ejection fraction echocardiography (%) 25.9±8.2 
C-reactive protein (mg/l) 10.8±13.2 
Glucose (mmol/L) 4.8±1.1 
Total cholesterol (mmol/l) 4.2±0.8 
Haemoglobin (g/dl) 12.5±1.7 
Fas/Apo-1 (U/l) 6.3±4.1 
TNF-alpha (pg/ml) 4.9±4.2 
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Table 3.1 Baseline characteristics of study population (n=100) EDD= end-diastolic diameter; ESD= 
end-systolic diameter; TNF= tumor necrosis factor 
 
3.3.2 Follow up  
Fifteen patients died within the follow-up period of 6 months, and eight patients moved to remote areas and 
were not available for full follow-up assessments. Patients lost to follow-up were observed for a median of 3 
months (range 1–5 months). They were contactable through phone and were alive. Eleven patients died 
despite optimal medical therapy because of progression of heart failure in hospital and the other four patients 
experienced sudden death. All the patients died during the first 3 months after enrolment in the longitudinal 
study. Women who had a prior history of PPCM had no difference in mortality when compared with the 
women who had no previous history of PPCM. However, they had an intensive monitoring by the 
cardiologist and obstetrician throughout their pregnancy and post-partum. Baseline characteristics of patients 
that were not available for full follow-up assessment did not differ from the others. None of these patients 
died. Cardiac transplantation or LV assist device for the population studied was unavailable for the duration 
of the trial due to economic reasons. 
 
3.3.3 Medication 
During the first months after enrolment, patients received standard therapy for heart failure, which included 
furosemide [n = 96, median daily dose 160 mg (80–250)], accupril [n = 96, median daily dose 10 mg (10–
20)], and carvedilol [n = 95, median daily dose 25 mg (6.25–50)]. Carvedilol was uptitrated as long as SBP 
was > 100 mmHg or symptoms such as dizziness occurred. Clinical data and NYHA FC were compared at 
first presentation at the cardiac clinic at baseline (n = 100) and after 6 months of standard care (n = 77) as 
detailed in table 3.2. 
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3.3.4 Left ventricular function, dimensions and heart rate 
Patients who completed 6 months of treatment showed a significant reduction of heart rate, left ventricular 
dimensions and significant improvement in scintigraphic and echocardiographic derived values for left 
ventricular ejection fraction (p< 0.0001, Table 3.2) and NYHA functional class (p< 0.001). However, 
normalization of LVEF (>50%) was only observed in 18 (23%) of the patients. 
Parameter Baseline 6 months P-value 
Systolic BP (mmHg) 111.6±16.8 116.1±17.6 0.018 
Diastolic BP(mmHg) 71.0±12.6 72.6±11.3 0.37 
HR (beat/min) 92.8±18.4 74.2±12.9 0.001 
NYHA FC (%) 
FC I   =  0 
FC II  =  23 
FC III =  38 
FC IV = 16 
FC I    =   55 
FC II   =   17 
FC III  =   5 
FC IV =   0 
< 0.001 
0.36 
<0.0001 
<0.0001 
EDD ( mm) 61.2±7.1 55.6±8.9 <0.0001 
ESD (mm) 53.4±7.7 43.7±10.3 <0.0001 
ECHO EF (%) 26.2±8.2 42.9±13.6 <0.0001 
MUGA EF (%) 23.9±8.1 43.1±15.1 <0.0001 
Table 3.2 Clinical variables and left-ventricular function at baseline and after 6 months follow-up (n=77); 
BP=blood pressure; HR=heart rate; EDD= end-diastolic diameter; ESD= end-systolic diameter 
 
3.3.5 C-reactive protein, TNF-alpha, FasApo-1 and other blood result 
The median plasma level of C-reactive protein for the 100 PPCM patients was 10.0 mg/L (range 1–90) with 
45% of patients having values of .10 mg/L (table 1). Only ten patients had a C-reactive protein level of 3 
mg/L. Baseline plasma levels of C-reactive protein correlated positively with LV end-diastolic (rs = 0.33, P 
= 0.0026) and endsystolic dimensions (rs = 0.35, P = 0.0012), whereas the correlation with LVEF (rs = 
20.27, P = 0.015) was inverse (figure 3.1). Plasma C-reactive protein levels also correlated inversely with 
levels of total cholesterol (rs = 20.29, P = 0.01). Baseline plasma levels of C-reactive protein, TNF-alpha, 
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and Fas/Apo-1 were elevated in patients with PPCM when compared with 20 age, sex, body mass index, and 
parity comparable healthy volunteers (TNF-alpha 4.9±4.2 vs. 1.4±1.3 pg/mL, Fas/Apo-1 6.3±4.1 vs. 
0.84±0.2 U/L, C-reactive protein 10.8±13.2 vs. 3.1±0.9 mg/L, P = 0.01). There was no correlation between 
baseline plasma levels of C-reactive protein, TNF-alpha, and Fas/Apo-1 among the PPCM patients.  
 
 
 
Figure 3.1 Correlation co-efficients of total cholesterol and C-reactive protein vs. parameters of LV 
dimensions and function. 
 
3.3.6 Predictors of outcome: 
In the population studied, mortality remained high (15%). Significant differences in the baseline data 
between deceased patients and survivors were seen in NYHA FC, and values of SBP, end-diastolic and end-
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systolic dimensions, LVEF, plasma AST, a marker of hepatic congestion and liver cell death (table 3.3 ), and 
plasma levels of Fas/Apo-1 (table 3.3 and Figure 3.2 ). Logistic regression analysis of NYHA FC, SBP, 
EDD, ESD, EF, AST, and Fas/Apo-1 revealed that only the baseline plasma levels of Fas/Apo-1 (OR = 3.56, 
CI 95% = 1.35–9.42) and NYHA FC (OR = 2.67, CI 95% = 1.04–6.83) were independent predictors of death 
(tables 3.4 and 3.5 ). 
 
Parameter 
Deceased 
(n=15) 
Survivors 
(n=77) 
p-value 
Age (years) 28.9±1.2 32±6.4 0.30 
No of children (n) 2.3±1.2 2.9±1.4 0.14 
Onset of symptoms post 
delivery (months) 2.1±1.4 2.2±1.3 0.68 
HR (beats/min) 98.4±21.0 92.2±18.4 0.29 
Systolic BP (mmHg) 102.1±22.1 111.6±16.8 0.03 
NYHA FC 3.3±0.7 2.0±0.8 0.04 
EDD (mm) 64.9±5.8 61.2±7.2 0.03 
ESD (mm) 57.7±7.3 53.4±7.7 0.03 
ECHO EF (%) 22.2±6.0 26.2±8.2 0.04 
AST (iU/l) 50.4±34.4 34.8±24.0 0.04 
C-reactive protein (mg/l) 12.4±7 10.4±14.6 0.10 
Total Cholesterol (mmol/l) 4.3±1.1 4.3±0.9 0.87 
Fas/Apo-1 (U/ml) 9.8±4.2 5.9±3.8 0.002 
TNF (pg/ml) 4.8±5.1 5.1±4.2 0.30 
Table 3.3 Baseline characteristics of deceased versus surviving patients 
BP=blood pressure; HR=heart rate; EDD= end-diastolic diameter; ESD= end-systolic diameter; 
TNF=tumor necrosis factor and AST=Aspartate amino transferase 
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Figure 3.2: Baseline plasma inflammatory markers of deceased patients vs. survivors. Only differences in 
Fas/Apo-1 were significant (p=0.002) 
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Parameter Odds ratio 
95% confidence 
interval p-value
Age (years) 0.96 0.89–1.04 0.3 
SBP (mmHg) 0.96 0.93–1.00 0.06 
NYHA FC 2.35 1.03–5.34 0.04 
EDD (mm) 1.07 0.99–1.16 0.07 
ESD (mm) 1.07 0.99–1.15 0.06 
Echo EF (%) 0.95 0.89–1.02 0.14 
Fas/Apo-1(U/ml) 1.25 1.08–1.45 0.003 
AST (U/l) 1.02 0.99–1.04 0.07 
TNF-alpha (pg/ml) 0.99 0.86–1.14 0.83 
Table 3.4 Univariate logistic regression analysis of survivors vs. deceased patients 
 
 Odds ratio 95% Confidence interval P-value 
Fas/APO-1 (U/L) 
(tertiles) 3.56 1.35-9.42 0.01 
NYHA FC 2.67 1.04-6.83 0.04 
Table 3.5: Backward logistic regression analysis (all variables from univariate analysis were included (P < 
0.15), but were not part of the final model, as they were not significant. 
 
3.4 Summary 
Plasma markers of inflammation were significantly elevated in PPCM patients and correlated with increased 
left ventricular dimensions and lower ejection fraction at presentation.  Baseline Fas/Apo-1 and higher 
NYHA functional class were the only predictors of mortality. These results contribute to previous findings 
by our group and others that apoptosis and chronic  inflammation may contribute to the pathogenesis of 
PPCM (4, 115, 148) and deserve studies aimed at defining the mechanisms for such chronic insults. Despite 
standard medical therapy normalization of LVEF was only observed in 23% of this cohort of African PPCM 
patients. 
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SECOND SECTION OF RESULTS 
4. KINETICS OF CARDIAC FUNCTION BIOMARKERS, PRO-INFLAMMATORY CYTOKINES, 
MARKERS OF RE-MODELING AND PROLACTIN IN 43 PATIENTS WITH PERIPARTUM 
CARDIOMYOPATHY OVER A SIX MONTHS PERIOD 
 
4.1 Introduction 
Peripartum cardiomyopathy is a disabling condition characterized by new onset of heart failure in previously 
healthy women between one month antepartum and five months post-delivery (1). While established 
treatment options do not differ from those of other patients with cardiomyopathy, the aetiology of PPCM has 
been subject of numerous studies suggesting a wide range of contributing factors, such as multiparity (25), 
twin pregnancy (26, 27), advanced maternal age (6), tocolytic therapy (34), entero- (32) and cardiotropic 
viruses (49-51), heat (11), poor nutrition and selenium deficiency (24), maternal cocaine abuse (31), sexually 
transmitted diseases (36), chlamydia pneumoniae (37) and strenuous aerobic exercise (38). However, due to 
the rare incidence of PPCM, these data were either limited to small numbers of patients, obtained before the 
advent of echocardiography or not acquired in a systematic fashion.  
Recent studies conducted on a large cohort of PPCM patients by Sliwa et al. in South Africa described a pro-
inflammatory response  in PPCM patients with elevated levels of TNF-alpha, IL-6 (148) and a positive 
correlation between C-reactive protein levels and LV end-diastolic and end-systolic diameters (192).  
T cell-mediated autoimmune responses have been discussed in the pathogenesis of dilated 
cardiomyopathy and the role of IFN-gamma in the progression from early (viral) to late (autoimmune) 
phases of myocarditis has been documented. Treatment with antibody to IFN-gamma reduced early disease, 
but had little effect on the severity of cardiac lesions at later times (202). CD4(+) Th1 cells promote 
activation of the autoimmune CD8(+) alpha β TCR(+) effectors via an IFN-gamma mediated mechanism 
(203). The inhibition of T cell responses and suppression of Th1-type and inflammatory cytokines via 
inactivation of nuclear factor-kappaB by administration of a statin in autoimmune myocarditis have also 
been reported. The lipid lowering agent fluvastatin reduced production of Th1-type cytokines including IFN-
gamma and inhibited expression of inflammatory cytokine mRNAs in the myocardium. Infiltration of CD4-
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positive T cells into the myocardium and T cell proliferative responses were suppressed by fluvastatin. 
(204). Li et al. documented improved cardiac function in mice after reduction of IFN-gamma levels with 
atorvastatin (205). We reasoned that measurement of IFN-gamma as an indicator of an ongoing autoimmune 
process would provide some insights as to the potential role of this cytokine in perpetuating autoimmune 
insult in the heart of PPCM patients.  
Fett and colleagues prospectively followed a large cohort of patients in Haiti and reported an 
association between high levels of C-reactive protein and PPCM. They hypothesized that Fas-mediated 
apoptosis contributes to cardiomyocyte loss, left ventricular dilatation and eventually clinically detectable 
left ventricular systolic failure (147). The role of programmed cell death (apoptosis) is an area of intense 
investigation (206) and has been identified as an essential process in the progression to heart failure (207). 
Indeed, Sliwa et al. have identified Fas/APO-1 as a predictor of death in PPCM patients (148). Cenac et al. 
found that low values of NT-ProBNP and hsCRP indicate complete remission of cardiac failure and normal 
heart volume in PPCM. In their view the synchronous variation of NT-ProBNP/hsCRP and their positive 
correlation supported the hypothesis of inflammatory process (myocarditis) in PPCM (208).  
Plasma oxLDL is a marker of oxidative stress in patients with dilated cardiomyopathy (209). Tsutamoto and 
colleagues reported that left ventricular dysfunction in dilated cardiomyopathy may be partly due to the 
oxidative stress measured by plasma oxLDL. They also found a significant positive correlation between 
oxLDL and TNF-alpha, concluding that TNF-alpha may stimulate oxidative stress in the failing heart (210). 
In a different study Tsutsui et al. found a significant negative correlation between the plasma level of oxLDL 
and left ventricular ejection fraction and a significant positive correlation between the plasma level of 
oxLDL and plasma norepinephrine level (209).  
Ansari et al. have focused on the specific immune environment of pregnancy (4). An echocardiographic 
assessment of the haemodynamics in normal pregnancies demonstrated a 10% increase in left ventricular 
end-diastolic volume, a 45% increase in cardiac output and a 26% to 28% decrease in end-systolic wall 
stress. In order to accommodate higher pre-load during pregnancy, the left ventricle undergoes re-modeling 
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and reversible left ventricular hypertrophy (76, 211). Cardiac remodeling is the restructuring and reshaping 
of the heart that underlies heart failure progression and is a major determinant of the clinical course of 
chronic heart failure, irrespective of its etiology (206). Matrix metalloproteinases can alter myocardial 
extracellular matrix and thereby contribute to adverse ventricular remodeling in progressive heart failure 
(212). Cardiac-specific, constitutively active MMP-2 expression leads to impaired contraction and 
diminished responses to inotropic stimulation (213) and has been identified as an independent predictor of 
mortality in patients with chronic heart failure (214). The selective inhibition of MMP-2, MMP-9 and others 
has been shown to reduce replacement fibrosis and interstitial fibrosis by 29% in dogs (215). Vellaichamy et 
al. report that reduced NPRA signaling activates MMP-2 and 9, TGF-β1 and TNF-alpha expression in Npr1-
/- mouse hearts, promoting hypertrophic growth and extracellular matrix remodeling, leading to the 
development of cardiac hypertrophy, myocardial fibrosis, and congestive heart failure (216). TNF-alpha may 
stimulate the expression of MMP’s, contribute to myocardial remodeling and lead to the development and 
progression of congestive heart failure (217).  
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Figure 4.1: Transition from normal pregnancy to reversible or irreversible PPCM respectively 
 
The importance of fibrosis in different cardiac pathologies appears to be increasingly relevant and is thought 
to be partially mediated by transforming growth factor-β1 (TGF-β1), a potent stimulator of collagen-
producing cardiac fibroblasts. Watanabe et al. demonstrated a reduction in the area of myocardial fibrosis 
and expression of TGF-β-1 levels in a model of rats with dilated cardiomyopathy through inhibition of the 
RAAS with ACE-inhibitors (218, 219). Previously, TGF-β1 had been implicated solely as a modulator of the 
myocardial remodeling seen after infarction. However, recent studies indicate that dilated, ischaemic and 
hypertrophic cardiomyopathies are all associated with raised levels of TGF-β1 (220).  
Hilfiker-Kleiner and colleagues demonstrated an association between enhanced cardiomyocyte apoptosis 
and fibrosis with increased levels of VEGF in the pressure-overloaded mouse heart (221). Other others 
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studied the influence of VEGF on capillary density (222). Heart size and cardiac function are angiogenesis 
dependent, and disruption of coordinated tissue growth and angiogenesis in the heart contributes to the 
progression from adaptive cardiac hypertrophy to heart failure. Shiojima et al. showed that inhibition of 
angiogenesis via a decoy VEGF receptor in mice with dilated cardiomyopathy led to decreased capillary 
density, contractile dysfunction, and impaired cardiac growth.  (223). 
In vivo and in vitro studies suggest that the effector hormones, angiotensin II and aldosterone, of the RAAS 
are primarily involved in regulating the structural remodeling of the myocardial collagen matrix (224). 
Inflammation is a key mechanism in the initiation and progression of cardiomyopathy. Angiotensin II, the 
major effector peptide of the RAAS, plays a significant role in the advent and perpetuation of inflammatory 
cardiovascular disease. Among others, TNF-alpha, and C-reactive protein have diagnostic and prognostic 
values in cardiovascular disease and are modified by angiotensin-converting enzyme inhibitors (225). 
Hyperactivation of the RAAS, heightened sympathetic drive and uncontrolled synthesis of inflammatory 
cytokines exacerbates ventricular contractile dysfunction in heart failure patients (226). Several studies 
suggest a link between the pathogenesis of congestive heart failure, circulating levels of  TNF alpha IL-1, 
IL-6 (227) and clinical status (228).  
Besides the RAAS, most endocrinal glands are affected by chronic heart failure and elevated serum prolactin 
levels were observed as the most frequent hormonal disturbance in a group of male patients with chronic 
heart failure of different aetiologies (229) as well as in males and females with ischaemic or dilated 
cardiomyopathy (230). Prolactin represents a stimulatory link between the neuroendocrine and immune 
systems, but its involvement in the neurohumoral adaptations to heart failure has not been explored (230). It 
is physiologically upregulated postdelivery and has been implicated in cardiac tissue injury and modulation 
of the autoimmune response (81, 82).  
While this process of remodeling happens physiologically during the peripartum period without myocyte 
loss or injury and thus without triggering unwanted innate immune pathological responses (231), some 
women develop PPCM during this period.  
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We therefore stratified our approach to study the kinetics of the above described markers of cardiac 
function, re-modeling and inflammation as well as levels of the pregnancy associated hormone prolactin in 
patients presenting with PPCM to our clinic for diagnosis and anti-failure therapy. While the incidence of 
PPCM has been reported between 1: 2392 and 4000 live births in the USA (13, 14) and 1:300 in Haiti (14), 
PPCM is ubiquitous on the African continent with an incidence ranging from 1: 100 to 1: 1000 deliveries 
(22). In an attempt to improve the understanding of the mechanisms and pathways involved in the 
pathogenesis of PPCM, we enrolled 41 patients with new onset of the disease and systematically obtained 
clinical and echocardiographic data as well as serum/plasma samples from all patients at baseline and after 
six month of treatment. In order to identify mechanisms involved in the onset of PPCM, we measured the 
biomarkers outlined above and compared these to non-PPCM women from our local population in the 
peripartum period. This was necessary to distinguish such markers that would be physiologically 
upregulated in all women during the peripartum period from those that are pathologically elevated. Since 
PPCM has a high rate of recovery ranging between and 23 and 54% (5, 192), we were also interested in the 
kinetics of biomarkers that differed between such patients who subsequently improved their cardiac function 
and those who did not. We therefore obtained another set of serum/plasma samples after six months of 
therapy and repeated the clinical and echocardiographic examinations at the same time. We grouped the 
results into patients who improved their cardiac function versus those who did not and describe the kinetics 
of these biomarkers over time.  
 
4.2 Patients and Methods 
4.2.1 Study design and patient recruitment 
This study was approved by the Human Research Ethics Committee (HREC) of the University of the 
Witwatersrand, Johannesburg, South Africa (PRC 990409) and complies with the Declaration of Helsinki. 
All patients and controls gave written informed consent before study entry. We screened a total of 54 
patients to recruit 43 consecutive PPCM patients.  
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The study was conducted at Chris Hani Baragwanath Hospital, a tertiary institution located in Soweto, South 
Africa and linked to the University of the Witwatersrand, Johannesburg. It is the sole tertiary medical facility 
for this community. Patients were referred form local clinics, secondary hospitals, and the Department of 
Obstetrics at Chris Hani Baragwanath Hospital. History of pre-eclampsia and mode of delivery were 
obtained from the patient and confirmed by examining the obstetric card carried by each patient. The history 
of onset of symptoms and signs were recorded during first presentation at the cardiac clinic at Chris Hani 
Baragwanath Hospital (baseline) and after a follow-up period of six months (6 months visit). These were the 
two time points of the study. Clinical assessment, echocardiography, and blood analysis were done at 
baseline and after 6 months of standard therapy. Three tubes of blood (4 ml each) were collected from every 
patient to obtain serum and plasma for measurement of cytokine levels and FBC. Echocardiography was 
taped on video and stored at the Division of Cardiology at Chris Hani Baragwanath Hospital for further 
reference and audit purposes. Following the initial screening and baseline visits, monthly outpatient visits 
were scheduled for clinical assessment and evaluation of medication compliance. 
All patients received treatment with diuretics and the angiotensin-converting enzyme inhibitor enalapril. 
Patients with an EF ≤ 25% or LV thrombus received anti-coagulation therapy. Carvedilol was added after 
resolution of overt heart failure, and the dose was slowly titrated up to a target of 25 mg twice daily as long 
as SBP was ≥ 100 mmHg or symptoms such as dizziness did not occur. Patients attended the cardiac clinic at 
least once a month for routine follow-up. 
 
4.2.3 Echocardiographic studies, assessment of New York Heart Association functional class and non-
invasive blood pressure measurements 
All studies were performed and interpreted by the same operator who was blinded to the protocol. 
Two-dimensional targeted M-mode echocardiography with Doppler color flow mapping was 
performed using a Hewlett Packard Sonos 5500 (Philips, Bothell, Washington) echocardiograph 
attached to a 2.5 or 3.5 MHz transducer. Left ventricular dimensions were measured according to the 
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American Society of Echocardiography guidelines (198). Measurements of LV dimensions and 
function were determined on an average of > 3 beats. All echocardiographic studies were recorded on 
videotape and stored at Chris Hani Baragwanath Hospital, Division of Cardiology for future 
reference and audit purposes. 
A physician, who was provided with the clinical data, but blinded to the study protocol and unaware 
of the results of the laboratory tests, evaluated the NYHA FC of each patient during baseline and 
follow-up visits.  
Heart rate, systolic and diastolic blood pressure were measured non-invasively with a Critikon Dinamap vital 
signs monitor 1846 and calculated as mean values from five readings. Measurements were made after a 30-
minute resting period in sitting position with two-minute intervals between successive measurements.  
 
 
4.2.4 Research specific blood tests 
A volume of 8 ml of blood was withdrawn from an antecubital vein and collected in prechilled vacutainer 
tubes containing ethylenediaminetetraacetic acid or clot activator respectively and mixed rapidly. Plasma or 
serum were separated by centrifugation at 2500 rpm for 12 minutes within 15 minutes of collection. Aliquots 
were stored at minus 70 degree Celsius.  
In order to differentiate physiologically upregulated biomarker expression levels during the peripartum 
period from pathological values and to obtain reference values, we obtained serum from 20 female 
volunteers without history of cardiac or recent infectious disease, normal ECG and physical examination, 
who were in the peripartum period. Controls were comparable in terms of age, race, body mass index, time 
after delivery and parity. All serum samples used in this study were thawed only once. 
None of the patients or volunteers received anti-inflammatory drugs during the four weeks preceding the 
sample they donated for the determination of inflammatory cytokines. All blood specimens were collected at 
Chris Hani Baragwanath Hospital and the plasma and serum obtained stored on site at minus 70 degrees 
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Celsius. The aliquotted samples were then transferred on dry ice to Emory University School of Medicine, 
Department of Pathology & Laboratory Medicine, Atlanta, USA.  
All plasma and serum samples used in this study were thawed only once for the measurement of biomarkers 
by commercially available enzyme linked immunosorbent assays (ELISA) according to the manufacturer’s 
instructions: Big endothelin-1 (Assay Designs, Ann Arbor, MI, USA),  NT-proBNP, prolactin (ALPCO, 
Wingham, NH, USA), 17-beta estradiol, Fas/APO-1, IFN-gamma, IL-1beta, IL-6, TNF-alpha, TGF-beta1 
(Biosource, Camarillo, CA, USA), ACE, MMP-2, MMP-9, PLGF, VEGF (R&D Systems, Minneapolis, MN, 
USA) and oxLDL (Mercodia, Uppsala, Sweden). Detailed protocols for each test are included in the 
appendix. Due to logistical reasons, oxLDL was measured only in 28 patients. The average of two 
measurements in undiluted plasma or serum was calculated.  
 
4.2.5 Statistical analysis 
Data were analysed using the SAS version 9.1 statistical program (SAS, Cary, NC, USA). Results are 
expressed as median (range) (201). We used Wilcoxon Scores (Rank Sums) for comparison between all 
patients at baseline versus healthy controls and improvers vs. non-improvers as data were non-normally 
distributed data.  
As data were non-normally distributed, we performed log transformation to the differences of all variables 
between six months and baseline for both groups, improvers and non-improvers. Subsequently we used 1-
way analysis of covariance (ANCOVA), adjusted for baseline left ventricular ejection fraction to compare 
between groups. Significance was assumed at a two-tailed value of P< 0.05.  
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4.3 Results 
Thirty-eight out of 43 patients completed the follow-up period of six months - three patients had died and 
two had moved to remote areas and were not available for follow-up. Patients presented with a median parity 
of 2 [1-6] and reported onset of symptoms at a median of 11 days postpartum [-22 - 111]. The median age 
was 30 years [17-45] and 23.2% had undergone caesarean section. The mean haemoglobin at time of 
presentation was 11.3±2.1 g/dl and mean BMI was 26.3±7.0. Cardiac transplantation or LV assist device for 
the population studied was unavailable due to economic reasons.  
In order to identify abnormal values in PPCM patients, we compared data to 20 controls from the same 
population who were also in the peripartum period. All were in NYHA FC I, had no cardiac history, ECG 
abnormality or cardiac physical findings. Age, sex, body mass index and parity of controls were comparable 
to the PPCM patients.  
During re-assessment after six months of standard cardiac failure therapy 25 patients were classified as 
cardiac function improvers and 13 as non-improvers. Patients were considered to be cardiac function 
improvers if their LVEF as determined by echocardiography improved by at least 10 units and their NYHA 
FC improved by at least one grade. Data were then analysed between cardiac function improvers and non-
improvers.  
 
4.3.1 Markers of cardiac function in improvers and non-improvers of PPCM 
Patients presented with a with a heart rate of 99.7±19 beats per minute, a mean systolic blood pressure of 
113.4±20.0 mmHg and a diastolic blood pressure of 75.6±13.4 mmHg. The median LVEF among all 
patients was 29.5% [13-39] with a median LVESD of 4.9 mm [3.6-6.3] and a median LVEDD of 5.6 mm 
[4.3-7.3]. Representing markers of cardiac function, we measured levels of angiotensin-converting enzyme 
(87), the marker of apoptosis Fas/APO-1, oxidized low density lipoprotein (oxLDL) and the indicator of 
heart failure NT-proBNP in PPCM patients at baseline and after 6 months. We compared values to samples 
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obtained from controls from the same population, who were in the peripartum period, from the same age 
group and parity without cardiac dysfunction or history thereof.  
 
Parameters Median baseline Range n Controls Range n p-value 
Fas/APO-1 
(ng/ml) 0.34 0.13-5.29 38 0.13 0.09-0.30 21 <0.0001 
oxLDL 
(IU/ml) 16.1 15.3-19.4 28 8.6 7.5-9.3 21 <0.0001 
NT-proBNP 
(fmol/ml) 1727.2 
988.7-
3077.7 36 339.5 
184.6-
715.6 21 <0.0001 
Table 4.1: Markers of cardiac function between PPCM patients and controls at baseline 
 
NT-proBNP is a marker of cardiac failure and PPCM patients had significantly elevated median 
serum levels at baseline as compared with healthy peripartum controls (P<0.0001) and median serum levels 
of NT-proBNP were significantly higher in non-improvers than in improvers (P=0.0013) at baseline (tables).  
While median plasma levels of the marker of apoptosis Fas/APO-1 and the marker of oxidative stress 
oxLDL were significantly (p<0.0001) elevated among PPCM patients as compared to healthy controls 
(P<0.0001), differences between improvers and non-improvers at baseline and after six months were non-
significant.  
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Parameters 
at baseline 
Improvers 
median 
baseline 
Range N 
Non-
improvers 
median 
Range n p-value 
Fas/APO-1 
(ng/ml) 0.33 0.12-5.29 27 0.34 0.12-0.82 11 NS 
oxLDL 
(IU/ml) 16.14 
14.59-
19.39 22 16.18 
15.42-
18.44 6 NS 
NT-proBNP 
(fmol/ml) 1635.1 
885.9-
2884.7 25 1818.1 
1427.8-
3077.7 11 0.0013 
Table 4.2: Markers of cardiac function between cardiac function improvers and non-improvers at baseline 
 
PPCM patients who were later identified as cardiac function improvers had a median LVEF at 
baseline of 23.0 [13-39] which is significantly lower (p=0.0084) than in non-improvers. While LVEF 
increased in this group to a median of 50.0% [25-63] after six months of treatment, the median LVEF of 
non-improvers was 32.0 [18-40] at baseline and increased only to 34% [21-46] after six months of treatment.  
The median NYHA FC was 3.0 [2.0-4.0] at baseline among improvers as well as among non-improvers 
(p=NS). The median NYHA FC after six months of treatment was 1 [1-3] among improvers and 2 [1-3] 
among non-improvers.   
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Parameter 
Median Δ 
Improvers 
baseline vs. 
6 months 
Range n 
Median Δ 
Non-
improvers 
baseline vs. 
6 months 
Range n p-value 
Fas/APO-1 
(ng/ml) -0.08 -0.56-0.59 27 -0.11 -0.49-0.13 11 NS 
oxLDL 
(IU/ml) -4.12 
-6.81-(-
0.46) 21 0.85 -2.88-2.44 5 NS 
NT-proBNP 
(fmol/ml) -616.28 
-2419.1-
255.55 24 -287.23 
-1008.5-
257.05 10 NS 
Table 4.3: Median Δ of markers of cardiac function from baseline to six months between improvers and 
non-improvers 
 
4.3.2 Markers of re-modeling in improvers versus non-improvers 
Parameter 
Patients 
median 
baseline 
Range n Controls median Range N p-value 
MMP-2 
(ng/ml) 368.5 
308.2-
474.9 36 142.2 
111.8-
184.9 21 <0.0001 
MMP-9 
(ng/ml) 873.2 
465.3-
1400.7 36 751.3 
465.1-
1338.8 21 NS 
TGF-β-1 
(ng/ml) 8.5 3.7-22.7 36 16.4 9.0-30.9 21 0.002 
VEGF 
(pg/ml) 83.8 1.1-1903.6 38 103.5 32.3-602.9 21 NS 
Table 4.4: Markers of re-modeling between PPCM patients and controls at baseline 
 
We reasoned that matrix-metallo-proteinase-2 (MMP-2), matrix-metallo-proteinase-9 (MMP-9), the anti-
apoptotic survival factor for T-lymphocytes transforming-growth factor β-1 (TGF-β-1) and vascular 
endothelial growth factor (VEGF) could serve as markers of re-modeling. Median baseline serum levels of 
MMP-2 were significantly higher among PPCM patients as compared to healthy controls (P<0.0001), while 
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levels of MMP-9 and VEGF were not. Interestingly, TGF-β-1 was significantly (P=0.002) lower in PPCM 
patients than among controls. None of these markers of re-modeling differed significantly between 
improvers and non-improvers at baseline or over time.  
 
Parameters 
at baseline 
Improvers 
median  Range n 
Non-
improvers 
median 
Range n p-value 
MMP-2 
(ng/ml) 356.7 
307.2-
461.0 25 391.1 
288.3-
474.9 11 NS 
MMP-9 
(ng/ml) 780.4 
1400.7-
334.1 25 961.9 
465.3-
1384.8 11 NS 
TGF-β-1 
(ng/ml) 8.55 3.05-22.65 25 7.30 2.4-16.45 11 NS 
VEGF 
(pg/ml) 79.0 0.0-1742.1 27 131.0 0.0-1903.6 11 NS 
Table 4.5: Medians of markers of re-modeling between improvers and non-improvers at baseline 
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Parameter 
Improvers 
baseline vs. 
6 months 
Range n 
Non-
improvers 
baseline vs. 
6 months 
Range n p-value 
Median Δ 
MMP-2 
(ng/ml) 
-64.13 -174.9-51.4 24 96.08 
-132.2- 
(-489) 
10 NS 
Median Δ 
MMP-9 
(ng/ml) 
-125.33 -560.7-226.3 24 -149.75 
-207.7-
298.15 10 NS 
Median Δ 
TGF-β-1 
(ng/ml) 
-4.15 -19.7-23.2 24 -1.2 -12.4-2.00 10 NS 
Median Δ 
VEGF 
(pg/ml) 
5.04 -821.38-851.64 27 -11.59 
-679.12-
263.30 11 NS 
Table 4.6: Median Δ of markers of re-modeling from baseline to six months between improvers and non-
improvers 
 
4.3.3 Kinetics of pro-inflammatory cytokines 
None of the patients included in this study had a concomitant inflammatory disease. Mean white cell count 
at time of presentation was 6.9±3.6 x109/L and well within normal limits. We measured levels of the Th1-
like proinflammatory cytokines interferon-gamma (IFN-gamma), interleukin-1 β (IL-1 β), interleukin-6 (IL-
6), tumor necrosis factor alpha (TNF-alpha) and C-reactive protein in this group of PPCM patients. Median 
baseline levels of all these pro-inflammatory markers were significantly higher among PPCM patients as 
compared to peripartum controls. While we were unable to detect significant differences of these markers 
between improvers and non-improvers at baseline, the kinetics over time revealed a significant reduction of 
median IFN-gamma levels among improvers (P=0.0181).  
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Parameter 
Patients 
median 
baseline 
Range N Controls median Range n p-value 
IFN-gamma 
(IU/ml) 2.9 1.9-5.6 36 0.16 0.05-0.31 21 <0.0001 
IL-1 β 
(pg/ml) 91.3 44.1-197.2 36 32.0 17.7-69.8 21 <0.0001 
IL-6 (pg/ml) 111.0 52.7-333.8 36 30.1 18.3-54.3 21 <0.0001 
TNF-alpha 
(pg/ml) 123.8 70.0-412.5 36 16.5 9.3-39.3 21 <0.0001 
CRP 12.2 1.0-250.7 39 2.6 1.0-42.8 21 0.0032 
Table 4.7: Pro-inflammatory cytokine levels between PPCM patients and controls at baseline 
 
We measured levels of the Th1-like proinflammatory cytokines interferon-gamma (IFN-gamma), 
interleukin-1 β (IL-1 β), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and C-reactive protein 
in this group of PPCM patients. Median baseline levels of all these pro-inflammatory markers were 
significantly higher among PPCM patients as compared to peripartum controls. While we were unable to 
detect significant differences of these markers between improvers and non-improvers at baseline, the 
kinetics over time revealed a significant reduction of median IFN-gamma levels among improvers 
(P=0.0181).  
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Parameters 
at baseline 
Improvers 
median Range N 
Non-
improvers 
median 
Range N p-value 
IFN-gamma 
(IU/ml) 2.95 1.87-5.59 25 2.09 1.82-3.79 11 NS 
IL-1 β 
(pg/ml) 86.8 37.9-140.4 25 96.8 36.3-197.2 11 NS 
IL-6 (pg/ml) 111.4 40.5-333.8 25 104.7 36.3-197.2 11 NS 
TNF-alpha 
(pg/ml) 135.1 58.5-330.0 25 111.3 51.2-412.5 11 NS 
CRP 12.1 1.0-250.7 27 12.2 1.0-88.4 12 NS 
Table 4.8: Medians of pro-inflammatory cytokines between improvers and non-improvers at baseline 
 
Parameter 
Improvers 
baseline vs. 
6 months 
Range N 
Non-
improvers 
baseline vs. 
6 months 
Range N p-value 
Median Δ 
IFN-gamma 
(IU/ml) 
-2.13 -5.43-2.06 24 1.21 -1.03-1.91 10 0.0181 
Median Δ 
IL-1 β 
(pg/ml) 
9.3 -113.55-99.6 24 -6.05 
-89.25-
44.20 10 NS 
Median Δ 
IL-6 (pg/ml) -48.2 
-259.8-
78.6 24 0.25 -89.25-52.7 10 NS 
Median Δ 
TNF-alpha 
(pg/ml) 
-38.05 -169.35-100.95 24 -18.18 
-98.95-
27.65 10 NS 
Median Δ 
CRP -4.4 
-146.3-
55.2 27 -8.6 -79.4-3.5 11 NS 
Table 4.9: Median Δ of pro-inflammatory cytokines from baseline to six months between improvers and 
non-improvers 
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4.3.4 Others 
 
Parameter 
Patients 
median 
baseline 
Range n Controls median Range N p-value 
Big E 
(pg/ml) 10.1 0.89-43.11 37 1.72 0.08-8.54 21 <0.0001 
PLGF 
(pg/ml) 6.17 0.00-376.6 38 4.57 2.48 21 NS 
Table 4.10: Other markers between PPCM patients and controls at baseline 
 
As in other forms of heart failure, patients usually present with tachycardia and fluid retention. Big 
endothelin-1 (Big E) is the precursor of endothelin-1. Activation is through endothelin converting enzyme. 
Endothelin-1 has a positive inotropic and chronotropic effect. Chronic inotropic and chronotropic 
stimulation leads to cardiac myocyte damage, apoptosis and progression of heart failure. Endothelin-1 also 
increases aldosterone activity which again leads to more fluid retention. Median big E plasma levels were 
significantly higher in PPCM patients than in controls (P<0.0001), but levels of placental growth factor 
(PLGF) did not show any significant differences between patients and controls, improvers vs. non-improvers 
or over time.  
Parameters 
at baseline Improvers Range n 
Non-
improvers Range N p-value 
Median Big 
E (pg/ml) 7.75 0.0-43.1 26 12.89 0.0-32.1 11 NS 
Median 
PLGF 
(pg/ml) 
6.32 0.0-376.6 27 6.01 1.28-10.94 11 NS 
Table 4.11: Other markers between improvers and non-improvers at baseline 
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Parameter 
Improvers 
baseline vs. 
6 months 
Range n 
Non-
improvers 
baseline vs. 
6 months 
Range N p-value 
Median Δ 
Big E 
(pg/ml) 
-4.57 -34.76-16.21 26 -10.19 -32.08-5.42 11 NS 
Median Δ 
PLGF 
(pg/ml) 
0.32 -372.93-117.63 27 0.15 -6.89-2.75 11 NS 
Table 4.12: Median Δ of other markers from baseline to six months between improvers and non-improvers 
 
 
4.3.5 Hormones 
Parameter Patients baseline Range n Controls Range N p-value 
Median 
estradiol 
(pg/ml) 
48.2 0.00-1547.0 38 0.00 0.00-309.6 20 NS 
Median 
prolactin 
(ng/ml) 
24.7 9.6-66.6 36 7.40 2.85-18.95 21 <0.0001 
Table 4.13: Hormone levels between PPCM patients and controls at baseline 
 
Kinetics of median estradiol plasma levels were difficult to interpret as the range of values is wide. In 
contrast, median prolactin serum levels were significantly higher in PPCM patients as compared with 
peripartum controls (P<0.0001), although there were no significant differences between improvers and non-
improvers at baseline or after six months. It is interesting to note though, that median prolactin serum levels 
among improvers decreased significantly (P=0.002) from 26.6 ng/ml [9.6-66.6] at baseline to 18.9 ng/ml 
[3.35-43.5] after six months. During the same time interval the decrease among non-improvers from 20.9 
ng/ml [10.8-54.0] to 17.8 ng/ml [2.1-46.6] was non-significant (P=0.069) 
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Parameters 
at baseline Improvers Range n 
Non-
improvers Range N p-value 
Median 
estradiol 
(pg/ml) 
62.1 0.0-1547.0 27 0.0 0.0-358.9 11 NS 
Median 
prolactin 
(ng/ml) 
26.6 9.6-66.6 25 20.85 10.8-53.95 11 NS 
Table 4.14: Median of hormones between improvers and non-improvers at baseline 
 
Parameter 
Improvers 
baseline vs. 
6 months 
Range N 
Non-
improvers 
baseline vs. 
6 months 
Range N p-value 
Median Δ 
estradiol 
(pg/ml) 
0 -1392.69-912.31 27 0 
-108.05-
330.86 11 NS 
Median Δ 
prolactin 
(ng/ml) 
-5.03 -47.65-10.85 24 -4.08 -28.85-6.9 10 NS 
Table 4.15: Median Δ of hormones from baseline to six months between improvers and non-improvers 
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5. IDENTIFICATION OF AGONISTIC AUTOANTIBODIES AGAINST THE ΒETA 1-
ADRENERGIC RECEPTOR AND THEIR POSITIVE CORRELATION WITH NT-PROBNP 
SERUM EXPRESSION LEVELS IN PERIPARTUM CARDIOMYOPATHY  
 
5.1 Introduction 
A general introduction to PPCM has been given in chapter one. We analysed the kinetics in serum and 
plasma expression levels of biomarkers in our previous studies (chapter 4 of this thesis), reflecting cardiac 
function, processes of remodeling, levels of pro-inflammatory cytokines and prolactin in PPCM patients 
over a period of six months. Several authors have described recovery of LV systolic function in up to 54% of 
PPCM patients (5, 192), while others develop chronic heart failure. In order to identify molecular pathways 
that determine whether cardiac function recovers or becomes chronically dysfunctional, we analyzed our 
data for differences between cardiac function improvers and non-improvers. While a wide range of 
parameters was elevated in all PPCM patients at time of first presentation, indicating their involvement in 
the initiation of the disease, we found significant differences over time between the two groups for IFN-
gamma (P=0.0181) and ACE serum levels (P=0.0493), indicating their role in disease progression. While 
higher ACE expression levels in cardiac function non-improvers reflect ongoing adrenergic stimulation, 
heightened IFN-gamma expression could indicate ongoing T-cell mediated autoimmune response and insult 
to the cardiac muscle, resulting in failure to improve left ventricular systolic function. Interestingly, Abel et 
al. observed that IFN-gamma response may play a role in the susceptibility of patients to develop chronic 
Chagas’ disease cardiomyopathy (232). Autoimmune mediated myocardial damage is likely to be a 
pathogenic mechanism for acquired dilated cardiomyopathies. Several authors described the possible role of 
agonist-like AAB that act against the β1-AR and the muscarinic M2-receptor in the pathogenesis of DCMO 
and Chagas' disease (125, 233). Beta-adrenergic signaling plays an important role in the natural history of 
dilated cardiomyopathies. Chronic activation of β-adrenergic receptors during periods of cardiac stress 
ultimately harms the failing heart by mechanisms that include alterations in gene expression (234). The 
myocardial β-AR are part of the family of G-protein coupled receptors. Three subtypes have been 
distinguished (β1-, β2- and β3-adrenoceptors), consisting of seven membrane-spanning domains, three intra- 
 118
and three extracellular loops, one extracellular N-terminal domain and one intracellular C-terminal tail (235). 
The β1-ARs mediate chronotropic and inotropic effects of catecholamines via the stimulatory G-protein 
(Gs). The β-adrenergic myocardial responsiveness and expression of the β1-AR receptor on the mRNA and 
protein level are reduced in DCMO patients, while expression of the inhibitory G-protein G(i) and the G-
protein receptor kinase are increased. This kinase induces uncoupling of β-AR and may either be induced 
through high catecholamine release or by agonist-like autoantibodies directed against the β1-AR found in 
patients with DCMO (125, 235, 236). The exposure to high levels of circulating catecholamines has been 
reported as toxic to cardiac myocytes, leading to myofibrillar degradation and increased cardiac collagen 
volume fraction mediated by β-AR stimulation (237, 238). Βeta1-AAB enhance the beating frequency of 
cultured neonatal rat cardiomyocytes, increase L-Type Ca2+ current, APD and contractility in freshly 
isolated cardiomyocytes mediated via β1-AR, possibly contributing to β1-AR mediated cardiotoxicity in 
heart failure (239). The postpartum exacerbation of autoimmune diseases has been described previously and 
is secondary to immune system changes during a normal pregnancy (240).  
The development of end-stage heart failure often involves an initial insult to the myocardium that reduces 
cardiac output and leads to a compensatory increase in sympathetic nervous system activity. Acutely, the 
sympathetic hyperactivity through the activation of β-adrenergic receptors increases heart rate and cardiac 
contractility, which compensate for decreased cardiac output. However, chronic exposure of the heart to 
elevated catecholamine levels may lead to further pathologic changes, resulting in continued elevation of 
sympathetic tone and a progressive deterioration in cardiac function. On a molecular level, altered β-AR 
signalling plays a pivotal role in the genesis and progression of heart failure (241).  
As described in chapter 4 of this thesis, we found significantly higher ACE serum levels over time in 
cardiac function non-improvers than in improvers (P=0.0493). In vivo and in vitro studies suggest that the 
effector hormones of the RAAS, angiotensin II and aldosterone, are primarily involved in regulating the 
structural remodeling of the myocardial collagen matrix (224). Henrich et al. found that renin release elicited 
by a circulating β-agonist functions independently of prostaglandin synthesis and that the pathway operates 
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via an extrarenal mechanism (242). Inflammation is a key mechanism in the initiation and progression of 
cardiomyopathy. Angiotensin II plays a significant role in the advent and perpetuation of inflammatory 
cardiovascular disease (225). Hyperactivation of the RAAS, heightened sympathetic drive and uncontrolled 
synthesis of inflammatory cytokines exacerbate ventricular contractile dysfunction in heart failure patients 
(226).  
In the present study we investigated the incidence of β1-AR AAB in serum of patients with PPCM  and their 
activity at time of presentation, after six and twelve months. We related the time-course pattern of their 
activity with changes in NYHA FC, LVEF, LVESD, heart rate and NT-proBNP expression levels. NT-
proBNP is suitable for heart failure monitoring and correlates well with clinical course in heart failure 
patients as described by others (243).  
 
5.2 Patients and Methods 
5.2.1 Study design and patient recruitment 
This study was approved by the Human Research Ethics Committee (HREC) of the University of the 
Witwatersrand, Johannesburg, South Africa (PRC 990409) and complies with the Declaration of Helsinki. 
All patients and controls gave written informed consent before entry into the study. We screened a total of 
39 patients to recruit 22 consecutive patients who met the inclusion criteria which are: (i) age ≥ 16 and ≤ 40, 
(ii) New York Heart Association functional class (NYHA FC) II-IV, (iii) symptoms of congestive heart 
failure that developed in the last month of pregnancy or during the first five months post-delivery, (iv) no 
other identifiable cause for heart failure, (v) left ventricular ejection fraction (LVEF) ≤ 40% by transthoracic 
echocardiography and (i) sinus rhythm.  
Exclusion criteria: (i) significant organic valvular heart disease, (ii) systolic blood pressure (SBP) > 160 
mmHg and/or diastolic blood pressure (DBP) > 100 mmHg, (iii) clinical conditions other than 
cardiomyopathy that could increase inflammatory markers, (iv) treatment with anti-inflammatory drugs, (v) 
 120
severe anaemia (haemoglobin < 9 g/dL), (vi) metabolic disorders affecting lipoprotein metabolism, i.e. 
thyroid disease.  
The study was conducted at Chris Hani Baragwanath Hospital, a tertiary institution located in Soweto, South 
Africa and linked to the University of the Witwatersrand, Johannesburg. The hospital is the sole tertiary 
medical facility for this community. Patients were referred from the department of obstetrics of our hospital, 
secondary hospitals and local clinics. Obstetric history, incl. pre-eclampsia and mode of delivery, was 
obtained from all patients and supplemented with data from the patients’ obstetric file. Clinical status, 
symptoms and signs, echocardiography and blood analysis were assessed at time of presentation (baseline), 
after six and twelve months of standard heart failure treatment. These were the three time points of the study. 
Besides the clinically indicated routine blood tests, we collected one additional tube of blood (4 ml) from 
every patient to obtain serum for measurement of research-specific β1-AR AAB and NT-proBNP expression 
levels.  
Following the initial screening and baseline visits, monthly outpatient visits were scheduled for clinical 
assessment and evaluation of medication compliance. All patients received treatment with diuretics and the 
angiotensin-converting enzyme inhibitor enalapril. Patients with an EF ≤ 25% or LV thrombus received anti-
coagulatory therapy. The β-blocker carvedilol was added after resolution of overt heart failure and the dose 
was slowly titrated up to a target of 25 mg twice daily as long as SBP was ≥ 100 mmHg or symptoms such 
as dizziness did not occur. 
Primary endpoints of this study were the activity of  β1-AR AAB in serum (measured as the number of 
additional beats per minute), New York Heart Association functional class (NYHA FC), left-ventricular 
ejection fraction (LVEF) and NT-proBNP serum expression levels at time of presentation, after six and 
twelve months.  
 
5.2.2 Echocardiographic studies, assessment of New York Heart Association functional class and non-
invasive blood pressure measurements 
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All studies were performed and interpreted by the same operator who was blinded to the protocol. 
Two-dimensional targeted M-mode echocardiography with Doppler color flow mapping was 
performed using a Hewlett Packard Sonos 5500 (Philips, Bothell, Washington) echocardiograph 
attached to a 2.5 or 3.5 MHz transducer. Left ventricular dimensions were measured according to the 
American Society of Echocardiography guidelines (198). Measurements of LV dimensions and 
function were determined on an average of > 3 beats. All echocardiographic studies were recorded on 
videotape and stored at Chris Hani Baragwanath Hospital, Division of Cardiology for future 
reference and audit purposes. 
A physician, who was provided with the clinical data, but blinded to the study protocol and unaware 
of the results of the laboratory tests, evaluated the NYHA FC of each patient during baseline and 
follow-up visits.  
Heart rate, systolic and diastolic blood pressure were measured non-invasively with a Critikon Dinamap vital 
signs monitor 1846 and calculated as mean values from five readings. Measurements were made after a 30-
minute resting period in sitting position with two-minute intervals between successive measurements.  
 
5.2.3 Research specific blood tests 
In order to measure the activity of β1-AR AAB and NT-proBNP serum expression levels, a volume of 4 ml 
of blood was withdrawn from an antecubital vein, collected in a prechilled vacutainer tube containing clot 
activator and mixed rapidly. Serum was separated by centrifugation at 2500 rpm for 12 minutes within 15 
minutes of collection. All serum samples from patients and controls were obtained at Chris Hani 
Baragwanath Hospital and stored on site at minus 70 degrees Celsius. To measure the activity of β1-AR 
AAB the aliquotted samples were transferred on wet ice to Max Delbrück Center for Molecular Medicine 
(MDC), Berlin, Germany. The immunoglobulin fraction was isolated from 1ml serum samples by 
ammonium sulfate precipitation at a saturation of 40% overnight. After centrifugation, the precipitate was 
washed and dissolved in buffer containing 154 mmol/l NaCl and 10 mmol/l sodium phosphate, pH 7.2. We 
repeated two cycles of precipitating, washing, centrifugation and dissolving. Finally, the precipitated 
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immunoglobulins were taken up in 0.7 ml buffer and dialyzed at 4°C for 60 hours against 1 L of this buffer. 
The buffer was exchanged five times during dialysis.  
Serum expression levels of Fas/Apo-1 were measured according to the manufacturers’ instructions, using 
commercially available enzyme immunoassays (ALPCO, Windham, NH, USA) and performed after 
shipment on dry ice at Emory University School of Medicine, Department of Pathology & Laboratory 
Medicine, Atlanta, USA.  
In order to differentiate physiologically upregulated NT-proBNP expression levels during the peripartum 
period from pathological values and to obtain reference values for the activity of β1-AR AAB, we obtained 
serum from ten female volunteers without history of cardiac or recent infectious disease, normal ECG and 
physical examination, who were in the peripartum period. Controls were comparable in terms of age, race, 
body mass index and parity. All serum samples used in this study were thawed only once. 
 
5.2.4 Cell culture and antibody characterization 
Autoantibodies against the β1-adrenoreceptor from patients with dilated cardiomyopathy (DCM) increase 
the beating frequency of cultured neonatal rat cardiomyocytes (239). Neonatal rat cardiomyocytes were 
isolated and cultured as previously described (244). Briefly, single cells were dissociated from minced 
ventricles of one to three days old Sprague Dawley rats with 0.2%  solution of crude trypsin and cultured 
with a density of 160,000 cells/cm2 in a SM 20-I medium, containing 10% neonatal calf serum and 2 µmol/l 
fluorodeoxyuridine to prevent proliferation and overgrowth of any non-myocytes (245). The cells were 
incubated with 2 ml fresh serum-containing medium on the fourth or eight day respectively. The contracting 
rate of eight to ten spontaneously beating single or clustered cardiomyocytes was counted for 15 seconds on 
the heated desk (37°C) of an inverted microscope. In order to yield results, we repeated this procedure in 
different cultures. The isolated autoantibodies (immunoglobulins), agonistic and antagonistic drugs, 
peptides, etc. were added either separately or cumulatively, as indicated. The immunoglobulin preparations 
were pretreated with monoclonal anti-human IgG1, IgG2, IgG3 and IgG4 antibodies for one hour at room 
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temperature in order to determine the IgG subclass. The samples were treated with a mouse anti-human IgG 
antibody to enlarge the immunoglobulin complex. After further 30 min. the samples were centrifuged for 15 
minutes at 13,000 rpm (Biofuge Fresco, Heraeus Instruments, Ostenrode, Germany) to obtain the 
supernatant used in the experiments. The antibodies were neutralized with peptides corresponding to the 
first, second, and third extra-cellular loop of the β1-AR in order to define the extra-cellular receptor 
structures that are recognized by the antibodies. The epitopes were identified using short overlapping 
peptides of the extra-cellular loops. In this experiment 50 µl of the human IgG preparation were incubated 
for one hour at room temperature with 50 µl of the short overlapping peptides (10µg/ml). The samples were 
centrifuged at 13,000 r.p.m. (as described above) to use the supernatant with the neutralized antibodies in the 
experiments. 
  
5.2.5 Statistical analysis 
Analyse-it version 1.71 statistical program (Analyse-it for Microsoft Excel, Leeds, UK) was used to describe 
the means ± standard deviation or medians and their range in [ ] as indicated. P-values for parametric data 
between baseline, six and twelve months were calculated by use of ANOVA 1-way repeated measures. P-
values for non-parametric data between baseline, six and twelve months were calculated by use of the 
Friedman test. Significance was assumed at a two-tailed value of P<0.05 and all significant results were 
calculated by both, ANOVA 1-way repeated measures and the Friedman test. In cases where results differed 
between the tests, we displayed the less significant P-value. We used Spearman rank correlation to analyze a 
possible correlation between differences of β-1 AR AAB activity and differences in NT-proBNP expression 
levels at the three time points of the study.   
 
5.3 Results 
After a follow-up period of twelve months, data from 20 out of 22 enrolled patients were available. Two 
patients had moved to remote areas and were not available for follow-up. Patients presented with a median 
 124
parity of 2 [1-5] and reported onset of symptoms at a median of 17.5 days postpartum [8-30]. The mean age 
was 28.9±6.3 years and 9.1% had undergone caesarean section. The mean haemoglobin at time of 
presentation was 12.6±1.4 g/dl and median BMI was 23.0 [21.3-27.5]. Cardiac transplantation or LV assist 
device were unavailable for the population studied for economic reasons. All patients in this cohort were 
HIV-negative. 
 
5.3.1 Functional characterization of β1-adrenoreceptor antibodies in PPCM patients 
The basal contracting rate of the spontaneously beating neonatal rat cardiomyocytes in the described model 
was 162 ± 8 beats/ min. Addition of the antibody-containing IgG preparation from PPCM patients to the 
spontaneously beating rat cardiomyocytes exerted a positive chronotropic response in these cells. The effect 
was dose dependent with a maximal response at an antibody dilution of 1:50 (Fig.5.1).  
 
Figure 5.1: Dose response curve of AAB against the β1-adrenoreceptor in PPCM patients 
 
 125
The positive chronotropic effect was antagonized by the selective β1-adrenergic antagonist bisoprolol 
(1µM). Addition of the angiotensin II blocker losartan (1µM) or the α1-adrenergic receptor antagonist 
prazosin (1µM) did not influence the agonistic effect induced by the β1-adrenoreceptor antibodies. 
Moreover, the peptide YFLL (1µg/ml) that was described as an inhibitory peptide of the human platelet 
thrombin receptor PAR-1 (proteinase activated receptor), was also without inhibitory effect (figure 5.2).  
 
Figure 5.2: AT1-, α1- and β1- adrenergic receptor antagonist effect 
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The agonistic effect of the diluted IgG preparation (1:20) from patients diagnosed with PPCM and DCMO in 
comparison to healthy controls is demonstrated in figure 5.3. While the addition of the selective β1-
adrenergic antagonist bisoprolol inhibited the positive chronotropic effect of the synthetic β1- and β2-
sympathomimetic isoprenaline on cardiomyocytes only partially, the effect induced by antibodies isolated 
from patients with PPCM was blocked completely, identifying them as β1-adrenoreceptor antibodies. 
Importantly, the addition of immunoglobulins obtained from non-PPCM controls, did not alter the 
cardiomyocyte beating rate. 
 
Figure 5.3: Influence of the β1-adrenergic antagonist bisoprolol 
 
In order to further define the β1-adrenoreceptor antibodies, we treated them with peptides corresponding to 
the first, second and third extra-cellular loop of the β1-adrenoreceptor. Beta-1 adrenoreceptor antibodies 
obtained from serum of PPCM patients exclusively recognized epitopes on the second extra-cellular loop, 
while those from DCMO patients bind to epitopes of the first (30%) and second extra-cellular loop (70%).  
In another set of experiments we characterized the epitopes recognized by the β1-adrenoreceptor antibodies 
of PPCM and DCMO patients. The β1-adrenoreceptor antibodies of PPCM patients were neutralized by the 
second extra-cellular loop peptides RAESDE and DEARRCY (figure 5.4), while the other peptides of this 
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loop did not influence the agonist-like activity of the antibodies. In contrast, the β1-adrenoreceptor 
antibodies of DCMO patients were neutralized by the peptides ARRCYND and PKCCDF (figure 5.5), while 
the epitopes DEARRCY and ARRCYND partially overlap.  
 
Figure 5.4: Epitope analysis in PPCM patients 
 
 
Figure 5.5: Epitope analysis in DCMO patients 
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Subsequently, we identified the IgG subclasses of agonistic β1-adrenoreceptor antibodies. From previous 
investigations we know that functional antibodies represent immunoglobulins of the IgG class (data not 
shown). Therefore, we used monoclonal anti-human IgG1, IgG2, IgG3 and IgG4 antibodies to precipitate the 
functional antibodies of the immunoglobulin fraction. Figure 5.6 shows agonist-like antibodies of the IgG2 
and IgG3 subclass prepared from PPCM patient serum samples.. The second extra-cellular loop β1-
adrenoreceptor antibodies of DCM patients are exclusively antibodies of the IgG2 subclass (Figure5.7). 
 
Figure 5.6: IgG subclasses of β1-adrenergic AAB in PPCM patients (II. loop) 
 
 
Figure 5.7: IgG subclasses of β1-adrenergic AAB in DCMO patients (II. loop) 
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The addition of the β1/2 adrenoreceptor agonist isoprenaline (10 µM) caused a positive chronotropic effect 
in the spontaneously beating rat cardiomyocytes and induced desensitization of the β-adrenergic response. 
After two hours of incubation with isoprenaline the chronotropic response was moderately reduced. 
However, after a washing procedure and subsequent re-stimulation with isoprenaline, cell response reached 
only one third of the agonist’s maximal response. In contrast, the β1-adrenoreceptor antibodies of PPCM 
patients exerted a long-lasting stimulatory effect on the cultured rat cardiomyocytes that was not reversed by 
washing with fresh, warm complete cell culture medium, but was interrupted by the β1-adrenergic antagonist 
bisoprolol. Apparently the addition of bisoprolol removed the β1-adrenergic receptor antibodies from their 
binding sites, because removal of β1-adrenergic antagonist did not induce an increase in beating rate. Under 
these conditions renewed stimulation with isoprenaline exerted a maximal response in beating rate, while 
long-lasting stimulation of β1-adrenoreceptors usually desensitizes the β1-adrenoreceptor signaling cascade. 
These results suggest that the PPCM patient’s β1-adrenoreceptor antibodies prevented desensitization of the 
β1-adrenoreceptor (figures 5.8 and 5.9).  
 
Figure 5.8: The β1-adrenoreceptor autoantibody in a dilution of 1:40 exerts a long-lasting positive 
chronotropic effect without desensitization of the β1-adrenoreceptor signal cascade 
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Figure 5.9: The β1-adrenoreceptor autoantibody prevents receptor desensitization induced by the β1-
adrenoreceptor agonist isoprenaline.   
 
 
5.3.2 Clinical status of PPCM patients and positive correlation of β1-adrenoreceptor antibodies with 
NT-proBNP serum expression levels 
 
Patients presented with a mean heart rate of 93.4±16.7 b.p.m., systolic blood pressure of 105.9±17.0 mmHg 
and a diastolic blood pressure of 69.8±13.9 mmHg. The mean LVEF among all patients at time of 
presentation was 29.3±8.5% with a mean LVEDD of 5.5±0.6 mm. and LVESD of 4.8±0.7 mm. Median 
levels of NT-proBNP were 1673.7 fmol/ml [1076.5-2593.3] and significantly higher (P<0.0001) than in 
controls 339.5 fmol/ml [252.8-440.6]. Addition of baseline serum samples from human PPCM patients as 
described above revealed the presence of agonist-like AAB directed against the β1-adrenoreceptor in all 
PPCM patients, but not in peripartum non-PPCM controls (figure 5.1 and 5.3) and was quantified as 23.2 
[19.2-27.2] additional beats per minute.  
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Figure 5.10: Decreasing activity of agonist-like AAB directed against the β1-adrenoreceptor (y-axis reflects 
additional beats per minute, x-axis indicates time in months.) 
 
Patients were followed-up once a month or more frequently, if clinically indicated. At time of re-assessment 
after six months, mean haemoglobin (13.6±1.3 g/dl, P=015) and median BMI were stable 23.3 [20.8-25.6] 
(P=0.27) as compared to baseline. The mean heart rate of the initially tachycardiac patients had dropped 
significantly (P=0.0006) since time of first presentation to 76.0.4±11.8 beats per minute and within normal 
range, while systolic (105.1±14.5 mmHg, P=0.91) and diastolic blood pressure were unchanged (67.5±12.7 
mmHg, P=0.42). The mean LVEF had improved significantly (P<0.0001) since baseline assessment to 
43.7±11.6%, mainly due to a significant reduction of LVESD (4.0±0.8 mm, P=0.0006), while the reduction 
of mean LVEDD (5.2±0.8 mm, P=0.09) was non-significant. During the same time interval NYHA FC 
(1.5±0.7, P<0.0001) and NT-proBNP levels improved significantly (P=0.0075) to 936.2 fmol/ml [713.7-
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2061.4]. Simultaneously the activity of agonist-like AAB directed against the β1-adrenoreceptor decreased 
significantly (P=0.0006) to 15.2 [10.4-19.2] as shown in figure 5.10.  
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Figure 5.11: Decreasing serum expression levels of NT-proBNP (fmol/ml) on the y-axis over time in 
months (x-axis) 
 
After twelve months of anti-failure treatment, mean haemoglobin (13.0±1.6 g/dl, P=0.98) and median BMI 
were unchanged 23.1 [20.5-26.1] (P=0.07) as compared to assessment at six months. The mean heart rate 
(82.0±14.1 b.p.m., P=0.1), systolic (110.0±15.5 mmHg, P=0.08) and diastolic blood pressure (69.5±12.5 
mmHg, P=0.50) were stable as well. Also the mean LVEF (43±13.0 %, P=0.88), LVEDD (5.1±0.8 mm, 
P=0.65), LVESD (4.0±0.9 mm, P=0.51) and NYHA FC (1.5±0.6 (P=0.71) remained unchanged. However, 
the activity of the agonist-like AAB directed against β1-AR continued to decrease significantly (P=0.0076) 
to 1.9 [0.00-14.5] in parallel with serum expression levels of NT-proBNP to 722.3 fmol/ml [480.3-1628.1] 
(P=0.0076). While changes in β-1 adrenoreceptor AAB activity and LVEF or NYHA FC did not correlate, 
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we found a significant positive correlation with NT-proBNP from baseline to twelve months (rs=0.58, 2-
tailed P=0.0228), 95% CI (0.10 to 0.84).   
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Figure 5.12: Positive correlation between kinetics of β-1 adrenoreceptor AAB and NT-proBNP expression 
levels 
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6. THE ADDITION OF BROMOCRIPTINE TO STANDARD HEART FAILURE THERAPY 
PREVENTS DETERIORATION OF LEFT VENTRICULAR DIMENSIONS AND SYSTOLIC 
FUNCTION IN PPCM PATIENTS WITH A SUBSEQUENT PREGNANCY 
 
6.1 Introduction 
A general introduction to PPCM has been given in chapter one and readers are referred to the more specific 
introduction to subsequent pregnancy in chapter 1.9. Recurrence of heart failure in a subsequent pregnancy 
in PPCM patients has been well described and women should be counseled to avoid a subsequent pregnancy 
after diagnosis of PPCM (9). If ventricular function does not return to normal after pregnancy, subsequent 
pregnancies have been associated with maternal mortality rates of 19 to 50 percent (196). Even in those 
whose LV function returns to normal, deaths have been reported with subsequent pregnancies (58).  
Fett et al. described the outcome of 16 subsequent pregnancies in 15 women with PPCM after the index 
pregnancies. Eight of these patients experienced worsening heart failure; of these, one died and one regained 
normal left ventricular systolic function. Seven patients tolerated pregnancy without worsening heart failure, 
and ventricular function recovered in these patients within 30 months after the subsequent pregnancy. 
However, all but one patient became pregnant before full recovery of LV systolic function and against 
medical advice. Eight of 15 patients had worsening heart failure during subsequent pregnancy and only one 
of these patients regained normal LV systolic function after subsequent pregnancy. Seven patients showed 
no worsening of heart failure during subsequent pregnancy and recovered normal LV systolic function 
during or after the subsequent pregnancy. Except for recovery of LV systolic function, the authors could not 
find a distinguishing feature between the group that fully recovered and the group that continued to have 
abnormal heart function (246).  
As much as doctors can advise patients to avoid subsequent pregnancies in known PPCM, some patients do 
present with a subsequent pregnancy, creating an ethically challenging dilemma. On the one hand the life of 
the mother should be preserved, especially if there are other children depending on her. On the other hand 
every effort should be made to safe the life of the unborn child.  
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In 2004 Hilfiker-Kleiner et al. described the occurrence of PPCM in cardiac tissue specific STAT3 knock-
out mice. As detailed in figure 6.1, the physiological postpartum activation of the prolactin receptor in 
healthy women results in secretion of a 24 kDa prolactin. Postpartum activation of this prolactin receptor in 
STAT3 knock out mice resulted in cathepsin D facilitated cleavage of the 24 kDa prolactin into 16 and 8 
kDa proteins. In vitro the 16 kDa prolactin inhibited endothelial cell proliferation and increased fibroblast 
proliferation. STAT3-deficient female mice showed increased cardiac apoptosis and reduced cardiac 
function and survival postpartum. Bromocriptine, a dopamine- D2 receptor antagonist that inhibits prolactin 
secretion, prevented PPCM in these mice, restored cardiac function and structure and prevented apoptosis 
(133, 136, 141). 
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Figure 6.1: Mechanism of STAT3 knock-out in the pathogenesis of PPCM,  
adapted from Hilfiker-Kleiner et al. (133)  
 
In light of the above findings, it seems appropriate to discuss the role of sex hormones and their effect on 
PPCM. It has long been established that both estrogen and prolactin have a reciprocal endocrinologic 
relationship and both hormones have pleiotropic effects on the immune system. Despite the presence of a 
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number of confounding variables, these hormones modulate immune response and have been implicated in 
the development of autoimmunity. However, mechanisms by which this modulation occurs remain obscure. 
Estrogen appears to suppress cell-mediated and augment humoral-based immunity. Prolactin appears to 
stimulate both cell and humoral-based immunity. Both hormones have been shown to modulate IFN gamma 
secretion. Experimental models of human autoimmune disease and autoimmune disease during pregnancy 
suggest disparate effects of estrogen and prolactin on autoimmune responses and disease pathogenesis. In the 
NZBXNZW (B/W) F1 mouse model of lupus, prolactin accelerates disease expression, whereas estrogen, 
devoid of its prolactin stimulating properties, is immunosuppressive and inhibits IL-2 production. Estrogen 
may directly or indirectly stimulate or inhibit immune responses due to its endocrinologic and immune 
effects. These dichotomous effects have limited its successful pharmacologic manipulation in human 
autoimmune disease with estrogen compounds, tamoxifen, oral contraceptives, antigonadotropic agents, or 
ovulation induction regimens. In contrast, reduction of immunostimulatory concentrations of prolactin with 
bromocriptine has successfully suppressed development, induction  or expression of murine and human 
autoimmune disease (80). 
The occurrence of a subsequent pregnancy in PPCM patients is rare and therefore the number of patients 
studied for this specific recurrent disease is small. Nonetheless, notwithstanding the small numbers, it's 
occurrence prompted a closer examination of the clinical and laboratory parameters and hence the rationale. 
Since the use of bromocriptine in addition to standard heart failure therapy was being evaluated in this 
population at the initiation of this study, the role of bromocriptine therapy on subsequent pregnancy can be 
viewed as the assessment of it's potential use as a preventive medication. Further studies are nonetheless 
needed to draw statistically meaningful conclusions and to determine a potential preventive/prophylactic and 
possibly curative effect of bromocriptine. However, since our data on PPCM patients with a subsequent 
pregnancy is very encouraging and the condition carries a high mortality rate, we decided to present it at an 
early stage.  
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6.2. Methods 
6.2.1 Study design and patient recruitment 
This study was approved by the Human Research Ethics Committee (HREC) of the University of the 
Witwatersrand, Johannesburg, South Africa (PRC 990409) and complies with the Declaration of Helsinki. 
All patients and controls gave written informed consent before entry into the study. Since PPCM occurs in 
previously healthy women who cannot be identified beforehand, we enrolled patients who had recovered 
from a previous episode of PPCM and presented with a subsequent pregnancy. All PPCM patients had been 
routinely advised to avoid subsequent pregnancies and referred to the gynecologist for choice of 
contraceptive method. However, some patients did present with a subsequent pregnancy and decided to 
carry the pregnancy to term. The inclusion criteria were: (i) documented previous episode of PPCM and (ii) 
decision to carry on with the current pregnancy.  
Exclusion criteria: (i) significant organic valvular heart disease, (ii) systolic blood pressure (SBP) > 160 
mmHg and/or diastolic blood pressure (DBP) > 100 mmHg, (iii) clinical conditions other than 
cardiomyopathy that could increase inflammatory markers, (iv) treatment with anti-inflammatory drugs, (v) 
severe anaemia (haemoglobin < 9 g/dL), (vi) metabolic disorders affecting lipoprotein metabolism, i.e. 
thyroid disease.  
The study was conducted at Chris Hani Baragwanath Hospital, a tertiary institution located in Soweto, South 
Africa and linked to the University of the Witwatersrand, Johannesburg. Obstetric history, incl. pre-
eclampsia and mode of delivery, was obtained in close collaboration with the Department of Obstetrics at 
our hospital. Clinical status, symptoms and signs, echocardiography and blood analysis were assessed pre- 
and post-delivery and three months postpartum. These were the three time points of the study. Besides the 
clinically indicated routine blood tests, we collected one additional tube of blood (4 ml) from every patient 
to obtain plasma for measurement of research-specific cathepsin-D, 16- and 23-kDa prolactin expression 
levels. Following the initial screening and baseline visits, monthly outpatient visits were scheduled for 
clinical assessment and evaluation of medication compliance.  
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6.2.2 Echocardiographic studies, assessment of New York Heart Association functional class and non-
invasive blood pressure measurements 
All studies were performed and interpreted by the same operator who was blinded to the protocol. 
Two-dimensional targeted M-mode echocardiography with Doppler color flow mapping was 
performed using a Hewlett Packard Sonos 5500 (Philips, Bothell, Washington) echocardiograph 
attached to a 2.5 or 3.5 MHz transducer. Left ventricular dimensions were measured according to the 
American Society of Echocardiography guidelines (198). Measurements of LV dimensions and 
function were determined on an average of > 3 beats. All echocardiographic studies were recorded on 
videotape and stored at Chris Hani Baragwanath Hospital, Division of Cardiology for future 
reference and audit purposes. 
A physician, who was provided with the clinical data, but blinded to the study protocol and unaware 
of the results of the laboratory tests, evaluated the NYHA FC of each patient during baseline and 
follow-up visits.  
Heart rate, systolic and diastolic blood pressure were measured non-invasively with a Critikon Dinamap vital 
signs monitor 1846 and calculated as mean values from five readings. Measurements were made after a 30-
minute resting period in sitting position with two-minute intervals between successive measurements.  
 
6.2.3 Research specific blood tests 
In order to measure cathepsin-D, 16- and 23-kDa prolactin expression levels, 4 ml of blood were withdrawn 
from an antecubital vein, collected in a prechilled vacutainer tube containing clot activator and mixed 
rapidly. Serum was separated by centrifugation at 2500 rpm for 12 minutes within 15 minutes of collection. 
All serum samples from patients and controls were obtained at Chris Hani Baragwanath Hospital and stored 
on site at minus 70 degrees Celsius. In order to differentiate physiologically upregulated cathepsin-D, 16- 
and 23-kDa prolactin expression levels during the peripartum period from pathological values, we obtained 
serum from 5 female volunteers in the peripartum period without history of cardiac or recent infectious 
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disease, normal ECG and physical examination. Controls were comparable in terms of age, race, body mass 
index and parity. All plasma samples used in this study were thawed only once. 
Western blot for 16kDa prolactin: For immuno-precipitation 100 μl human serum was incubated with the 
PRL antibody (10 μl, 3 h) and subsequently with protein A-agarose (Roche) (50 μl over night) in 1xPBS and 
complete mini protein inhibitor cocktail (Roche). Then A-agarose protein complex was precipitated and 
washed three times with RIPA buffer. Finally the pellet was re-suspended in 1xLaemmli buffer loaded on 
12% SDS page gel. Proteins were transferred to nitrocellulose membrane (Amersham) and incubated with 
the PRL antibody. Bands were visualized with ECL (Amersham) on x-ray film (Kodak). 
Cathepsin D Activity Assay: CD activity was determined in patient serum using the InnoZyme CD 
Immunocapture Activity Assay Kit (Calbiochem) and a FLUOstar Galaxy. 
 
6.2.4 Treatment 
During pregnancy all patients received treatment with the diuretic furosemide and the β-blocker carvedilol at 
clinically indicated doses. Post-delivery we added the angiotensin-converting-enzyme inhibitor enalapril as 
long as SBP was ≥ 100 mmHg or symptoms such as dizziness did not occur. While the first four consecutive 
patients received standard heart failure therapy alone as described above, the next four consecutive patients 
additionally received bromocriptine 2.5mg twice daily, starting four hours post-delivery for two months.  
 
6.2.5 Statistical analysis 
Analyse-it version 1.71 statistical program (Analyse-it for Microsoft Excel, Leeds, UK) was used to describe 
the means ± standard deviation or medians (range) as indicated. P-values for parametric data between groups 
at the three time points of the study were calculated by using an independent samples t-test. P-values for 
non-parametric data were calculated with a Median test. Significance was assumed at a two-tailed value of 
P<0.05. Single parameters were calculated by continuous summary descriptives as means ± standard 
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deviation or medians with range [ ] as appropriate. Due to the small sample size we did not calculate P-
values between the three time points of the study.   
 
6.3. Results 
6.3.1 Clinical and echocardiographic data of PPCM patients presenting with subsequent pregnancy 
either on standard heart failure therapy alone or receiving additional bromocriptine  
All eleven patients were indigenous black women (age range 26 to 39 years) and presented with a median 
gravida of 4 [2-5]. The subsequent pregnancy occurred one to 6 years after the PPCM index pregnancy. 
None were twin or multiple pregnancies and none of the patients had pregnancy associated hypertension or 
eclampsia. All patients had a normal vaginal delivery at term. All except one patient were in NYHA FC I at 
onset of subsequent pregnancy and remained asymptomatic until delivery. Two patients on standard 
treatment alone died from severe refractory heart failure within eight weeks postdelivery despite optimal 
medical therapy. Changes in left ventricular ejection fraction are shown in table 6.1. 
Predelivery 
parameters Group 1 (n=5) Group 2 (n=6) P-value 
Mean ejection 
fraction (%) 48.2±12.2 47.4±9.0 0.9068** 
Mean LVEDD (cm) 5.29±0.09 5.94±0.76 0.0951** 
Mean LVESD (cm) 3.99±0.35 4.42±0.95 0.3655** 
Mean NYHA FC 1.4±0.89 1.0±0 0.3466** 
Table 6.1: Pre-delivery parameters of PPCM patients with subsequent pregnancy.  
Group 1: Standard heart failure therapy plus bromocriptine 
Group 2: Standard heart failure therapy only  
** 2-tailed p-value 
 
Four of the six patients had persistent cardiomegaly and impaired ejection fraction (40%) at onset of the 
subsequent pregnancy. At eight months of pregnancy, left ventricular ejection fraction remained unchanged. 
However, one month postpartum a significant deterioration (10% decrease in ejection fraction) was observed 
in all but one patient. The single patient whose ejection fraction remained unchanged had normal systolic 
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function to start with. At three months postpartum, two of the six patients on standard therapy died due to 
heart failure, with no improvement in ejection fraction in the remaining patients. Both deaths occurred in 
patients who had persistent cardiomegaly and impaired ejection fraction at onset of subsequent pregnancy. 
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Figure 6.2: Time course pattern of left ventricular ejection fraction in PPCM patients with subsequent 
pregnancy on standard heart failure therapy and with addition of bromocriptine 
 
 
In the bromocriptine group heart failure symptoms occurred in one patient during the last month of 
pregnancy and coincided with defaulting treatment for three weeks. All patients in the bromocriptine group 
maintained left ventricular ejection fraction and the patient who had defaulted recovered well. None of the 
patients in the bromocriptine group died. As shown in table 6.1, echocardiographic parameters did not differ 
significantly between groups pre-delivery. 
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Post-delivery 
parameters Group 1 (n=5) Group 2 (n=4) P-value 
Median LVEF (%) 37.6 (37.0) 30.3 (39.0) 0.7143* 
Mean LVEDD (cm) 5.72±0.29 6.25±0.39 0.0507** 
Median LVESD 
(cm) 4.55 (1.2) 5.35 (1.8) 0.3333* 
Table 6.2: Post-delivery parameters of PPCM patients with subsequent pregnancy.  
Group 1: Standard heart failure therapy plus bromocriptine 
Group 2: Standard heart failure therapy only  
* exact, double 1-tailed p-value 
**  2-tailed p-value 
 
 
Three months post-
delivery parameters Group 1 (n=5) Group 2 (n=4) P-value 
Mean LVEF (%) 48.8±11.0 25.5±5.5 0.0069** 
Median LVEDD 
(cm) 5.8 (0.7) 6.6 (1.1) 0.3333* 
Median LVESD 
(cm) 4.1 (1.2) 5.8 (1.3) 0.3333* 
Table 6.3: Three months post-delivery parameters of PPCM patients with subsequent pregnancy.  
Group 1: Standard heart failure therapy plus bromocriptine 
Group 2: Standard heart failure therapy only  
* Median test exact, double 1-tailed p-value 
**  2-tailed p-value 
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6.3.2 Presence of 16-kDa prolactin isoform in human PPCM patients and increased cathepsin D 
activity 
 
Figure 6.3: Increased cathepsin D activity and presence of 16-kDa prolactin in PPCM patients in 
comparison to controls.  
 
 
Figure 6.4: Presence of 23-kDa prolactin during the peripartum period in all samples, but absence of 16-kDa 
prolactin in bromocriptine-treated PPCM patients and healthy peripartum controls.  
 
We observed significantly increased levels of cathepsin D activity in serum of lactating PPCM patients as 
compared to lactating non-PPCM women (figure 6.3) from the same population. In addition, we readily 
detected the cleaved 16kDa prolactin by Western blot (figure 6.4) in serum of  three out of the five lactating 
PPCM patients with documented cardiac dysfunction at the time of serum collection (mean EF: 24±7%). 
Sera from five non-PPCM patients failed to demonstrate detectable levels of the 16-kDa prolactin. 
Interestingly, we were unable to demonstrate the presence of the 16-kDa prolactin in serum of patients 
treated with bromocriptine 2.5 mg twice daily in addition to standard heart failure therapy.  
      a) Cathepsin D activity b) Presence of 16-kDa Prolactin 
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7. DISCUSSION AND CONCLUSIONS 
 
7.1 Discussion: Clinical profile of 100 patients diagnosed with PPCM 
  
This study documented the clinical profile of 100 PPCM patients at a tertiary level hospital in South Africa 
and examined the role of plasma/serum pro-inflammatory markers at the time of diagnosis and clinical 
outcome after 6 months of treatment. Despite appropriate and optimal clinical care including ACE-inhibitors 
and carvedilol, 15% of patients died and only 23% of the studied population normalized their LVEF after 6 
months of therapy. Prognosis of patients with PPCM seems to vary according to topographical region. 
Whereas Felker et al. (193) reported a 94% survival rate in 52 patients diagnosed at John Hopkins Hospital 
in the USA, 14% died in a prospectively studied population in Haiti and only 20% regained normal left 
ventricular function (149). Poor socioeconomic status, subtle yet undefined nutritional deficiencies, genetic 
factors and inadequate pre- and postnatal care could contribute to these geographical differences. The only 
options for patients who do not regain normal left ventricular function are the use of left ventricular assist 
devices and cardiac transplantation. However, such options are not available in resource poor settings, such 
as in Haiti and South Africa. Patients that died had lower NYHA FC, LVEF and larger left ventricular 
dimensions at diagnosis compared to those who survived, whereas age, parity or onset of symptoms did not 
appear to play a role. Demakis et al. found that pathological findings in the myocardium of patients whose 
hearts had returned to normal size within six months of treatment and those whose hearts had not returned to 
normal size were indistinguishable (23). 
CRP is an acute-phase protein which recognizes a range of pathogenic targets including membranes of 
apoptotic and reactive cells (200). As this inflammatory marker is associated with adverse prognosis in 
patients with idiopathic dilated cardiomyopathy (247, 248), we investigated if levels of plasma CRP at 
baseline could predict outcome in patients with PPCM. Almost half of the population investigated had raised 
levels of CRP reflecting possibly the presence of a low-grade chronic inflammatory process due to the 
release of endotoxin or endotoxin like substances and subsequent release of proinflammatory cytokines 
(249).  However, we did not find a correlation with NYHA FC or death. None of the patients with PPCM 
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presented with symptoms during the antepartum period. This is in contrast to studies performed by others (6) 
and more in keeping with a study from Haiti (149) documenting that 96% of patients with PPCM developed 
heart failure in the post partum period. Our failure to include PPCM patients during the prepartum period in 
the present study was not due to a lack of identifying such patients since the cardiologists at Chris Hani 
Baragwanath Hospital are routinely involved in the care of pregnant patients presenting with symptoms and 
signs of congestive cardiac failure.  The majority of cases developed symptoms in the first 4 weeks post 
partum. Twenty percent of patients studied were primiparous. We could not confirm factors mentioned by 
others (6) as multiparity, older age, or long-term use of tocolytic agents to be associated with the 
development of PPCM. At presentation this group of patients had acute onset heart failure of short duration. 
There was no evidence of chronic disease or cardiac cachexia that could account for a low lipid profile being 
a marker of severe, chronic disease. Mean plasma levels of total cholesterol of the patient population studied 
was 4.2±0.8 mmol/L and low compared to that reported in other studies (250-252). In a study by Rauchhaus 
and colleagues with an established plasma cholesterol cut-off level of < 5.2 mmol/L, low total cholesterol 
level was found to be predictive for impaired 1-year survival (251). In line with findings by others (250, 
251) demonstrating an increase in the rate of mortality with low serum total cholesterol levels, we found an 
association of low total cholesterol levels with larger left ventricular dimensions and lower EF. There was a 
trend, but no statistically significant association between the rate of mortality which could possibly be 
explained by the short duration of the trial, the limited number of patients studied and the spontaneous 
recovery rate typical for patients with PPCM. Levels of low plasma cholesterol correlated positively with the 
levels of the inflammatory marker CRP. These findings are in support of the endotoxin-lipoprotein 
hypothesis (249) suggesting that lower plasma levels of total cholesterol provide lesser protection against 
endotoxins making a susceptible group of patients more prone to severe heart failure. A recent trial by Albert 
and colleagues (253) showed a significant variation in the distribution of plasma CRP levels among various 
ethnic groups living in the United States. Median plasma CRP levels were significantly higher among black 
women compared to their white, Hispanic or Asian counterparts. Since 40% of the variance of plasma CRP 
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levels is genetically determined and PPCM is much more frequent in black patients one could hypothesize 
that an increase in the intensity of an inflammatory response could be one of many factors contributing 
towards the development of PPCM. This is supported by our previous research in PPCM patients presenting 
with subsequent pregnancy where we observed an exaggerated postpartum pro-inflammatory cytokine surge 
possibly playing a role in the development of PPCM (254). 
Plasma levels of Fas/Apo-1 in the PPCM patients were significantly higher compared to healthy controls and 
a predictor of mortality, indicating that cardiac myocyte apoptosis may play a causal role in the pathogenesis 
of PPCM. This view is further supported by a non-randomised study in patients with PPCM where we have 
demonstrated improved clinical outcome in patients receiving pentoxifylline, an immuno-modulating agent, 
when used as a supplement to conventional therapy (148) as discussed below.  
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7.2 Discussion: Kinetics of cardiac function biomarkers, pro-inflammatory cytokines, markers of re-
modeling and prolactin in 43 PPCM patients over a six months period 
 
 
Prolactin cytokine feedback loop: We assessed the kinetics of biomarkers reflecting cardiac function, 
processes of inflammation and re-modeling as well as the hormone prolactin in a cohort of patients 
diagnosed with PPCM. The aim was to identify pathways and/or mechanisms involved in the initiation and 
progression of the disease in an effort to stratify possible future treatment options. While we found a whole 
range of biomarkers significantly elevated in patients vs. controls at baseline, reflecting their role during 
initiation of the disease, the significantly different kinetics between baseline and six months in improvers vs. 
non-improvers were narrowed down to the pro-inflammatory cytokine IFN-gamma that is involved in 
fibrosis and autoimmune activation and the regulatory angiotensin-converting enzyme, suggesting their 
involvement in progression of the disease.  
This process could be further enhanced through pro-inflammatory cytokines like TNF-alpha, IL-1 β and IL6 
(all of these were higher in our PPCM patients than in controls, P<0.0001) that again increase ACTH release 
by stimulating secretion of corticotrophin-releasing hormone (255). Inflammatory cytokines promote a 
"prolactin–cytokine positive feedback loop" by stimulating the release of pituitary prolactin (80). Vice versa, 
elevated serum prolactin concentrations have been correlated with increased levels of inflammatory 
cytokines. Brand et al. demonstrated that prolactin causes an increase in the binding activity of the intra-
cellular transcription factors nuclear factor-kappaB (NFkappaB) and interferon regulatory factor-1 (IRF-1), 
which are known to promote TNF-alpha and IL-12 secretion, suggesting that prolactin promotes a pro-
inflammatory immune responses (256). Di Rosa et al. observed that prolactin, which is structurally related to 
several cytokines and is involved in regulating monocyte/macrophage functions, upregulates chitotriosidase, 
a chitinolytic enzyme that is mainly produced by activated macrophages. The group exposed human 
monocytes/macrophages to pro-inflammatory stimuli such as IFN-gamma, TNF-alpha and 
lipopolysaccharide, resulting in increased levels of chitotriosidase mRNA, as well as chitotriosidase activity 
 148
(257). Mavoungou et al. documented a strong positive correlation between prolactin and the pro-
inflammatory cytokines TNF-alpha, IFN-gamma, IL-1 and IL-6  in microfilaraemic women (258).  
Autoimmune disease: Interestingly, serum prolactin levels were significantly higher (P<0.0001) among 
PPCM patients than in peripartum controls in our study and serum levels decreased significantly (P=0.002) 
among improvers, but not in non-improvers. As thoroughly reviewed by others, autoimmune diseases such 
as systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, Hashimoto's thyroiditis and 
multiple sclerosis affect women predominantly (81, 259-261). Cyclic estrogen concentrations differ not only 
between female and male, but also appear to differ between races for unknown cause. African and Asian 
women have higher serum 17-β-estradiol concentrations than Caucasians (262), an epidemiological 
coincidence with the increased frequency of SLE in populations of African and Asian ancestry (263). 
Amelioration of autoimmune diseases like SLE, RA and MS during pregnancy followed by post-partum 
exacerbation has been previously described by others (264, 265). Interestingly, prolactin and the 
immunosuppressive drug cyclosporine appear to be antagonistic through a receptor-based mechanism (266). 
Investigations of prolactin in the lupus NZB/W mouse have shown that elevated serum prolactin 
concentrations are associated with accelerated autoimmune disease in both female and male mice (267-269).  
Schwarz et al. demonstrated induction of IFN-gamma gene expression in a Nb2 rat T lymphoma cell line 
induced by prolactin (270). Breidthardt et al. reported that human recombinant prolactin significantly 
amplified IFN-gamma yields after stimulation with either PHA or lipopolysaccharide in peripheral human 
whole blood cultures (271).  
Notably, in our present study the median Δ of IFN-gamma differed significantly (P=0.0181) from 
baseline to six months between cardiac function-improvers and non-improvers, suggesting a role for this 
cytokine not only during the initiation of PPCM, but also as an important factor in disease progression. This 
might reflect ongoing autoimmune activation and fibrosis, leading to irreversible cardiomyopathy among 
cardiac function non-improvers with PPCM. It is interesting to note that Abel et al. observed that IFN-
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gamma response may play a role in the susceptibility of patients to develop chronic Chagas’ disease 
cardiomyopathy (232). 
Lack of protection from apoptosis: Fas/APO-1 (CD95) is a type I membrane protein belonging to the 
tumor necrosis factor receptor family, is ubiquitously expressed and induces a death signal when bound to 
it’s ligands that is typically confined to inflammatory cells (272, 273). Elevated baseline levels of Fas/APO-
1 have previously been described as a predictor of mortality in PPCM patients (192). In the present study we 
were able to demonstrate their significant (P<0.0001) elevation vs. controls at baseline and were able to 
identify dysregulated molecular pathways involved in the expression levels of Fas/APO-1 in PPCM patients. 
On the one hand, a cellular lack of protection from increased Fas/APO-1 activity could be secondary to 
significantly (P=0.002) decreased serum levels of the antiapoptotic survival factor for T-lymphocytes TGF-
β1 in PPCM patients as compared to healthy controls. Cerwenka et al. described the existence of a TGF-β-
producing Th3 subset that might be identical with CD4/CD25 regulatory T-cells (62) and play an important 
inhibitory role during immune response and deliver anti-apoptotic signals to T-cells. This subset of CD4 T 
cells is highly potent in suppressing immune responses and it's experimental depletion resulted in organ-
specific autoimmunity (4). On the other hand we found significantly increased levels of oxidized low density 
lipoprotein (oxLDL) among PPCM patients (P<0.0001). Takarada et al. investigated the contribution of 
oxLDL to Fas/APO-1 mediated apoptosis in human vascular smooth muscle cells (VSMC) and provided 
evidence that oxLDL sensitizes human vascular smooth muscle cells to Fas/APO-1 (CD95) mediated 
apoptosis and that oxLDL is involved in Fas/APO-1 signal transduction, proposing a mechanism by which 
oxLDL upregulates cell surface Fas/APO-1 by inhibition of Fas/APO-1 degradation through the ubiquitin–
proteasome pathway (274). We therefore postulate that apoptosis is a crucial mechanism in the pathogenesis 
of PPCM and increased activity in PPCM patients results from a lack of the protective, antiapoptotic survival 
factor for T-lymphocytes TGF-β1 in combination with the inhibition of Fas/APO-1 degradation mediated by 
high levels of oxLDL.  
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Differential effects between the pro-inflammatory cytokine IL-1 β and the anti-inflammatory cytokine TGF-
β1 have been described by Ng et al. (199) and could help to understand the high median serum levels of IL-
1β in PPCM patients (P<0.0001) in the presence of decreased TGF-β1 serum levels among PPCM patients 
(P=0.002).  
B-Type natriuretic peptide (BNP) is considered an important component of the adaptive mechanism 
that helps reduce the load on the myocardium through systemic vasodilatation, reduction in venous return, 
and reduction in vascular volume (275). NT-proBNP concentrations have been shown to provide information 
similar to BNP, and the validity of the assay as a clinical tool is well documented (276). Intravascular 
volume is known to expand during pregnancy by 40-50% (277) and return to nearly its non-pregnancy value 
within a week post-delivery (278). The mean weight loss of 2–3 kg during this week is attributed to diuresis. 
Lev-Sagie et al. (279) studied the mean maternal blood NT-proBNP concentration in 62 women and 
documented a mean plasma concentration before delivery of 81±32 ng/L and 165±102 ng/L after delivery (n 
= 62, P <0.001). The 2-fold increase in NT-proBNP after delivery suggests that BNP may be involved in 
postpartum diuresis. Recently, it was found that BNP mRNA of the left ventricle was increased in 
postpartum rats. The authors of that study concluded that natriuretic peptides may be involved in the 
adaptation to volume alterations associated with pregnancy (280). Kale et colleagues reported significantly 
elevated levels of serum Nt-proBNP in pre-eclamptic patients (430+/-28.91 pg/mL) as compared to 
normotensive pregnant women (74+/-16.82 pg/mL, P < 0.001) (281). In our study, we documented 
significantly elevated serum levels of NT-proBNP in PPCM patients at baseline vs. non-PPCM controls in 
the peripartum period. Cardiac function non-improvers had significantly higher levels (P=0.0013) than 
improvers at baseline. While Cenac et al. reported that low NT-proBNP values indicate complete remission 
of cardiac failure and normal heart volume (208) in PPCM patients, we observed a reduction of median 
serum NT-proBNP levels, but not a normalization of these values in our patients after six months. 
Fibrosis: The importance of fibrosis in organ pathology and dysfunction appears to be increasingly relevant 
to a variety of distinct diseases. In particular, a number of different cardiac pathologies seem to be caused by 
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a common fibrotic process (220). Examining markers of re-modeling in our cohort of PPCM patients, we did 
not record significant changes in plasma levels of VEGF or MMP-9. However, MMP-2 serum levels were 
significantly elevated at baseline (P<0.0001). Martin-Chouly et al. described an overexpression of MMP-2 in 
lung fibroblasts leading to tissue destruction associated with airway inflammation and were able to 
demonstrate selective inhibition of pro-MMP-2 secretion induced by TNF-alpha with phosphodiesterase type 
4 inhibitors (282). Therefore increased baseline levels of TNF-alpha could explain initial elevation of MMP-
2 serum levels. Fibrosis is thought to be partially mediated by TGF-β1, a potent stimulator of collagen-
producing cardiac fibroblasts. Previously, TGF-β1 had been implicated solely as a modulator of the 
myocardial remodeling seen after infarction. However, recent studies indicate that dilated, ischaemic and 
hypertrophic cardiomyopathies are all associated with raised levels of TGF-β1 (220). In contrast, median 
baseline TGF-β1 serum levels of PPCM patients were lower than in controls (P=0.002), suggesting that 
remodeling does not play a key role in the aetiology of PPCM.   
As expected, our results reflect cardiac failure in this cohort of PPCM patients. Interestingly, we 
were able to demonstrate oxidative stress that might contribute to left ventricular dysfunction and 
tachycardia. Other than in dilated, ischaemic and hypertrophic cardiomyopathy, decreased levels of TGF-β1 
suggest a lack of antiapoptotic protection rather than myocardial re-modeling as an aetiologic factor in the 
pathogenesis of PPCM, giving a possible explanation for the high rate of spontaneous recovery in this 
disease entity. Our results might reflect a prolactin induced pro-inflammatory immune response 
accompanied by apoptosis at onset of disease, although it is difficult to say whether elevated postpartum 
prolactin levels induce the pro-inflammatory response, or if a pro-inflammatory immune environment 
induces prolactin secretion. However, the expression of IFN-gamma, that differed significantly between 
cardiac function improvers and non-improvers over time, appears to be interrelated with the kinetics of the 
pituitary gland hormone prolcatin. Double-blind, placebo-controlled studies on the use of the prolactin 
inhibitor bromocriptine are limited, but clinical observations and trials support the use of bromocriptine as a 
nonstandard primary or adjunctive therapy in the treatment of recalcitrant rheumatoid arthritis, SLE, Reiter's 
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syndrome and psoriatic arthritis unresponsive to traditional approaches (283). While the role of prolactin in 
the pathogenesis of PPCM deserves further investigation, clinicians should consider the possible negative 
effect of drugs in these patients that potentially increase prolactin levels, such as the calcium-channel 
blocker verapamil, alpha-methyldopa, selective serotonin-uptake inhibitors such as fluoxetine and H2-
receptor antagonists like cimetidine. 
The significant kinetics of IFN-gamma levels between improvers and non-improvers are likely to 
reflect an ongoing T-cell mediated autoimmune response and insult to the cardiac muscle of these PPCM 
patients, resulting in failure to improve left ventricular function. It would be interesting to study, whether 
agonistic autoantibodies against the β 1-adrenergic receptor that were found in patients with other forms of 
dilated cardiomyopathy (125, 235, 236) also exist in PPCM patients and if their presence or absence  would 
be related to kinetics of left ventricular function. 
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7.3 Discussion: Identification of agonistic autoantibodies against the beta1-adrenergic receptor and 
their positive correlation with NT-proBNP serum expression levels in PPCM 
 
We have demonstrated the presence of agonist-like AAB directed against the β1-adrenoreceptor in serum of 
all 22 PPCM patients in this cohort and mapped their reactivity to the second extracellular loop (RAESDE 
and DEARRCY). These AAB were not present in any of the non-PPCM peripartum controls, differ from 
those found in serum of local DCMO patients in recognized epitopes and IgG subclass, suggesting that 
PPCM is a distinct form of cardiomyopathy.  
The activity of the agonist-like β1-adrenoreceptor AAB correlated with expression levels of NT-proBNP, 
but not with left ventricular ejection fraction and NYHA FC. The correlation of NT-proBNP changes with 
the clinical course in heart failure patients has been described before (243, 284) and increased circulating 
concentrations of NT-proBNP have been observed in asymptomatic left ventricular dysfunction (285-287). 
While clinical and echocardiographic assessment between six and twelve months indicate stabilization of left 
ventricular systolic function in our PPCM patients, the continued and significant decrease of NT-proBNP 
levels is likely to reflect ongoing resolution of asymptomatic heart failure and immune reconstitution 
mechanisms on the molecular level, accompanied by decreasing β1-adrenoreceptor AAB activity. Possibly, 
the expression of NT-proBNP serum levels is a more subtle marker of myocardial dysfunction than clinical 
and echocardiographic assessment in this cohort of PPCM patients.  
Obviously it would be interesting to know, whether the decrease in β1-adrenoreceptor AAB activity induced 
clinical improvement in PPCM patients or vice versa. Immunization of rats with a synthetic peptide 
corresponding to the second extracellular loop of the β1-adrenorecptor induced cardiac dysfunction and 
desensitization of the β1-adrenoreceptor, suggesting a pathogenetic role of the autoantibodies (236, 288). 
Gimenez et al. showed progressive decrease in left ventricular wall thickness, LV mass and fractional 
shortening in β1-adrenoreceptor immunized mice accompanied by a decrease in β1-adrenoreceptor density, 
myofibril disarray and fibrosis, pointing towards remodeling as a consequence of the long-term presence of 
 154
anti-receptor antibodies (233). Stork et al. identified β1-adrenoreceptor autoantibodies as independent 
predictors of  increased all-cause and cardiovascular mortality in a model with 65 DCM patients (289). 
Abnormalities in β-adrenergic receptor signal transduction are not only involved in functional cardiac 
impairment, but also in structural changes in the transition from compensated cardiac hypertrophy to 
decompensated heart failure (168, 290). Veliotes et al. suggest that aldosterone receptor blockade, through 
load-independent effects, may be useful in preventing the transition from compensated LVH to dilatation 
and pump dysfunction mediated by chronic β-adrenoreceptor activation (291). Immunoadsorption and 
plasmapheresis assisted removal of immunoglobulins in anti-β1-adrenoreceptor positive DCMO patients 
resulted in improved cardiac function and quality of life (236, 292). Dorffel et al. found increased antibody 
titers accompanied by deterioration of cardiovascular function in patients with severe idiopathic dilated 
cardiomyopathy and documented improved short- and long-term haemodynamics after immunoadsorption 
(293). Jahns et al. described the β1-adrenoreceptor-directed autoimmune attack as a possible cause of 
cardiomyopathy, which is now referred to as anti- β1-AR-induced dilated immune-cardiomyopathy (294).  
However, autoantibodies might not be directly responsible for many of the manifestations of autoimmune 
disease (295). While these data indicate a clinical relevance of β1-adrenoreceptor AAB in DCM and 
encourage further research into antibody-directed strategies as a therapeutic principle (289), Tabak'ian et al. 
found that detection of antibodies did not depend on the aetiology of systolic cardiac failure (IHD, DCM) or 
the severity of haemodynamic impairment (296). Mobini et al. showed similar acute and prolonged 
improvement of haemodynamics and left ventricular ejection fraction during immunoadsorption therapy in 
both, antibody-positive and -negative DCMO patients, suggesting that beneficial haemodynamic effects 
induced by immunoadsorption are not directly associated with the removal of β1-adrenoreceptor 
autoantibodies. However, the group only measured antibodies against the second extracellular loop (297). 
Similarly, Larsson et al. found that improvement of cardiac function is not due to neutralization of β1-
adrenoreceptor autoantibodies (298). 
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However, a possible explanation for improvement of left ventricular systolic function in the presence of β1-
adrenoreceptor AAB would be the recognition of an epitope by the AAB that does not correlate with disease, 
e.g. an upregulation of uterine β1-adrenoreceptors may absorb all the agonist-like AAB directed against the 
β1-adrenoreceptor. One could also imagine patients to improve cardiac function in the presence of agonist-
like AAB directed against β1-adrenoreceptor, if the intracellular pathway desensitized in vivo while the β1-
adrenoreceptors are expressed.  
The diminished beta-adrenergic myocardial responsiveness in DCMO patients (235) might serve a protective 
purpose since chronic beta-adrenoreceptor stimulation induces myocardial apoptosis (299) and heart failure 
in transgenic animals (235). Interestingly, Ishikawa et al. described the suppression of heterologous 
desensitization of β-adrenoreceptor by IFN-gamma (300), suggesting that high IFN-gamma levels, as we 
found in non-improving PPCM patients (chapter 4 of this thesis), lead to β-adrenoreceptor being highly 
susceptible towards stimulation. In this light our results help to understand the progression of PPCM from 
acute heart failure in a setting of pro-inflammatory activation to chronic heart failure, accompanied by high 
serum expression levels of IFN-gamma and angiotensin converting enzyme in the presence of PPCM-
specific agonist-like β1-adrenoreceptor autoantibodies.  
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7.4 Discussion The addition of bromocriptine to standard heart failure therapy prevents deterioration 
of left ventricular dimensions and systolic function in PPCM patients with a subsequent pregnancy 
 
Subsequent pregnancy in PPCM is associated with a risk of reoccurrence or deterioration of heart failure or 
even death (13). The exact mechanism of recurrent depression of cardiac function associated with 
subsequent pregnancy is not clear but might be related to reactivation of the same underlying idiopathic 
process responsible for the initial cardiomyopathy (196) and may exist even in patients who seem to recover 
their left ventricular function (195). While Reimold et al. suggest that the haemodynamic stress of pregnancy 
might be responsible for deterioration of left ventricular function (301), Sliwa et al. documented 
deterioration of LVEF uniformly postpartum (254).  
Hilfiker et al derived a STAT3 cardiac tissue specific knock out mouse model that presented with symptoms 
much alike human PPCM. Studies conducted by her suggest that cathepsin D facilitates cleavage of the 24 
kDa prolactin into 16 and 8 kDa proteins postdelivery causing in vitro inhibition of endothelial cell 
proliferation, increased fibroblast proliferation and increased cardiac apoptosis and reduced cardiac function 
and survival postpartum. Bromocriptine, a dopamine- D2 receptor antagonist that inhibits prolactin 
secretion, prevented PPCM in these mice, restored cardiac function and structure and prevented apoptosis 
(133, 136, 141). In the present study we were able to demonstrate the presence of the cleaved 16 kDa 
prolactin in three of five PPCM patients, but not in non-PPCM controls during the postpartum period, 
leading us to the conclusion that bromocriptine would also have beneficial effects in human PPCM patients. 
The present prospective study provides for the first time a comparative description of the effect of 
bromocriptine as an add on therapy in subsequent pregnancy in human PPCM patients. We compared data 
from a cohort of four patients with subsequent pregnancy on standard heart failure therapy alone with 
another cohort of four patients with subsequent pregnancy in PPCM who was treated with bromocriptine 2.5 
mg twice daily for two months in addition to standard heart failure therapy. All patients who received 
additional bromocriptine survived and even improved their left ventricular ejection fraction from 49.0±8.1% 
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at onset of subsequent pregnancy to 52.5±5.5% at three months postdelivery. This is in contrast to our 
findings in patients on standard heart failure therapy alone, in which one patient died and left ventricular 
ejection fraction deteriorated from 47.6±11.9% at baseline to 38.7±20.6%. The data in our bromocriptine 
group is also in contrast to findings by Elkayam et al. who described significant deterioration of LVEF from 
36±9% to 32±11% (p=0.08) in women with left ventricular dysfunction prior to subsequent pregnancy 
(mortality 19%) and in women who had normal LVEF prior to subsequent pregnancy and experienced a 
deterioration of LVEF from 56±7% to 49±10% (p=0.002). It is important though to point out that mortality 
was 0% in 40 patients who had recovered left ventricular function prior to subsequent pregnancy (196).  
One could argue that patients in our cohort who did not receive bromocriptine also had greater left 
ventricular dimensions (5.9±0.7 as compared to 5.0±0.6cm, p=NS) and therefore a greater chance to 
deteriorate their LVEF. The report by Elkayam failed to include measurements of left ventricular dimensions 
of the subsequent pregnancy patients, but we described the outcome of six subsequent pregnancies out of 
whom two patients with persistent cardiomegaly died within three months postdelivery (254). During risk 
assessment of patients with a subsequent pregnancy in PPCM it appears advisable to consider left ventricular 
dimensions as well as left ventricular ejection fraction. We documented significantly higher cathepsin D 
serum expression levels in PPCM patients than in healthy controls. A link between cathepsin D, autophagic 
degeneration and cell death has been suggested in several models of heart failure (302, 303) and might play a 
causal role in PPCM.  
While mortality appears to be very low in patients with normal left ventricular function and dimensions at 
onset of subsequent pregnancy, the risk is higher when these parameters are impaired. The results obtained 
by the addition of bromocriptine to standard heart failure treatment in this study are encouraging. 
Bromocriptine may represent a novel therapeutic approach in the treatment of PPCM, but the data need to be 
considered as preliminary and need to be confirmed in a larger cohort of patients.  
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7.5 Conclusions 
 
We described the clinical profile of 100 patients presenting with PPCM to our clinic and found a positive 
correlation between baseline C-reactive protein plasma levels and LV end-diastolic (rs = 0.33, P = 0.0026) 
and end-systolic dimensions (rs = 0.35, P = 0.0012). The mortality rate was 15% within six months and 
logistic regression analysis revealed baseline plasma levels of Fas/Apo-1 (OR = 3.56, CI 95% = 1.35–9.42) 
and NYHA FC (OR = 2.67, CI 95% = 1.04–6.83) as independent predictors of death.  
While several authors have described recovery of LV systolic function in up to 54% of PPCM patients (5, 
192), other patients develop irreversible heart failure. In order to identify molecular pathways that determine 
whether cardiac function recovers or becomes chronically dysfunctional, we studied the kinetics of 
biomarkers reflecting cardiac function, processes of inflammation and re-modeling as well as the hormone 
prolactin over a six months period. While a wide range of parameters, reflecting cardiac dysfunction and 
pro-inflammatory immune activation, were elevated in all PPCM patients at time of first presentation, 
indicating their involvement in the initiation of the disease, we found significant differences over time 
between cardiac function improvers and non-improvers for ΔIFN-gamma (P=0.0181), indicating its role in 
disease progression. Heightened IFN-gamma expression could indicate an ongoing T-cell mediated 
autoimmune response and an insult to the cardiac muscle, resulting in fibrosis and inability to improve left 
ventricular systolic function.  
In a next step we analysed serum of PPCM patients, identified beta1-adrenergic autoantibodies in all PPCM 
patients and mapped their reactivity to the second extracellular loop (RAESDE and DEARRCY). These 
autoantibodies were not present in any of the non-PPCM peripartum controls and are different from those in 
serum of DCMO patients, suggesting that PPCM is a distinct form of cardiomyopathy.  
NT-proBNP correlates well with clinical course in heart failure patients (243) and statistical analysis of the 
activity of the beta1-adrenergic autoantibodies found in our cohort of PPCM patients revealed a positive 
correlation with NT-proBNP serum expression levels (rs=0.58, 2-tailed P=0.0228), 95% CI (0.10 to 0.84).  
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Prolactin represents a stimulatory link between the neuroendocrine and immune systems (230). 
Several authors have suggested that prolactin promotes pro-inflammatory immune responses (256, 258). 
Interestingly, we found significantly higher (P<0.0001) serum prolactin levels in PPCM patients at time of 
first presentation than in peripartum controls, suggesting the hormone’s role during the initial acute phase of 
PPCM. Interestingly, several authors have described the induction of IFN-gamma by prolactin (270), (271). 
Disease progression and the ongoing autoimmune insult by beta1-adrenergic autoantibodies appear to be 
driven by IFN-gamma. This pro-inflammatory cytokine remained high in PPCM non-improvers, decreased 
in improvers, has previously been implicated in the development of autoimmune disease (202) and its 
suppression leads to desensitization of β-adrenoreceptors (300).  
Hyperactivation of inflammatory cytokines exacerbate ventricular contractile dysfunction in heart failure 
patients (226).  
We measured significantly higher cathepsin D serum expression levels in PPCM patients than controls at 
time of first presentation. Circulating cathepsin D is a ubiquitous lysosomal enzyme with high renin 
sequence homology. Cathepsin D release from damaged myocardial tissue could contribute to angiotensin 
formation by acting as an enzymatic alternate to renin (304). Furthermore, cathepsin D has been shown to 
efficiently cleave PRL into its 16kDa form as found in our PPCM patients (305, 306).  
In view of the above it appeared reasonable to interrupt the expression of the pituitary gland hormone 
prolactin during the time when onset or exacerbation of disease would normally be expected. Therefore we 
administered bromocriptine in addition to standard heart failure therapy in patients with known PPCM who 
presented with a subsequent pregnancy. Instead of the expected deterioration, left ventricular dimensions and 
systolic function remained stable or even improved. Although the number of patients in this interventional 
analysis is too small to draw statistically meaningful conclusions, the results are very encouraging. 
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Figure 7.1: Multifactorial pathogenesis of PPCM 
 
While the pathogenesis of PPCM appears to be multifactorial, our task as scientists remains to find out, how 
the monolith was erected. Specifically, it appears promising to investigate the effects of bromocriptine in 
addition to standard heart failure therapy in a randomised, double-blinded clinical study. Although some 
authors argue that prolactin regulated expression of IFN-gamma and other cytokines may explain the 
gender-specific differences in autoimmunity (78), others have shown that elevated serum prolactin 
concentrations are associated with accelerated autoimmune disease in both female and male mice (267-269). 
Possibly, prolactin does not only play a role in the pathogenesis of PPCM, but also in other forms of 
cardiomyopathy, affecting males and females alike. It would be interesting to study prolactin serum 
 161
expression levels in male and female patients with idiopathic DCMO. Clearly, further studies into the 
unfolding pathogenesis of PPCM are indicated. 
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STUDY LIMITATIONS 
The results of this thesis should be assessed in a larger study population.  
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INTRODUCTION:  
Good day, my name is Dr. Olaf Förster / Prof. Karen Sliwa-Hähnle. I am a Medical Doctor at Chris Hani 
Baragwanath Hospital, Department of Cardiology. I would like you to consider participating in a research 
study, entitled "Peripartum Cardiomyopathy – an autoimmune disease?"  
• Before agreeing to participate, it is important that you read and understand the following explanation 
of the purpose of the study, the study procedures, benefits, risks, discomforts, and precautions as well 
as the alternative procedures that are available to you, and your right to withdraw from the study at 
any time. This information leaflet is to help you to decide if you would like to participate, You 
should fully understand what is involved before you agree to take part in this study.  
• If you have any questions, do not hesitate to ask me.  
• You should not agree to take part unless you are satisfied about all the procedures involved.  
• You may not participate in another medical research study, nor take any other investigational 
medicine during your participation in this study. You should not have participated in an 
investigational medicine research study within the past 30 days. 
• Please be completely truthful with me regarding your health history, since you may otherwise harm 
yourself by participating in this study.  
• If you decide to take part in this study, you will be asked to sign this document to confirm that you 
understand the study. You will be given a copy to keep.  
• If you have a personal doctor. please discuss with or inform him/her of your possible participation in 
this study. If you wish, I can also notify your personal doctor in this regard. 
 
PURPOSE OF THE STUDY:  
• You have been diagnosed as suffering from "Peripartum Cardiomyopathy" and I would like you to 
consider taking part in the research of a new medicine called "Pentoxifylline".  
• The purpose of this study is to determine the improvement of your cardiac function  
 
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS:  
• The study will be performed at Chris Hani Baragwanath Hospital 
• Approximately 100 patients will participate in this study  
• The patients will be between the ages of 18 and 50 years  
You will be required to come for follow up to Cardiac Clinic at Chris Hani Baragwanath Hospital once a 
month for a duration of 6 months.  
• Once you have completed 6 months of treatment you can decide to continue with this study for 
another 6 months to complete a total of 12 months. You will experience no disadvantage if you 
decide not to continue with this study after 6 months. In that case you will be treated as a regular 
patient in the Cardiac Clinic at Chris Hani Baragwanath Hospital.  
 
PROCEDURES:  
If you agree to take part in this study, you will first be asked questions and examined to see if you qualify for 
this study. Before receiving your first dose of study medicine, I will examine you and draw several blood 
samples from you.  
At each following visit you will undergo:  
• Enrolment visit: Examination plus ECG plus bloods (15 tubes for FBC, U+E, CRP, LFT, TLR3, 
immunoglobulins, 4 x serum, 3 x plasma for cytokines, selenium and autoantibodies, 4 x for PBMC, 
HIV, CD4) plus Echocardiography. Echocardiography will be taped on Video and stored in the 
Department of Cardiology at Chris Hani Baragwanath Hospital for further reference and audit 
purposes.   
• Follow up visit 2  (after 1 month):   Check up 
• Follow up visit 3  (after 2 months):  Check up 
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• Follow up visit 4  (after 3 months):  Check up 
• Follow up visit 5  (after 4 months):  Check up 
• Follow up visit 6  (after 5 months):  Check up 
• Follow up visit 7  (after 6 months):  Check up plus bloods (15 tubes for FBC, U+E, CRP, 
LFT, TLR3, immunoglobulins, 4 x serum, 3 x plasma for cytokines, selenium and autoantibodies, 4 x 
for PBMC, HIV, CD4) plus Echocardiography. Echocardiography will be taped on Video and 
stored in the Department of Cardiology at Chris Hani Baragwanath Hospital for further reference and 
audit purposes.  
 
After completing 6 months you can decide if you prefer to continue participating in this study for an 
additional 6 months to complete 12 months of study or if you do not wish to extend your participation in 
the study.   
• Follow up visit 8  (after 7 months):   Check up 
• Follow up visit 9  (after 8 months):  Check up 
• Follow up visit 10  (after 9 months):  Check up 
• Follow up visit 11  (after 10 months):  Check up 
• Follow up visit 12  (after 11 months):  Check up 
• Follow up visit 13  (after 12 months):  Check up plus bloods (15 tubes for FBC, U+E, CRP, 
LFT, TLR3, immunoglobulins, 4 x serum, 3 x plasma for cytokines, selenium and autoantibodies, 4 x 
for PBMC, HIV, CD4) plus Echocardiography. Echocardiography will be taped on Video and 
stored in the Department of Cardiology at Chris Hani Baragwanath Hospital for further reference and 
audit purposes.  
 
The blood samples will be analysed to determine the effect of the treatment you received on your 
"Peripartum Cardiomyopathy" and will help to find out the cause of "Peripartum Cardiomyopathy". The 
echocardiography will be done to determine the effect of the treatment you received on the performance of 
your heart muscle.  
 
WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE?  
• Venipunctures (i.e. drawing of blood) are normally done as part of routine medica1 care and present 
a slight risk of discomfort. Drawing blood may result in faintness, inflammation of the vein, pain, 
bruising or bleeding at the puncture site. There is also a slight possibility of infection. Your 
protection is that experienced personnel perform the procedures under sterile conditions. A total of 
75 ml of blood (i.e. 15 teaspoons) will be collected every 6 months.  
• Echocardiography is a commonly used diagnostic procedure in Cardiology that allows the examiner 
to assess the function of your heart muscle. It does not pose any harm to the patient  
• ECG (Electrocardiogram): This examination allows the doctor to determine the rhythm of your heart. 
It is a commonly used diagnostic procedure and does not pose any harm to the patient.  
• As part of the study your HIV status will be checked. HIV pre-test and post-result counseling will be 
provided. 
(   ) I would like to know the HIV test result and wish to participate in appropriate     counseling  
(   ) I would not like to know the HIV test result 
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BENEFITS:  
The potential benefit from your participation in this study may be control of your "Peripartum 
Cardiomyopathy".  However, you may not benefit from this study. Your participation in this study will 
contribute to medical knowledge that may help other patients that, that like you, have "Peripartum 
Cardiomyopathy"  
 
ALTERNATIVE TREATMENT:  
If you decide not to take part in this study you will still receive the best current care, from your usual doctor; 
this may or may not include the study medicine.  
 
BENEFITS AND RISKS OF STANDARD ALTERNATIVE TREATMENT:  
Participating in the study you will always receive standard treatment.  
 
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY PARTICIPATION IN 
THIS STUDY?  
Due to your diagnosis "Peripartum Cardiomyopathy" you should not fall pregnant again. Therefore effective 
contraception is strongly recommended.  
 
INTERACTIONS:  
It is important that you let me know of any medicines (both prescriptions and over-the-counter medicines), 
alcohol or other substances that you are currently taking.  
 
RIGHTS AS A PARTICIPANT IN THIS STUDY: 
• Voluntary: Your participation in this study is entirely voluntary and you can decline to participate, or 
stop at any time, without stating any reason. Your withdrawal will not affect your access to other 
medical care.  
• Discontinuation of study treatment: You must inform me if you wish to stop taking your study 
medicine. I will supervise any discontinuation with your health as the first priority.  
• New findings: I will provide you with any additional information that becomes available during the 
study, which may affect your willingness to continue on the study  
 
WITHDRAWAL FROM THIS STUDY:  
• Your withdrawal will not affect your access to other medical care.  
• I retain the right to withdraw you from the study if it is considered to be in your best interest. If your 
participation is ended early, you may be asked to return for study-ending tests and procedures for 
your safety. 
• If you did not give an accurate history or did not follow the guidelines of the study and the 
regulations of the study facility, you may be withdrawn from the study at any time.  
• Pregnancy: Peripartum Cardiomyopathy is defined as a cardiomyopathy without any other 
attributable cause in the period of one month antepartum to 5 months postpartum. Pregnancy is 
therefore no defined reason for withdrawal from the study.  
 
EMERGENCY CARE AND HOSPITALISATION:  
If you seek emergency care or if hospitalisation is required at any time during the study, please inform the 
treating doctor that you are/were enrolled in this research study and that you are diagnosed with "Peripartum 
Cardiomyopathy". Please ask the treating doctor to inform me about your condition.  
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FINANCIAL ARRANGEMENTS:  
• The Department of Cardiology, Chris Hani Baragwanath Hospital will provide payment for all study 
procedures and reasonable medical expenses that you may incur as a direct result of this study as 
determined by the Department of Cardiology, Chris Hani Baragwanath Hospital and me.  
• Neither you nor your medical scheme will be expected to pay for any study medication, study related 
visit or study procedures.  
 
REIMBURSEMENT FOR STUDY PARTICIPATION:  
You will not be paid to participate in this study but your transport costs will be reimbursed adequately.  
 
ABPI STATEMENT ON COMPENSATION: 
All patients enrolled in this study are public hospital patients at Chris Hani Baragwanath Hospital. No 
specific sponsor exists for this study. It is an investigator driven study. 
 
ETHICAL APPROVAL:  
• This clinical study protocol has been submitted to the University of the Witwatersrand, Human 
Research Ethics Committee (HREC) and written approval has been granted by that committee.  
• The study has been structured in accordance with the Declaration of Helsinki (last updated: October 
2000), which deals with the recommendations guiding doctors in biomedical research involving 
human subjects. A copy may be obtained from me should you wish to review it.  
• This study is investigator driven and I do not have any financial or personal interests that may bias 
my actions.  
 
SOURCE OF ADDITIONAL INFORMATION:  
• For the duration of the study, you will be under the care of Dr. Olaf Förster. If at any time between 
your visits, you feel that any of your symptoms are causing you any problems, or you have any 
questions during the study, please do not hesitate to contact me.  
Doctors from the Department of Cardiology who are working on this study are:  
Professor Karen Sliwa-Hähnle 083-457-4823 
Dr. Olaf Förster   082-555-9859 
They can be contacted at the above 24 hour telephone numbers. 
• If you want any information regarding your rights as a research participant, or complaints regarding 
this research study, you may contact Prof. Cleaton-Jones, Chairperson of the University of the 
Witwatersrand, Human Research Ethics Committee (HREC), which is an independent committee 
established to help protect the rights of research participants at the following number: 011-717-2229  
• For research information you can contact Prof Huddle, Head of Department of  Medicine, Chris Hani 
Baragwanath Hospital on 011-933-8940  
• South African Medicines Control Council: If you have questions about this trial you should first 
discuss them with your doctor or the ethics committee (contact details as provided on this form). 
After you have consulted your doctor or the ethics committee and if they have not provided you with 
answers to your satisfaction, you should write to the South African Medicines Control Council 
(MCC) at:  
 
The Registrar  
SA Medicines Control Council  
Department of Health  
Private Bag X828  
Pretoria 0001  
Fax: 012-323-4474  
E-mail: labusa@health.gov.za  
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CONFIDENTIALITY:  
• All information obtained during the course of this study, including hospital records, personal data 
and research data will be kept strictly confidential. Data that may be reported in scientific journals 
will not include any information that identifies you as a participant in this study. 
• This information will be reviewed by authorized representatives of the Department of Cardiology, 
Chris Hani Baragwanath Hospital.  
The information might also be inspected by the University of the Witwatersrand. Human Research Ethics 
Committee (HREC), the South African Medicines Control Council (MCC) and/or the United States Food 
and Medicine Administration (FDA), as well as your personal doctor. Therefore, you hereby authorize me to 
release your medical records to the Department of Cardiology, Chris Hani Baragwanath Hospital, its 
employees or agents, domestic and foreign regulatory health authorities, the South African Medicines 
Control Council and the University of the Witwatersrand, Human Research Ethics Committee (HREC). 
These records will be utilized by them only in connection with carrying out their obligations relating to this 
clinical study.  
Any information uncovered regarding your test results or state of health as a result of your participation in 
this study will be held in strict confidence. You will be informed of any finding of importance to your health 
or continued participation in this study but this information will not be disclosed to any third party in 
addition to the ones mentioned above without your written permission. The only exception to this rule will 
be cases of communicable diseases where a legal duty of notification of the Department of Health exists. In 
this case, you will be informed of my intent to disclose such information to the authorized state agency.  
 
PERSONAL DOCTOR / SPECIALIST NOTIFICATION OPTION:  
Please indicate below, whether you want me to notify your personal doctor or your specialist of your 
participation in this study:  
 
(   ) Yes, I want you to inform my personal doctor / specialist of my participation in this study. 
(   ) No, I do not want you to inform my personal doctor / specialist of my participation in this study  
(   ) I do not have a personal doctor / specialist  
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INFORMED CONSENT:  
• I hereby confirm that I have been informed by the study doctor, Dr. Olaf Förster / Prof Karen Sliwa-
Hähnle, about the nature, conduct, benefits and risks of the clinical study "Peripartum 
Cardiomyopathy – an autoimmune disease?", protocol number 020907. 
• I have also received, read and understood the above written information (Patient Information leaflet 
and Informed Consent) regarding this clinical study.  
• I am aware that the results of the study, including personal details regarding my sex, age, date of 
birth, and diagnosis will be anonymously processed into a study report.  
• In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerized system by the Department of Cardiology, Chris Hani Baragwanath 
Hospital or on its behalf.  
• I may, at any stage, without prejudice, withdraw my consent and participation in the study.  
• I have had sufficient opportunity to ask questions and of my own free will declare myself prepared to 
participate in the study.  
 
 
 
Patient: ________________________________________________________________ 
Printed Name  Signature/Mark/Thumbprint Date and Time 
 
I, Prof. Karen Sliwa-Hähnle / Dr. Olaf Förster, herewith confirm that the above patient has been fully 
informed about the nature, conduct and risks of the above study. 
 
Study Doctor: ___________________________________________________________ 
Printed Name  Signature   Date and Time 
 
Study nurse/translator/other person explaining Informed Consent (Designation): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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INFORMED CONSENT CONCERNING EXTENSION OF MY PARTICIPATION IN THE STUDY 
“PERIPARTUM CARDIOMYOPATHY-AN AUTOIMMUNE DISEASE?” FROM  6 MONTHS TO 
12 MONTHS 
  
• I hereby confirm that I have been informed by the study doctor, Dr. Olaf Förster / Prof Karen Sliwa-
Hähnle, about the nature, conduct, benefits and risks of the clinical study "Peripartum 
Cardiomyopathy – an autoimmune disease?", protocol number 020907  
• I have also received, read and understood the above written information (Patient Information leaflet 
and Informed Consent) regarding this clinical study.  
• I am aware that the results of the study, including personal details regarding my sex, age, date of 
birth, and diagnosis will be anonymously processed into a study report.  
• In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerized system by the Department of Cardiology, Chris Hani Baragwanath 
Hospital or on its behalf.  
• I may, at any stage, without prejudice, withdraw my consent and participation in the study.  
• I have had sufficient opportunity to ask questions and of my own free will declare myself prepared to 
participate in the study.  
 
(   ) Yes, I would like to extend my participation in this study from 6 months to 12  months 
 
(   )  No, I would not like to extend my participation in this study from 6 months to 12  months.  
 
I am aware that I may attend the Cardiac Clinic at Baragwanath Hospital as a regular patient for 
further follow up independent from my decision concerning the extension of my participation in this 
study.  
 
 
Patient: _________________________________________________________________ 
Printed Name  Signature/Mark/Thumbprint Date and Time 
 
 
I, Prof. Karen Sliwa-Hähnle / Dr. Olaf Förster, herewith confirm that the above patient has been fully 
informed about the nature, conduct and risks of the above study. 
 
Study Doctor: ____________________________________________________________ 
Printed Name  Signature   Date and Time 
 
 
Study nurse/translator/other person explaining Informed Consent (Designation): 
 
________________________________________________________________________ 
Printed Name  Signature   Date and Time 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name  Signature   Date and Time 
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INFORMED CONSENT FOR PARENTS/LEGAL GUARDIANS:  
(On behalf of minors under 18 years old)  
 
Prof. Karen Sliwa-Hähnle / Dr. Olaf Förster has provided me with a copy of the Patient Information Leaflet 
and Consent regarding the clinical study about "Peripartum Cardiomyopathy – an autoimmune disease?" 
020907 and has fully explained to me the nature, risks, benefits and purpose of the study. The study doctor 
has given me the opportunity to ask any questions concerning both the medicine and the study.  
It has been explained to me that I will be free to withdraw my child from the study at any time without any 
disadvantage to future care. I have understood everything that has been explained to me and I consent for my 
child to participate in this clinical study.  
 
Parent / Legal Guardian:  
 
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
 
 
 
Patient Assent: *(Seven years old and above)  
 
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
 
(* Minors competent to understand must participate as fully as possible in the entire procedure)  
 
 
Study Doctor:  
 
________________________________________________________________________ 
Printed Name    Signature    Date and Time 
 
 
 
Research nurse/translator/other person explaining Informed Consent (Designation): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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VERBAL PATIENT INFORMED CONSENT:  
(Applicable when patients cannot read or write or are incapable of giving consent)  
 
• I, the undersigned, Prof. Karen Sliwa-Hähnle / Dr. Olaf Förster have read and have explained fully to 
the patient, named ____________________________________ and/or her relative/friend/legal 
representative, __________________________ the patient information leaflet.  
• The account I have given has explained both the possible risks and benefits of the study as well as the 
alternative treatments available for his/her illness. The patient and/or her relative/friend/legal 
representative understands these.  
• The patient and/or her relative/friend/legal representative indicated that he/she understands that the 
patient will be free to withdraw from the study at any time for any reason and without jeopardizing 
his/her subsequent treatment.  
• I have also informed the patient and/or his/her relative/friend/legal representative of the existence of 
relevant compensation arrangements in case of an injury attributable to the medicine(s) used in the 
clinical study, to which he/she agrees.  
 
I hereby certify that, the patient and/or his/her relative/friend/legal representative acting on her behalf, have 
agreed to participate in this study.  
 
Patient:  
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
 
 
Study Doctor:  
________________________________________________________________________ 
Printed Name    Signature    Date and Time 
 
 
Research nurse/translator/other person explaining Informed Consent (Designation): 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
 
Parent/Legal Guardian/Legal Representative/Friend:  
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
 
 
Witness (if applicable): 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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INFORMED CONSENT ON DNA SAMPLING:  
 
As part of the study 2 tubes of blood (10 ml approx. 2 teaspoons) will be drawn for genetic testing / RNA 
sampling. These samples will be sent to Emory University in Atlanta, USA and to Medizinische Hochschule 
Hanover, Germany for testing. Testing may also be done at the University of the Witwatersrand / Chris Hani 
Baragwanath Hospital, South Africa. Any of these results will not be available to any unauthorized person.  
   
• I am aware that the results of the study, including personal details regarding my sex, age, date of 
birth, and diagnosis will be anonymously processed into a study report.  
• In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerized system by the Department of Cardiology, Chris Hani Baragwanath 
Hospital or on its behalf.  
• I have had sufficient opportunity to ask questions and of my own free will declare myself prepared to 
participate in the study.  
 
 
 
Patient: _________________________________________________________________ 
Printed Name  Signature/Mark/Thumbprint Date and Time 
 
 
Study Doctor: _________________________________________________________________ 
Printed Name  Signature   Date and Time 
 
 
Study nurse/translator/other person explaining Informed Consent: 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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INFORMED CONSENT FOR NON-PPCM CONTROLS ON DNA SAMPLING:  
 
As part of the study on Peripartum cardiomyopathy (PPCM) blood from people who are not affected by 
PPCM needs to be analysed. The purpose is to compare results from PPCM patients with results of people 
who are not affected by PPCM. 2 tubes of blood (10 ml approx. 2 teaspoons) will be drawn for genetic 
testing / RNA sampling. These samples will be sent to Emory University in Atlanta, USA and to 
Medizinische Hochschule Hanover, Germany for testing . Testing may also be done at the University of the 
Witwatersrand / Chris Hani Baragwanath Hospital, South Africa. Any of these results will not be available 
to any unauthorized person. Blood samples may be stored on the premises of the University of the 
Witwatersrand for future analysis related to PPCM. 
• I am aware that the results of the study, including personal details regarding my sex, age, date of 
birth, number of children and diagnosis will be anonymously processed into a study report.  
• As part of the study your blood will be analysed for HIV. This result will not be available to you or 
any unauthorized person. In view of the requirements of research, I agree that the data collected 
during this study can be processed in a computerized system by the Department of Cardiology, Chris 
Hani Baragwanath Hospital or on its behalf.  
• I have had sufficient opportunity to ask questions and of my own free will declare myself prepared to 
participate in the study.  
 
 
Non-PPCM Control Volunteer: 
 
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
 
 
Study Doctor: 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
 
Study nurse/translator/other person explaining Informed Consent: 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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INFORMED CONSENT FOR NON-PPCM CONTROLS ON BLOOD TESTS FOR CYTOKINES, 
AUTOANTIBODIES AND OTHER BLOOD TESTS RELATED TO RESEARCH ON 
PERIPARTUM CARDIOMYOPATHY:  
 
As part of the study on Peripartum cardiomyopathy (PPCM) blood from people who are not affected by 
PPCM needs to be analysed. The purpose is to compare results from PPCM patients with results of people 
who are not affected by PPCM. 8 tubes of blood (40 ml approx. 8 teaspoons) will be drawn for analysis of 
cytokines, autoantibodies and other tests related to research on PPCM. These samples will be sent to Emory 
University in Atlanta, USA and to Medizinische Hochschule Hanover, Germany for testing. Testing may 
also be done at the University of the Witwatersrand / Chris Hani Baragwanath Hospital, South Africa. Any 
of these results will not be available to any unauthorized person. Blood samples may be stored on the 
premises of the University of the Witwatersrand for future analysis related to PPCM.  
 
   
• I am aware that the results of the study, including personal details regarding my sex, age, date of 
birth, number of children and diagnosis will be anonymously processed into a study report.  
• As part of the study your blood will be analysed for HIV. This result will not be available to you or 
any unauthorized person.  
• In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerized system by the Department of Cardiology, Chris Hani Baragwanath 
Hospital or on its behalf.  
• I have had sufficient opportunity to ask questions and of my own free will declare myself prepared to 
participate in the study.  
 
 
Non-PPCM Control Volunteer: 
 
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
 
Study Doctor: 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
Study nurse/translator/other person explaining Informed Consent: 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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EXTENSION OF THE PROTOCOL "PERIPARTUM CARDIOMYOPATHY – AN AUTOIMMUNE 
DISEASE?" TO ASSESS THE EFFECT OF BROMOCRIPTINE IN WOMEN PRESENTING WITH 
A SUBSEQUENT PREGNANCY AND A PREVIOUS EPISODE OF PERIPARTUM 
CARDIOMYOPATHY  
 
 
PURPOSE OF THE STUDY:  
• You have previously been diagnosed with "Peripartum Cardiomyopathy" (PPCM). You are now 
presenting with a subsequent pregnancy. As you may remember we explained to you initially that 
this may not be good for your heart. Recent research has suggested that a drug called Bromocriptine 
may reduce the risk to your heart. I would like you to consider taking part in the research of a new 
medicine called "Bromocriptine".  
• The purpose of this study is to determine the improvement of your cardiac function  
• This study will compare your standard treatment for "Peripartum Cardiomyopathy" with 
Bromocriptine added. The results will be compared to data that was collected from patients before 
this new treatment was considered for this condition.  
 
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS:  
• The study will be performed at Chris Hani Baragwanath Hospital 
• Approximately 6 patients will participate in this study  
• The patients will be between the ages of 18 and 50 years  
• You will be required to come for follow up to Cardiac Clinic at Chris Hani Baragwanath Hospital 
once a month for a duration of 8 months before giving birth up to 6 months after giving birth.  
• Once you have completed 6 months after giving birth, you can decide to continue with the study on 
"PPCM – an autoimmune disease?". You will experience no disadvantage if you decide to 
discontinue your participation. In that case you will be treated as a regular patient in the Cardiac 
Clinic at Chris Hani Baragwanath Hospital.  
 
PROCEDURES:  
If you agree to take part in this study, you will first be asked questions and examined to see if you qualify for 
this study. Before receiving your first dose of study medicine, I will examine you and draw several blood 
samples from you. If you are already in an advanced stage of pregnancy there will be less follow up visits 
before delivery. 
At following visits you will undergo:  
• Enrolment visit: Examination plus ECG plus bloods (14 tubes for FBC, U+E, LFT, 4 x serum, 3 x 
plasma for cytokines, autoantibodies, 4 x for PBMC, HIV, CD4) plus Echocardiography. 
Echocardiography will be taped on video and stored in the Department of Cardiology at Chris Hani 
Baragwanath Hospital for further reference and audit purposes.   
• Follow up visit 2  (after 1 month):   Check up 
• Follow up visit 3  (after 2 months):  Check up 
• Follow up visit 4  (after 3 months):  Check up 
• Follow up visit 5  (after 4 months):  Check up 
• Follow up visit 6  (after 5 months):  Check up 
• Follow up visit 7  (after 6 months): Check up 
• Follow up visit 8  (after 6 months / before delivery): Check up plus bloods (14 tubes for FBC, 
U+E, LFT, 4 x serum, 3 x plasma for cytokines, autoantibodies, 4 x for PBMC, HIV, CD4) plus 
Echocardiography. Echocardiography will be taped on Video and stored in the Department of 
Cardiology at Chris Hani Baragwanath Hospital for further reference and audit purposes.  
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• Follow up visit 9  (after delivery): Check up plus bloods (14 tubes for FBC, U+E, LFT, 4 x 
serum, 3 x plasma for cytokines, autoantibodies, 4 x for PBMC, HIV, CD4) plus 
Echocardiography. Echocardiography will be taped on Video and stored in the Department of 
Cardiology at Chris Hani Baragwanath Hospital for further reference and audit purposes.  
• Follow up visit 10 (1 month post partum): Check up 
• Follow up visit 11 (2 months post partum): Check up 
• Follow up visit 12 (3 months post partum): Check up plus bloods (14 tubes for FBC, U+E, 
LFT, 4 x serum, 3 x plasma for cytokines, autoantibodies, 4 x for PBMC, HIV, CD4) plus 
Echocardiography. Echocardiography will be taped on Video and stored in the Department of 
Cardiology at Chris Hani Baragwanath Hospital for further reference and audit purposes. 
• Follow up visit 13 (4 months post partum): Check up 
• Follow up visit 14 (5 months post partum): Check up 
• Follow up visit 15 (6 months post partum): Check up plus bloods (14 tubes for FBC, U+E, 
LFT, 4 x serum, 3 x plasma for cytokines, autoantibodies, 4 x for PBMC, HIV, CD4) plus 
Echocardiography. Echocardiography will be taped on Video and stored in the Department of 
Cardiology at Chris Hani Baragwanath Hospital for further reference and audit purposes.  
 
Any analysis of serum, plasma, PBMC will be strictly in direct connection with our research on 
Peripartum Cardiomyopathy. 
 
The blood samples will be analysed to determine the effect of the treatment you received on your 
"Peripartum Cardiomyopathy" and will help to find out the cause of "Peripartum Cardiomyopathy". The 
Echocardiography will be done to determine the effect of the treatment you received on the performance of 
your heart muscle.  
 
WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE?  
• Venipunctures (i.e. drawing of blood) are normally done as part of routine medica1 care and present 
a slight risk of discomfort. Drawing blood may result in faintness, inflammation of the vein, pain, 
bruising or bleeding at the puncture site. There is also a slight possibility of infection. Your 
protection is that experienced personnel perform the procedures under sterile conditions. A total of 
70 ml of blood (i.e. 14 teaspoons) will be collected every 6 months.  
• Echocardiography is a commonly used diagnostic procedure in Cardiology that allows the examiner 
to assess the function of your heart muscle. It does not pose any harm to the patient  
• ECG (Electrocardiogram): This examination allows the doctor to determine the rhythm of your heart. 
It is a commonly used diagnostic procedure and does not pose any harm to the patient.  
• As part of the study your HIV status will be checked. HIV pre-test and post-result counseling will be 
provided. 
(   ) I would like to know the HIV test result and wish to participate in appropriate     counseling  
(   ) I would not like to know the HIV test result 
 
RISKS OF THE STUDY MEDICINE:  
Bromocriptine is a registered drug in South Africa. It has been used for many years to treat diseases other 
than Peripartum Cardiomyopathy, such as Parkinson's disease. If you participate in this study you will be 
among the first people to use Bromocriptine for prevention of Peripartum Cardiomyopathy.   
 
UNFORSEEN RISKS:  
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The study medicine is investigational and there may be other risks or side effects which are unforeseen or 
unknown. You should immediately contact me if any side effects occur throughout your participation in this 
study.  
 
BENEFITS:  
The potential benefit from your participation in this study may be control of your "Peripartum 
Cardiomyopathy".  However, you may not benefit from this study. Your participation in this study will 
contribute to medical knowledge that may help other patients that, that like you, have "Peripartum 
Cardiomyopathy"  
 
ALTERNATIVE TREATMENT:  
• Alternative treatment in the form of standard treatment is used to treat "Peripartum Cardiomyopathy" 
• If you decide not to take part in this study you will still receive the best current care, from your usual 
doctor; this may or may not include the study medicine.  
 
BENEFITS AND RISKS OF STANDARD ALTERNATIVE TREATMENT:  
Participating in the study you will always receive standard treatment. In addition you will receive 
Bromocriptine 
 
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY PARTICIPATION IN 
THIS STUDY?  
You should not participate in the study if you have one of the following: 
• Hypersensitivity to Bromocriptine 
• Systolic blood pressure > 170 mmHg/<100 mmHg or diastolic > 105 mmHg 
• Clinical conditions other than cardiomyopathy that could increase plasma levels of inflammatory 
markers (sepsis, rheumatoid arthritis etc.)  
• Significant liver disease (defined as enzymes > 2 times the upper limit of normal) or impaired renal 
function ( defined as urea / creatinine more than 1.5 upper limit of normal)  
• Contraindications to bromocriptine (history of psychotic disorders, parkinsonism with dementia, 
compromised cerebral circulation, ischaemic heart disease, liver disease, history of peptic ulcers) 
 
Due to your diagnosis "Peripartum Cardiomyopathy" you should not fall pregnant again. Therefore effective 
contraception is strongly recommended.  
 
INTERACTIONS:  
It is important that you let me know of any medicines (both prescriptions and over-the-counter medicines), 
alcohol or other substances that you are currently taking.  
 
RIGHTS AS A PARTICIPANT IN THIS STUDY: 
• Voluntary: Your participation in this study is entirely voluntary and you can decline to participate, or 
stop at any time, without stating any reason. Your withdrawal will not affect your access to other 
medical care.  
• Discontinuation of study treatment: You must inform me if you wish to stop taking your study 
medicine. I will supervise any discontinuation with your health as the first priority.  
• New findings: I will provide you with any additional information that becomes available during the 
study, which may affect your willingness to continue on the study  
 
WITHDRAWAL FROM THIS STUDY:  
• Your withdrawal will not affect your access to other medical care.  
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• I retain the right to withdraw you from the study if it is considered to be in your best interest. If your 
participation is ended early, you may be asked to return for study-ending tests and procedures for 
your safety. 
• If you did not give an accurate history or did not follow the guidelines of the study and the 
regulations of the study facility, you may be withdrawn from the study at any time.  
• Pregnancy: Peripartum Cardiomyopathy is defined as a cardiomyopathy without any other 
attributable cause in the period of one month antepartum to 5 months postpartum. Pregnancy is 
therefore no defined reason for withdrawal from the study.  
 
EMERGENCY CARE AND HOSPITALISATION:  
If you seek emergency care or if hospitalisation is required at any time during the study, please inform the 
treating doctor that you are/were enrolled in this research study and that you are diagnosed with "Peripartum 
Cardiomyopathy". Please ask the treating doctor to inform me about your condition.  
 
FINANCIAL ARRANGEMENTS:  
• The Department of Cardiology, Chris Hani Baragwanath Hospital will provide payment for all study 
procedures and reasonable medical expenses that you may incur as a direct result of this study as 
determined by the Department of Cardiology, Chris Hani Baragwanath Hospital and me.  
• Neither you nor your medical scheme will be expected to pay for any study medication, study related 
visit or study procedures.  
 
REIMBURSEMENT FOR STUDY PARTICIPATION:  
You will not be paid to participate in this study but your transport costs will be reimbursed adequately.  
 
ABPI STATEMENT ON COMPENSATION: 
All patients enrolled in this study are public hospital patients at Chris Hani Baragwanath Hospital. No 
specific sponsor exists for this study. It is an investigator driven study. 
 
ETHICAL APPROVAL:  
• This clinical study protocol has been submitted to the University of the Witwatersrand, Human 
Research Ethics Committee (HREC) and written approval has been granted by that committee.  
• The study has been structured in accordance with the Declaration of Helsinki (last updated: October 
2000), which deals with the recommendations guiding doctors in biomedical research involving 
human subjects. A copy may be obtained from me should you wish to review it.  
 
SOURCE OF ADDITIONAL INFORMATION:  
• For the duration of the study, you will be under the care of Dr. Olaf Förster. If at any time between 
your visits, you feel that any of your symptoms are causing you any problems, or you have any 
questions during the study, please do not hesitate to contact me.  
• Doctors from the Department of Cardiology who are working on this study are:  
Professor Karen Sliwa-Hähnle 083-457-4823 
Dr. Olaf Förster  082-555-9859 
They can be contacted at the above 24 hour telephone numbers. 
 
• If you want any information regarding your rights as a research participant, or complaints regarding 
this research study, you may contact Prof. Cleaton-Jones, Chairperson of the University of the 
Witwatersrand, Human Research Ethics Committee (HREC), which is an independent committee 
established to help protect the rights of research participants at the following number: 011-717-2229  
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• For research information you can contact Prof Huddle, Head of Department of  Medicine, Chris Hani 
Baragwanath Hospital on 011-933-8940 
• South African Medicines Control Council: If you have questions about this trial you should first 
discuss them with your doctor or the ethics committee (contact details as provided on this form). 
After you have consulted your doctor or the ethics committee and if they have not provided you with 
answers to your satisfaction, you should write to the South African Medicines Control Council 
(MCC) at:  
 
The Registrar  
SA Medicines Control Council  
Department of Health  
Private Bag X828  
Pretoria 0001  
Fax: 012-323-4474  
E-mail: labusa@health.gov.za  
 
CONFIDENTIALITY:  
• All information obtained during the course of this study, including hospital records, personal data 
and research data will be kept strictly confidential. Data that may be reported in scientific journals 
will not include any information that identifies you as a participant in this study. 
• This information will be reviewed by authorized representatives of the Department of Cardiology, 
Chris Hani Baragwanath Hospital.  
The information might also be inspected by the University of the Witwatersrand. Human Research Ethics 
Committee (HREC), the South African Medicines Control Council (MCC) and/or the United States Food 
and Medicine Administration (FDA), as well as your personal doctor. Therefore, you hereby authorize me to 
release your medical records to the Department of Cardiology, Chris Hani Baragwanath Hospital, its 
employees or agents, domestic and foreign regulatory health authorities, the South African Medicines 
Control Council and the University of the Witwatersrand, Human Research Ethics Committee (HREC). 
These records will be utilized by them only in connection with carrying out their obligations relating to this 
clinical study.  
Any information uncovered regarding your test results or state of health as a result of your participation in 
this study will be held in strict confidence. You will be informed of any finding of importance to your health 
or continued participation in this study but this information will not be disclosed to any third party in 
addition to the ones mentioned above without your written permission. The only exception to this rule will 
be cases of communicable diseases where a legal duty of notification of the Department of Health exists. In 
this case, you will be informed of my intent to disclose such information to the authorized state agency.  
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PERSONAL DOCTOR / SPECIALIST NOTIFICATION OPTION:  
Please indicate below, whether you want me to notify your personal doctor or your specialist of your 
participation in this study:  
(   ) Yes, I want you to inform my personal doctor / specialist of my participation in this study. 
(   ) No, I do not want you to inform my personal doctor / specialist of my participation in this study  
(   ) I do not have a personal doctor / specialist  
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INFORMED CONSENT ON BROMOCRIPTIN FOR PATIENTS PRESENTING WITH A 
SUBSEQUENT PREGNANCY AND A PREVIOUS EPISODE OF PERIPARTUM 
CARDIOMYOPATHY:  
 
• I hereby confirm that I have been informed by the study doctor, Dr. Olaf Förster / Prof Karen Sliwa-
Hähnle, about the nature, conduct, benefits and risks of the clinical study "Peripartum 
Cardiomyopathy – an autoimmune disease?", protocol number 020907. I had sufficient time and 
opportunity to seek advice before deciding to participate in this study. I received sufficient 
information on the option to terminate my pregnancy. I have decided out of my own free will not to 
terminate my pregnancy. All my question in this regard have been answered. 
• I have also received, read and understood the above written information (Patient Information leaflet 
and Informed Consent) regarding this clinical study.  
• I am aware that the results of the study, including personal details regarding my sex, age, date of 
birth, and diagnosis will be anonymously processed into a study report.  
• In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerized system by the Department of Cardiology, Chris Hani Baragwanath 
Hospital or on its behalf.  
• I may, at any stage, without prejudice, withdraw my consent and participation in the study.  
• I have had sufficient opportunity to ask questions and of my own free will declare myself prepared to 
participate in the study.  
 
 
 
Patient: ________________________________________________________________ 
Printed Name  Signature/Mark/Thumbprint Date and Time 
 
I, Prof. Karen Sliwa-Hähnle / Dr. Olaf Förster, herewith confirm that the above patient has been fully 
informed about the nature, conduct and risks of the above study. 
 
Study Doctor: ___________________________________________________________ 
Printed Name  Signature   Date and Time 
 
Study nurse/translator/other person explaining Informed Consent (Designation): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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